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Parasitic nematodes, particularly soil transmitted helminths (STHs), are among 
the most frequent causes of physical and intellectual growth retardation in humans. 
Furthermore, parasitic nematodes of livestock and crops result in substantial economic 
losses, threatening the overall sustenance of the expanding population. Although rarely 
lethal, infections typically result in chronic, disabling, and disfiguring morbidity 
adversely affecting the essential components of human development. Chemotherapy 
continues to serve as the mainstay for treatment and control of nematode infections as 
there are no vaccines for human use.  The global strategy for the control involves regular 
administration of anthelminthic drugs to the high risk-populations. STHs mainly effect 
resource limited and poverty-stricken populations. This segment of the population can 
neither afford conventional treatment nor improve their infrastructure for better sanitation 
and hygiene facilities. Furthermore, there is limited research investment in the 
anthelmintics market due to high costs and modest profit levels, which has slowed down 
the anthelmintic drug discovery over the years. In addition, the widespread resistance to 
the limited armamentarium of anthelmintic drugs in the veterinary field has raised 
concerns in human medicine as well. It is prudent to restore the depleted drug-discovery 
pipeline before the existing antiparasitic drugs are rendered unviable. Thus, research 
should be directed towards identification and development of novel antinematodal targets 
and new therapeutics. 
We have described a novel nicotinic acetylcholine receptor formed by a non-α 
subunit, EAT-2, from the pharynx of Caenorhabditis elegans, a model nematode. We 




avermectins, which target glutamate-gated chloride (GluCl-) channels in pharyngeal 
tissue. For the first time we find that a non-alpha nicotinic subunit can form a homomeric 
ligand gated ion-channel when expressed in vitro. Even though EAT-2 is most closely 
related to vertebrate α-7 nAChRs, its pharmacological profile is distinct from previously 
characterized vertebrate channels and nematode somatic muscle nAChRs. The 
pharyngeal receptor was not activated by many of the cholinergic anthelmintics 
(levamisole, tribendimidine, pyrantel) and was insensitive to α-bungarotoxin and 
dihydro-β-erythroidine (DHβE). We also characterized the homologous receptor from 
Ascaris suum, a model for human parasitic nematode A. lumbricoides. We investigated 
the A. suum pharynx using electrophysiology and identified a significant cholinergic 
component that was pharmacologically similar to the A. suum EAT-2 receptor expressed 
in oocytes. This receptor was not sensitive to existing cholinomimetic anthelmintics and 
therefore represents a promising drug target. Importantly, the EAT-2 nAChR from both 
of the nematode species requires a novel auxiliary protein, EAT-18, for functional 
expression. EAT-18 directly interacts with the non-α subunits and modifies the 
pharmacological profile of the receptor. To the best of our knowledge this is only the 2nd 
auxiliary protein described for nAChRs and the first report of an auxiliary protein that is 
essential for functional expression in any cys-loop ligand-gated ion channel (LGIC). Both 
EAT-2 and EAT-18 proteins from A. suum were expressed in tissues other than the 
pharynx suggesting the receptor may serve multiple physiological functions. Thus, we 
have identified a non-canonical homomeric channel formed by non-alpha nAChR 





Secondly, we have identified an ACR-16 nAChR subunit homologue from 
Ancylostoma caninum, a model for human hookworm infections. Aca-ACR-16 forms a 
functional homomeric channel when expressed in Xenopus laevis oocytes. A. suum ACR-
16 nAChRs have been studied previously and reported to be a suitable target for the 
development of therapeutic drugs. In this study we explored the effects of several 
cholinergic agonists and antagonists on the expressed A. caninum ACR-16 nAChR using 
two-electrode voltage-clamp. The pharmacological profile of the Acn-ACR-16 receptor 
showed some similarities to the A. suum ACR-16 nAChRs. Both the homologues were 
unresponsive to many of the existing cholinomimetic anthelmintics (levamisole, pyrantel, 
morantel, bephenium and tribendimidine). Like Asu-ACR-16, the Aca-ACR-16 nAChR 
was also highly sensitive to mecamylamine and d-TC; moderately sensitive to derquantel 
and hexamethonium. In addition to similarities, the A. caninum ACR-16 nAChR showed 
marked differences in pharmacological sensitives from A. suum homologue which makes 
it scientifically interesting. As opposed to Asu-ACR-16, 3-Bromocytisine was the most 
potent agonist of Aca-ACR-16 while oxantel failed to activate the A. caninum nAChR. 
The mean time constants of agonists for desensitization rates were longer for Acn-ACR-
16 (between 6.2 and 12.6s) in comparison to Asu-ACR-16 (between 1.5 and 4.8s). In 
contrast to Asu-ACR-16, the A. caninum receptor was completely inhibited by DhβE and 
moderately inhibited by α-BTX. In conclusion, we have successfully recapitulated a fully 
functional homomeric ACR-16 nAChR from A. caninum. The pharmacology of the 
receptor is distinct from other somatic muscle nematode receptors. The ACR-16 




ACR-16. Therefore, we suggest that A. caninum ACR-16 may be a valid target site that 
should be further exploited for the development of agents against hookworm infection. 
Lastly, we have shown that the monoterpenoid compounds, menthol and 
carvacrol, can be potentially used for antinematodal therapy in combination with existing 
cholinergic compounds. We examined the effects of twelve monoterpenoid 
phytocompounds on a heterologously expressed levamisole sensitive nAChR from 
Oesophagostomum dentatum and a nicotine sensitive nAChR from A. suum using the 
two-electrode voltage-clamp technique. The majority of these compounds acted as 
antagonists when tested at 100 µM concentration. Carvacrol produced significant non-
competitive inhibition suggesting the compound acts at site different from the ligand 
binding sites. This monoterpenoid phytocompound has also been shown to target GABA 
(gamma amino-butyric acid) and tyramine receptors in previous studies. This 
multifaceted polypharmacological effect of carvacrol might make it efficacious as an 
anthelmintic, alone or in combination, and help circumvent the development of 
resistance. Interestingly, menthol potentiated the amplitude of acetylcholine currents in 
our antagonist experiments. Further investigation revealed that both 0.1 µM and 10 µM 
menthol potentiated acetylcholine and levamisole mediated responses in the levamisole 
sensitive nAChR. We also investigated the effects of 0.1 µM menthol on the contractility 
of A. suum somatic muscle strips. Menthol significantly potentiated the peak contractions 
at each concentration of acetylcholine tested. We have provided promising evidence of 
positive allosteric modulation by menthol in both in vivo and in vitro experiments.  Thus, 
menthol could possibly be used in combination therapy with cholinomimetic drugs like 




menthol and carvacrol can contribute to antinematodal phytotherapy and alleviate the 




















CHAPTER 1. GENERAL INTRODUCTION 
1.1 Introduction 
Nematodes are highly evolved metazoan organisms with ubiquitous existence. 
They exhibit complex physiological behaviors, including locomotion, navigation, feeding 
and reproduction, that are regulated by a sophisticated neuromuscular system. Parasitic 
nematodes are dependent on these behaviors for survival in the host and the environment. 
These biological functions are often targeted through chemotherapy to kill them or 
disrupt their life cycle. There are three major classes of anthelmintic drugs: the 
benzimidazoles (BZs), macrocyclic lactones (MLs), and imidazothiazoles/ 
tetrahydropyrimidines. The benzimidazoles such as thiabendazole, mebendazole, and 
albendazole inhibit microtubule synthesis by targeting β-tubulin. Underlying nematode 
neuromuscular system is a large repertoire of ion channels, including nicotinic 
acetylcholine receptors (nAChRs) and glutamate-gated chloride channels (GluCls). These 
ionotropic channels integrate with the normal biological functions to maintain viability. 
GluCls are target site of macrocyclic lactones (e.g. ivermectin, abamectin) while 
imidazothiazoles/tetrahydropyrimidines (e.g. levamisole, pyrantel, oxantel) act on 
nicotinic acetylcholine receptors. nAChRs are evolutionarily conserved membrane-
spanning protein complexes that are required for fast excitatory chemical-to-electrical 
transduction in nematodes. Many of these cation-selective receptors are localized to 
neuromuscular junction and are prime loci for fundamental cellular functions. Nematodes 
have a greater number of nAChR subunits than mammals. By varying the subunit 
composition and stoichiometry different pharmacological sensitivities can be achieved, 




on muscles, hold emblematic position as anthelmintic targets for treatment of soil 
transmitted helminth (STH) infections. There are topographical differences in binding 
sites between nematodes and vertebrates, making these channels “druggable”. 
Cholinergic anthelmintics, including levamisole, pyrantel and more recently introduced 
monepantel cause prolonged activation of excitatory nAChRs in nematodes leading to 
rapid immobilization and expulsion from the host. STHs infect about 1.5 billion people 
worldwide and hamper socioeconomic development through human debility and by 
decimating livestock and crop production. Chemotherapy has brought manifold 
improvements in health, agricultural economics, livestock production and overall food 
security. Nevertheless, repeated mass drug administration of monotherapies with limited 
classes of antiparasitic agents has driven widespread resistance in veterinary 
anthelmintics. There are reports of reduced cure rates in humans and increased risk of 
development of drug resistance.  Furthermore, there are no vaccines for humans use. 
There is an accepted need for discovery and development of novel chemotherapeutic 
targets as well new therapeutics.  
These doctoral studies were undertaken to address strategies that can circumvent 
the issue of drug resistance and strengthen the future defense against nematode 
infections. The first aim was to characterize the pharmacology of a novel nAChR, EAT-
2, from free-living (Caenorhabditis elegans) and parasitic (Ascaris suum) nematodes. We 
also identified a novel auxiliary subunit for EAT-2 cation selective channels, EAT-18, 
which is an essential element of the receptor complex and modulates its pharmacology. 
The second aim was to validate ACR-16 nAChR from Ancylostoma caninum, a 




anthelmintics against hookworm infections. The third aim was to evaluate the potential 
anthelmintic effects of monoterpenoid compounds to identify alternatives to current 
synthetic nematocidal agents. 
 
1.2 Thesis organization 
In this thesis, Chapter-1 provides a general introduction about parasitic nematodes 
and the importance of nicotinic acetylcholine receptors as chemotherapeutic targets. In 
view of widespread drug resistance in veterinary anthelmintics and the risk of 
development of resistance in human medicine, it is prudent to develop novel strategies for 
sustainable control of parasitic infections in foreseeable future. We have highlighted the 
importance of characterization of new drug targets and development of phytotherapeutics 
as anthelmintic agents as means of addressing drug resistance concerns. In Chapter-2, I 
have reviewed the literature pertaining to parasitic nematodes and associated infections, 
particularly ascariasis, hookworm infections and oesophagostomiasis, nicotinic 
acetylcholine receptors (nAChRs), auxiliary protein subunits of nematodes, C. elegans 
and A. suum pharynx and monoterpenoid compounds. In Chapters 3, 4 and 5, I present 
research work done by myself and collaborators that has been published (Chapter 5) or in 
preparation for publication (Chapter 3 and 4). Chapter 3 describes the pharmacological 
characterization of a novel homomeric pharyngeal nAChR formed by a non-alpha 
subunit, EAT-2, from C. elegans (free-living nematode) and A. suum (nematode model 
for human ascariasis). EAT-2 requires a small single-pass novel auxiliary protein, EAT-
18, for successful heterologous expression. Both the proteins may be used for potential 




work outlined in this paper, except in vivo electrophysiology recordings from A. suum 
pharynx and isolation of cytoplasm for single-cell PCR which were done in our lab. 
Chapter 4 describes the cloning and in vitro expression of ACR-16 nAChRs from A. 
caninum, a clade V nematode parasite.  We generated a comparative pharmacological 
analysis of the homomeric channel and established ACR-16 as a potential target in the 
hookworm parasites. All the work in this chapter was done by me with input from our 
collaborators at the Iowa State University. Chapter 5 describes the potential of 
monoterpenoid compounds as anthelmintic compounds. We identified menthol as a 
promising candidate for combination therapy with cholinergic anthelmintics. I did most 
of the work presented in this paper. The cloning of the receptor subunits was done by a 
former graduate student in our lab and the A. suum muscle flap contraction studies were 
conducted by our collaborators from Belgrade. Chapter 6 is a general discussion and 
conclusions of my PhD research and suggestions for future work. Appendix A is an 
invited review on advances in anthelmintic drug development and Appendix B is a list of 












CHAPTER 2. LITERATURE REVIEW 
2.1 Soil-transmitted helminth (STH) infections 
Helminth parasites have accompanied humans throughout the ages and continue 
to be a nuisance especially in regions where poverty persists. The term helminth is 
derived from Greek word meaning “worm”. Primitive civilizations had knowledge of 
parasites and parasitic infections to a certain extent. Many ancient texts provide abundant 
evidence and detailed descriptions of infections that clearly support the presence of 
helminthic manifestations. Ebers papyrus (1500 B.C.), the Egyptian medical record 
mentions worms, which most certainly are Ascaris lumbricoides and the Guinea-worm, 
Dracunculus medinensis (Hoeppli 1956). Many of the characteristic clinical features of 
helminth infections are described in historical records of Arabic physicians, particularly 
Rhazes (AD 850 to 923) and Avicenna (AD 980 to 1037), Roman physicians from 700 
BC to 400 AD, Chinese writings from the 2nd and 3rd century BC and written records by 
Hippocrates, known as the Corpus Hippocratorum (Hoeppli 1956; Jones and 
Whithington 1948-1953; Grove 1990). There is mention of the “fiery serpents” in the 
Bible that struck down the Israelites in the region of the Red Sea after the Exodus from 
Egypt somewhere about 1250 to 1200 BC (Cox 2002); most parasitologists believe these 
were Guinea worms. A condition interpreted as dracunculiasis has also been described in 
the Assyrian texts present in the library of King Ashurbanipal from the 7th century BC 
(Hoeppli 1959). A. lumbricoides eggs have been found in coprolites from pre-Hispanic 
and pre-Columbian Peruvian populations dating back to 2277 B.C. (Horne 1985; 
Patrucco, Tello, and Bonavia 1983) and Brazilian populations around 1660-1420 BC 




lumbricoides infestation in an Egyptian mummy dating between 1938-1600 BC 
(Cockburn, Cockburn, and Reyman 1998) and an ancient Western Han Dynasty corpse 
from 1368-1644 AD (Wei et al. 1981). Fossilized ova of Ancylostoma sp.  have been 
found in human feces dating somewhere between 3350 BC and 480 AD (Ferreira et al. 
1987). Paleo-parasitological investigations have established that the people of the Korean 
Joseon Dynasty were also heavily infected by helminth parasites (Ki, Bae, and Shin 
2013). The Babylonian Talmud (4th to 5th century AD) mentions the common human 
parasites and contains highly developed hygiene laws (Hoeppli 1956). The ancient Indian 
text, Atharvaveda, also contains references to parasites and corresponding infections; 
some of these have been interpreted to be the intestinal helminths, A. lumbricoides and 
Enterobius vermicularis (Jolly and Kashikar 1951). Thus, the history of helminth 
parasitology is fascinating. Many of the important parasites encountered today had a 
widespread existence and our ancestors were aware of their manifestations. The current 
trend of helminths and corresponding infections resulting from their interaction with 
humans is still an enduring issue, influenced by socio-cultural spectrum (Alum, Rubino, 
and Ijaz 2010). 
Helminths are a diverse group of metazoan organisms that include both parasitic 
and free-living worms. Humans are hosts to nearly 341 helminth species, but only 25 of 
those produce sufficient adverse impact to be considered as globally significant (Coombs 
and Crompton 1992). These worms are highly evolved, opportunistic organisms and are 
responsible for the most common parasite infections (Lindquist and Cross 2017; 
Cleaveland, Laurenson, and Taylor 2001; Jones et al. 2008; Awasthi, Bundy, and Savioli 




(tapeworms and trematodes), Nematoda (roundworms or nematodes), Acanthocephala 
(spiny-headed worms), and Nematophora (hairworms); only worms belonging to the first 
two are endoparasites of humans (Despommier et al. 2017).  The phylum Nematoda is a 
diverse group of helminths, characterized by species richness, biodiversity, abundance 
and ecological omnipresence (Dieterich and Sommer 2009; Blaxter et al. 1998). The 
word Nematoda comes from the Greek words “nematos”, meaning thread, and “eidos”, 
meaning form. More than 25,000 nematode species have been described in literature, 
including nearly 16,000 parasitic species, with new species still being identified and 
recorded (Dieterich and Sommer 2009; Okulewicz, Perec, and Hildebrand 2005). 
Parasitic nematodes can infect a wide spectrum of hosts and threaten the health of 
humans, animals and plants on a global scale. These include soil-transmitted helminths 
(STHs) that affect over 1.5 billion people worldwide (WHO 2019). These are also 
known as soil-transmitted nematodes (STN) or geohelminths. They share a common 
transmission mechanism involving contact with infective parasitic eggs or larva 
through exposure to fecally contaminated water, soil or contaminated food. The 
predominant species involved in STH infections are: Ascaris lumbricoides 
(roundworm), Necator americanus and Ancylostoma duodenale (hookworms), Trichuris 
trichiura (whipworm) and Strongyloides stercoralis (the threadworm). STH infections 
are among the major contributors to the global burden of infections and are endemic in 
more than half of the world’s countries  (Figure 2.0) (WHO 2017a, 2017b). 
Ascariasis is reported in 771.7–891.6 million people, while whipworms infect around 
429.6–508.0 million people and an estimated 406.3–480.2 million are infected with 






 Figure 2.0 Global prevalence of various species of STH worms (Jourdan et al. 2018). A. 
Ascaris lumbricoides (2010). B.  Trichuris trichiura (2010).  C.  Necator americanus and 
Ancylostoma duodenale (for 2010).  D.  Strongyloides stercoralis (2011). 
 
limited and poverty-stricken regions of sub-Saharan Africa, Asia and the Americas, are 
infected with at least one species of STH (Hotez et al. 2007; Hotez et al. 2006; WHO 
2019; Stolk et al. 2016).  Heavy burdens of STH worms are associated with 
gastrointestinal manifestations (abdominal pain, diarrhea, blood and protein loss, rectal 
prolapse), pruritis, anemia and malnutrition through loss of blood and nutrients (Bethony 
et al. 2006). Children are particularly susceptible to these geohelimths and in many cases 
they harbor all three types of STH (hence the moniker “the unholy trinity”) (Despommier 
et al. 2017).  Childhood malnutrition can have profound impact on the physical 
development and cause cognitive deficits impacting educational attainment and future 
productivity (WHO 2019; Bethony et al. 2006). STH infections perpetuate a persistent 
drain on social-economic development of low-income regions of the world (King 2010). 




representing a significant economic and welfare burden and a substantial threat to 
global food security.  
2.1.1 Ascariasis 
A. lumbricoides is a large roundworm responsible for causing a spectrum of 
disease symptoms known as ascariasis in humans. It is one of the most common parasites 
in the world and infects around 800 million people worldwide (Vos et al. 2017). It is 
responsible for around 1 million DALYs (Disability adjusted life years; measure of 
overall disease burden, expressed as the number of years lost due to ill-health, disability 
or early death) with more than 60,000 deaths annually (Shah and Shahidullah 2018; de 
Vlas et al. 2016). The intensity and frequency of infections with A. lumbricoides is 
highest in children aged 5-15 years (Bethony et al. 2006; Hotez et al. 2008).  Ascaris 
suum, which causes ascariasis in pigs, can occasionally cause infection in humans 
through contact with domestic pigs (Nejsum et al. 2012; Leles et al. 2012). A. 
lumbricoides has a widespread distribution in temperate and subtropical regions with the 
highest prevalence in rural populations of tropical zones, where hygiene and sanitation 
are inadequate. The warm and humid climate in these regions favors year-round 
transmission of infection (Shah and Shahidullah 2018; Pullan et al. 2014).  
Humans are the definitive hosts in the A. lumbricoides lifecycle (Figure 2.1) and the 
individuals are infected through fecal-oral transmission (Despommier et al. 2017; Dold 
and Holland 2011). After the infective eggs are swallowed, first-stage larvae (L1) hatch 
in the jejunum and molt into second-stage larvae (L2). These L2 larvae then penetrate the 
intestinal mucosa and reach the liver via the portal blood, where the L2 cuticle is shed. 





Figure 2.1 Lifecycle of Ascaris lumbricoides (Despommier et al. 2017). 
 
the capillaries of the lungs, they grow bigger and molt twice. The developed larvae break 
through the capillaries, move across the alveolar wall and ascend the tracheobronchial 
tree to the larynx. They are swallowed into the intestine where they molt and mature into 
adults. Mature male and female worms measure 15-31 cm and 20-35 cm, respectively. 




thousands of fertilized or unfertilized eggs daily, that are passed in the stool (Sinniah 
1982). The time period between infection and egg production is usually 2-3 months. 
Unembryonated eggs are very durable and remain viable in warm, moist soil for years.  
The majority of infections with A. lumbricoides are asymptomatic and pathology 
of the disease is largely related to worm burden (De Silva, Guyatt, and Bundy 1997). 
When symptoms do occur, they can be mild such as abdominal discomfort to heavy such 
as diarrhea, anemia, malnutrition leading to impaired physical and mental growth in 
children (Bethony et al. 2006; Crompton 2001). The major serious sequalae of heavy 
worm burden is intestinal obstruction, volvulus or intussusception which can be fatal in 
upto 6% of cases (Pullan et al. 2014; Bethony et al. 2006; Tietze and Tietze 1991). The 
migration of worms through the body can lead to coughing and sometimes coughing up 
of worms and wheezing (Roberts and Kemp 2001; Dold and Holland 2011). Obstruction 
of the gall bladder can result in cholangitis, cholecystitis, biliary colic, liver abscess, and 
pancreatitis (Roberts and Kemp 2001). A. lumbricoides can cause type-1 hypersensitivity 
reactions to the larval stages and also induce a T-helper-2 cell (Th2) immune response 
(Jarrett and Miller 1982; Fitzsimmons, Falcone, and Dunne 2014; Akuthota and Weller 
2012). 
The diagnosis of ascariasis is usually made by microscopic examination of fecal 
samples for the presence of eggs. Visualization and description of the worms can also 
establish identification (Knopp et al. 2008; Nikolay, Brooker, and Pullan 2014; Bethony 
et al. 2006). Treatment of ascariasis includes administration of a single dose of 
albendazole (400 mg) or mebendazole (500 mg) (WHO 2019; Claus et al. 2018; Keiser 




2.1.2 Hookworm infections 
Adult hookworms of the two species, Necator americanus and Ancylostoma 
duodenale, account for most infections in humans, parasitizing the upper part of the small 
intestine. Hookworm infections are common throughout sub-Saharan Africa, tropical 
regions of the Americas, South China and Southeast Asia (Bethony et al. 2006; de Silva 
et al. 2003b; Hotez et al. 2004). N. americanus is the more predominant hookworm 
worldwide, except in some focal areas of India, China and Egypt (Despommier et al. 
2017). Ancylostoma ceylanicum, hookworm species of humans and other mammals, is 
found in Southeast Asia but is not considered an important pathogen (Ngui et al. 2012). 
The canine hookworm species, A. caninum, can cause zoonotic infections resulting in 
enteritis, localized myositis and cutaneous larva migrans (Landmann and Prociv 2003; 
Prociv and Croese 1996; Traversa 2012). A. braziliense, hookworm of dogs and cats, can 
also penetrate the human skin causing cutaneous larva migrans (Blackwell and Vega-
Lopez 2001). An estimated 500 million people are infected by hookworms and the 
associated infections account for >4 million disability adjusted life years (DALYs) lost 
annually (Loukas et al. 2016; Vos et al. 2017; Bartsch et al. 2016).  
The percutaneous lifecycle of hookworm, N. americanus, is shown in Figure 2.2 
(Despommier et al. 2017). The larvae of A. duodenale and N. americanus are free-living 
in the soil. The infection begins when the filariform L3 larval stage actively penetrates 
the cutaneous tissue of the skin usually through hair follicles or an abraded area. The 
filariform larvae are carried passively to the lung capillaries through the bloodstream. 
The larvae then penetrate the alveolar wall, crawl up the bronchi and trachea and pass to 




twice resulting into development of mature adult worms over a period of 1-2 months. The 
adult worms have an average life span of up to one year for A. duodenale and 3-5 years in 
case of N. americanus (Hoagland and Schad 1978). Adult female hookworms, similar to 
roundworms, can produce thousands of eggs daily which are released in the stool. The 
released eggs take 5-10 days to hatch in warm, moist, sandy soil or in feces. The hatched 
larvae (L1 or rhabditiform larvae) molt into L3, the infective stage larvae, that can 
survive for weeks. The A. duodenale are also infective through oral ingestion. Orally 
ingested larvae undergo two molts without leaving the intestinal tract of the host. This 
results in a syndrome known as Wakana disease, characterized by nausea, vomiting, 
pharyngeal irritation cough and dyspnea (Kojima 1999).  
The blood feeding hookworms do not directly account for substantial mortality; 
instead the major clinical manifestations of hookworm infection are the consequences of 
chronic intestinal blood loss (Loukas et al. 2016; Hotez et al. 2004). Depending on the 
stage of infection, route of transmission and degree of worm burden, the hookworm 
infections lead to four potential manifestations, dermatitis, pneumonia, abdominal pain, 
and chronic iron deficiency anemia. Larval penetration through skin, often through the 
feet of barefooted individuals, may result in ground itch accompanied by intense pruritic, 
tortuous vesicular lesions due to larval migration. The amount of blood loss through the 
intestine of the host is dependent on the species of the worm as A. duodenale results in 
greater blood loss (Albonico et al. 1998). In contrast to ascariasis, there is a steady rise in 
prevalence and intensity of hookworm infections with age (Bethony et al. 2002). The 
pattern of these infections is also dependent on sex of the person as the prevalence and 





Figure 2.2 Lifecycle of Necator americanus (Despommier et al. 2017). 
 
chronic blood loss as they have lower iron stores (Stoltzfus, Chwaya, et al. 1997; 
Stoltzfus, Dreyfuss, et al. 1997). Heavy infections in children lead to iron-deficiency 
anemia which in turn results in retarded physical growth and behavioral deficits (Hotez 
2008; Loukas et al. 2016; Hotez et al. 2004; Despommier et al. 2017). Hookworm 




growth, birth weight and increases the likelihood of premature birth; in severe cases 
infections may contribute to maternal mortality (Hotez et al. 2008; Loukas et al. 2016; 
Brooker, Hotez, and Bundy 2008; Bethony et al. 2006; Bundy, Chan, and Savioli 1995). 
Stool microscopy is the standard method for diagnosing the presence of 
hookworm by identifying hookworm eggs (Jourdan et al. 2018). In some cases, capsule 
endoscopy can be used (Wu, Chen, et al. 2016). A single dose of a benzimidazole 
anthelmintic, either albendazole (400 mg) or mebendazole (500 mg) is recommended for 
treatment. Pyrantel pamoate and levamisole are regarded as alternative drugs for the 
treatment of hookworm. Iron supplements and additional nutritional support is used in 
severe cases (Bethony et al. 2006; Keiser and Utzinger 2008; Sacko et al. 1999).  
2.1.3 Oesophagostomiasis 
The disease, oesophagostomiasis, is caused by species of roundworms belonging 
to the genus Oesophagostomum, falling under the family Strongylidae. The adult worms 
inhabit the lumen of caecum and colon in the host. The infection is characterized by the 
presence of nodular abscesses in the intestinal wall caused by the tissue-dwelling larval 
stage; hence the parasite is also known as the “nodular worm”. Most species of the 
oesophagostomes are parasitic in primates, with a few infecting swine, and ruminants 
(Gutierrez 2011). In humans most of the cases of oesophagostomiasis are normally 
considered as zoonotic infections, with the exception of O. bifurcum which does not 
require an animal reservoir (Polderman et al. 1991). O. bifurcum is the most common 
species infecting humans in Africa (Ghai et al. 2014; Despommier et al. 2017). The 
infection is focally endemic in northern Ghana and Togo with an estimated 250,000 




et al. 2001; Polderman et al. 1991; Polderman and Blotkamp 1995). Sporadic cases have 
been reported from parts of Asia and South America as well (Ziem et al. 2006).  
The adult worms are roughly 1-2 cm long. Figure 2.3 shows the life cycle of 
Oesophagostomum spp. Mature females produce about 5,000 eggs daily, which are 
passed in the feces (Krepel and Polderman 1992). These eggs develop into L1 (first-
stage) larvae when the temperature is conducive. L1 larvae feed on bacteria in the 
environment and molts twice to hatch into mature infective L3 (third-stage) larvae. The 
infective larvae are ingested by the host which subsequently invade the mucosa and sub-
mucosa of the large intestine. At this stage distinct nodules can be recognized in the 
intestinal wall. After a few days, the larvae develop to fourth stage (L4) and escape the 
nodules to return to the lumen of the large intestine.  The development of the L4 larvae 
into adult worms takes place in the lumen of large intestine (caecum and colon) 
(Anderson 1992; Despommier et al. 2017; Blotkamp et al. 1993). Egg production usually 
starts about 30 days post-infection.   
Patients with oesophagostomiasis do not exhibit a definitive set of signs and 
symptoms. O. bifurcum infection can result in development of either a single nodular 
mass or a multi-nodular disease (Gigase et al. 1987; Storey et al. 2000). The uni-nodular 
disease, often referred to as Dapaong tumor, is the more predominant form of 
oesophaostomiasis, affecting 85% of patients. It presents as a palpable and painful 
protruding mass (30-60 mm in diameter) adherent to the abdominal wall, formed as a 
result of intense tissue reactions around a nodule containing single or a small cluster of 
encapsulated juvenile worms. This nodule can instigate peritonitis if ruptured and result 





Figure 2.3 Lifecycle of Oesophagostomum spp. Modified from 
https://www.cdc.gov/dpdx/oesophagostomiasis/index.html (Accessed on 04-01-19 at 
4:48PM CST). 
 
secondary tissue reaction. The less common, multi-nodular oesophagostomiasis is 
characterized by the formation of hundreds of pea sized nodules containing worms and 
pus along the colon wall. This form of the infection can give rise to bowel obstruction, 
peritonitis, and intestinal volvulus (Polderman et al. 2010). Prevalence rate is higher in 
children belonging to ages 2-10, and females older than 5 years of ages. Although, male 
patients have larger sized nodules than females (Storey et al. 2001). 
Microscopic examination of fecal samples is the diagnostic method of choice. 
Ultrasound and PCR amplification of DNA from fecal samples are also helpful for 
diagnosis and epidemiological studies (Storey et al. 2002; Verweij et al. 2001). Pyrantel 




2004). Surgical excision of the nodules is sometimes necessary for management of the 
infections (Storey et al. 2000). 
 
2.2 Nematode body structure 
 The nematodes are cylindrical, bilaterally symmetrical, non-segmented 
roundworms that typically lack external appendages. Most of the nematodes are 
vermiform with tapering anterior and posterior ends. The phrase “tube within a tube” is 
used to describe their body structure as they possess a spacious fluid filled cavity that 
separates the outer body wall from the alimentary canal (Brusca and Brusca 1990; 
Gardner 2013). This cavity is not a true coelom as it is not completely lined with 
mesodermally derived cells and lacks a cellular lining or peritoneum, hence nematodes 
are called “pseudocoelomates”. The pseudocoelom consists of two to six fixed cells 
(celomocytes) and is mostly filled with intestinal and reproductive tissues. The 
pseudocoelomic fluid serves as a distributing medium for digested food and for collection 
of waste products (Chandler 1949; Brusca and Brusca 1990). It is under a positive 
pressure, relative to their environment, and assists with maintaining the worm’s body 
form. The body wall is composed of an outer cuticle and an inner layer of longitudinal 
somatic cells separated by a thin sheet of hypodermis (Lee 1965; Bird 1991). These 
layers appear as three concentric rings in a transverse section of the worms (Figure 2.4C). 
The cuticle is a translucent non-cellular flexible outer covering, secreted by the 
underlying hypodermis that surrounds the entire body of the worms (Chandler 1949; 
Despommier et al. 2017; Castro 1996). It is primarily proteinaceous in composition with 
trace amounts of lipid and carbohydrates (Fetterer and Rhoads 1993). It lines the buccal 




forms; it may be smooth or ornamented with rings, longitudinal striations, or spikes. In 
some nematodes, the cuticle may have well-developed protruding fin-like projections 
either in the neck region, called cervical alae, in others in the tail region of the males 
supported by fleshy papillae called caudal alae (Gardner 2013). Another variability of 
cuticular complexes, known as bursa, are present on the posterior end of the male 
nematodes of some species. These are flaplike extension of the cuticle are used to grasp 
the female during copulation (Chandler 1949). The cuticle is structurally rigid to maintain 
the integrity of the worms, but flexible enough to permit bending and stretching. It serves 
as an interface connecting nematodes with their host. The cuticle is extremely resistant 
and protects the worms from getting digested in the inhospitable stomach environment of 
the vertebrate hosts. It is also involved in active transport of small molecules, including 
water, electrolytes, and organic compounds. During the worm’s life-cycle, the cuticle is 
shed periodically, usually four times, before reaching the adult stage (Castro 1996; 
Chandler 1949; Despommier et al. 2017; Basyoni and Rizk 2016). 
The cellular protoplasmic syncytial layer underlying the cuticle is the hypodermis. 
The nuclei of this subcuticular layer are present in four thickened chords, a dorsal, a 
ventral, and two lateral chords that divide the pseudocoelomic cavity into quadrants. 
Excretory tubules are located in the lateral chord while longitudinal nerve fibers are 
associated with the dorsal and ventral chords. The primary function of the hypodermis is 
to secrete the cuticle. It is also involved in the active exchange of water and small 
molecules (Fetterer and Wasiuta 1987; Gardner 2013; Poinar 2015; Chandler 1949).  
 The longitudinally arranged spindle-shaped somatic muscle cells are grouped 




1996; Chandler 1949; Stretton 1976). The somatic musculature forms the innermost layer 
of the body wall and surrounds the perienteric cavity. Each muscle cell consists of a 
contractile part with myofibrils and a non-contractile part (cell body) in which the 
nucleus, mitochondria and other organelles are found (Lee and Atkinson 1976; 
Rosenbluth 1965a). The muscle cells are closely associated with hypodermis and 
connected to the cuticle by fibers passing from the contractile part of the cell (Rosenbluth 
1965a; del Castillo et al. 1989). The nematodes do not possess circular body muscles 
which limits their movement pattern. They exhibit a characteristic waveform motion 
accomplished by contractions and relaxation of dorsal or ventral musculature in 
apposition with the rigid cuticular layer that limits the motion (Harris and Crofton 1957a; 
Gardner 2013; Stretton 1976; Weisblat and Russell 1976).  The musculature of the 
nematode, Ascaris spp., is discussed in detail in the next section. 
 
2.3 Nematode neuromuscular system 
The neuromuscular system of the nematodes differs from other animals and is a good 
example of the multiple specialization in metazoan cells. Here we discuss the 
neuromuscular system of the Ascaris spp. The structure of helminth somatic muscle cells 
is unique as is the peculiar spatial relations of these cells with the nervous system. The 
nerves of these worms do not branch out to the muscle, but instead, an innervation 
process is extended from the non-contractile part of the muscle cells to terminate on one 
of the longitudinal nerves (Rosenbluth 1965a, 1963; Stretton 1976; del Castillo et al. 
1989; Schneider 1866).  Additionally, the neuromuscular system of nematodes, including 




feature that makes nematodes different is the small and constant number of identifiable 
neurons in each worm species (del Castillo et al. 1989). 
2.3.1 Nematode muscular system 
The muscle cells in Ascaris are longitudinally directed and circumferentially 
arranged beneath the hypodermis. The somatic musculature is formed by 5x 104 number 
of mononucleated cells, separated into the dorsal and ventral fields by the two lateral 
hypodermal chords (Stretton 1976). Each muscle cell is geometrically complex and 
consists of three structurally distinct parts (Figure 2.4); a ribbon-like contractile part 
situated most peripherally, the more centrally located balloon-like 200 μm perinuclear 
part, known as the bag or belly, and lastly the slender, elongated innervation process, or 
arm, that extends from the belly and divides into several finger like projections that 
synapse on the nerve fibers (Rosenbluth 1965a). The contractile part of the muscle cells, 
also known as the spindle region, is anchored to the hypodermis. It is composed of 
obliquely striated (~2mm in length) myofibers that contains interdigitating arrays of thick 
and thin myofilaments (Rosenbluth 1963, 1965a). The muscle bag floats freely facing the 
pseudocoelom and contains the nucleus, submembrane mitochondria, particulate 
glycogen and other organelles (Rosenbluth 1965b). The non-myofibrillar muscle arms 
project from the base of the bag, cross the muscle field transversely to reach over the 
nerve cord surface, and eventually divide into thin, terminal projections or fingers just 
before receiving innervation from the nerve cord. Most muscle cells have a mean number 
of 2.7 arms (Stretton 1976). The fingers of the muscle arm intertwine with the fingers of 
adjacent arms, forming a ribbon-shaped plexus. This plexus extends longitudinally in 





Figure 2.4 A. Transverse section of Ascaris muscle cells and myoneural junctions. The 
arm of the innervation process subdivides as it approaches the nerve cord (Lee and 
Atkinson 1976). B. Ascaris muscle cell showing the muscle bag, spindle, arm, syncytium 
and nerve cord (Martin et al. 1991). C. Transverse section of anterior section of Ascaris 
(The image was kindly provided by Mark Mchugh, Department of Biomedical Sciences, 
Iowa State University). The worm is surrounded by cuticle (C), beneath which lies the 
hypodermis (H). The intestine (I) lies between the two lateral lines (L). The somatic 
muscle fibers (F) are seen as radial structures subjacent to the hypodermis and are 
continuous with the balloon-like muscle bellies (B). The muscle arms (A) can be seen 
converging on a nerve cord (N).  
 
interlocking processes, forming a functional syncytium (Rosenbluth 1965a; DeBell 
1963). The syncytium and nerve cord fibers form the neuromuscular junctions in Ascaris. 
2.3.2 Nematode nervous system 
The nervous system of the nematodes is remarkably consistent. Ascaris spp. 
contains only about 250 neurons. It is composed of a nerve ring (or circumpharyngeal 
commissure) and associated ganglia in the head region, the major dorsal and ventral 
nerve cords and the smaller subdorsal and subventral cords, and another, smaller set of 
ganglia in the posterior region (Figure 2.5 A&B). The dorsal and ventral nerve cords pass 
caudally along the length of the body (Stretton et al. 1978). The motor nervous system is 
the region that is sufficient to exhibit locomotor behavior when the anterior and posterior 





Figure 2.5 A. The nervous system of the head and the tail region of Ascaris female (Lee 
and Atkinson 1976). B. Organization of the motor nervous system in one segment of 
Ascaris. Each segment contains eleven motoneurons and six non-segmental interneurons. 
The seven morphological types of motoneurons are indicated as DI: dorsal inhibitory, VI: 
ventral inhibitory, DE1: dorsal excitatory 1, DE2: dorsal excitatory 2, DE3: dorsal 
excitatory 3, V1 and V2: ventral excitatory (Martin 1993). 
 
the motor nervous system are concentrated in the ventral and dorsal nerve cords and 
classified into three categories: motor neurons, large interneurons and small interneurons. 
The motor neurons make synapses with muscle cells either in the dorsal nerve cord or the 
ventral nerve cord. The large interneurons make synapses onto certain motor neurons, 
while the small interneurons synapse onto each other or onto large interneurons. The cell 
bodies of the motor neurons are located in the ventral nerve cord, and they are linked to 
the dorsal nerve cord by single or paired lateral processes known as commissures. These 
commissures repeat in a pattern down the length of the body and each repeat, also called 
the segment, consists of three paired right-hand commissures and one left-hand 
commissure. The motor neurons are geometrically simple and have been classified into 
seven distinct types based on the morphological distribution of axons and dendrites. Each 
type of motor neuron is arranged serially along the length of the worm in five segments; 
each segment contains 11 copies of the cell (Figure 2.5 C). Out of the seven types, DI, 




types namely, DE1, VI, V1 and V2 occur twice. V1 and V2 are confined to the ventral 
nerve cord and the rest have processes in both the dorsal and ventral nerve cords (Stretton 
et al. 1992; Stretton et al. 1978; Martin 1993; Martin et al. 1991).  
 
 
2.4 Nicotinic acetylcholine receptors (nAChRs) 
Nicotinic acetylcholine receptors are pentameric membrane-spanning ligand-gated ion 
channels (LGICs). nAChRs mediate excitatory neurotransmission in both vertebrates and 
invertebrates through the finely tuned spatial and temporal regulation of ion flow across 
cell membranes. The discovery of the nAChRs played a key role in the advancement of 
pharmacology. These were the first membrane receptors of a neurotransmitter and ion 
channel to be characterized as a protein (Changeux 2012). The nicotinic actions were first 
encountered by Europeans when Columbus's crew sampled tobacco in 1492. The plant 
was named Nicotiana after Jean Nicot, the French ambassador to Portugal, who 
introduced it and later the active alkaloid of tobacco was named nicotine (Charlton 2004). 
The concept of a pharmacological receptor was discovered as a result of investigation to 
localize the physiological action of tobacco and curare. It was Claude Bernard, who in 
1857, deduced that curare acted at the junction between motor nerve and muscle (Cousin 
2013; Martindale and Lester 2014; Bennett 2000). Alfred Vulpian repeated Bernard’s 
experiments in the 1860’s and articulated that curare caused disruption of 
communication between nerve and muscle (Monassier 2017; Bennett 2000; Martindale 
and Lester 2014). However, his conclusions did not specify structure through which 
curare exerted its effects. In 1885, Paul Ehlrich suggested that toxins chemically 




Although, Ehlrich is credited with the term “chemoreceptors”, it was John Newport 
Langley, who in 1905 proposed that muscle contraction was mediated by a "receptive 
substance", which combined with nicotine and curare (Langley 1901, 1905; Bennett 
2000). These “receptive substances” are presently designated as receptors. Langley 
concluded that the receptors could receive stimulus from the nerve and transmit it to the 
effector cell. David Nachmansohn (1955) postulated that receptors are proteins and it was 
not until 1970 that the first neurotransmitter nAChR (from electric ray, Torpedo 
californica) was identified, purified and biochemically characterized (Miledi and Potter 
1971; Changeux, Kasai, and Lee 1970). In the 1980s, the nAChR family and an extended 
family of homologous pentameric receptors was identified using molecular biology 
techniques (Le Novère and Changeux 1995; Patrick et al. 1983). With the advent of more 
refined scientific techniques since then, various nAChR subunits have been identified 
and cloned. The agonist binding sites and the channel-lining residues have also been 
mapped in the subunit sequences. Using electron microscopy, the shape of the receptor 
complex and the arrangement of its subunits have been deciphered (Corringer, Novère, 
and Changeux 2000; Sumikawa et al. 1982; Karlin 2002; Le Novère, Corringer, and 
Changeux 1999; Miyazawa et al. 1999; Unwin 2005; Kao et al. 1984). High resolution 
structure (4.0 Å and 4.6 Å) of the marine ray Torpedo nAChR has been invaluable and 
provided useful insights into the structure of cys-loop LGICs (Miyazawa et al. 1999; 
Unwin 2005). The discovery of the acetylcholine binding protein crystal structure from 
Lymnea stagnalis, has offered detailed three-dimensional information about the 
relative positioning of the principal and complementary part of the ligand-binding site 




neurotransmitter receptors and arguably the most thoroughly characterized of all the 
ligand-gated ion channels. 
The nicotinic acetylcholine receptors are the prototype of the cys-loop family of 
ligand-gated ion channels that also includes ionotropic receptors for 5-hydroxytryptamine 
(5-HT), γ-aminobutyric acid (GABA), glycine, histamine and glutamate (Thompson, 
Lester, and Lummis 2010b).  nAChRs are cell-surface polytopic complexes composed of 
five co-assembled subunit proteins, arranged to form a rosette with a central non-
selective cation conducting pore (Changeux 2012). Each receptor has an extracellular 
ligand-binding domain, cys-loop (two cysteine residues separated by 13 amino acids), six 
loops (A-F), four transmembrane domains (TM1 – TM4) that allows ions to pass across 
the membrane, and an intracellular cytoplasmic domain that plays a role in channel 
conductance and receptor modulation (Figure 2.6). These receptors are assembled from a 
diverse collection of subunits (Sine and Engel 2006; Corringer, Novère, and Changeux 
2000). The subunits include α-subunits which differ from non-α subunits by having 
“vicinal” (adjacent) cysteines residues on the extracellular loop-C. These cysteines are 
believed to be essential in ligand binding and thus, the binding of the ligands occurs at 
the interface of an α-subunit and an adjacent subunit (Kao et al. 1984; Arias 1997). The 
nAChRs can be homomeric (containing five copies of a single α-subunit) or heteromeric 
(multiple subunits with at least 2 α) (Corringer, Novère, and Changeux 2000; Karlin 
2002). nAChRs are expressed in the nervous system, at the neuromuscular 
junction (Changeux and Edelstein 2006) as well as in the non-neuronal cells such as 







Figure 2.6 Structure of nicotinic acetylcholine receptors. A. Three-dimensional protein 
structure (ribbon structure) of individual subunit showing the extracellular, 
transmembrane and intracellular domain. Each nAChR consists of five subunits 
arranged around a cationic channel pore. Representation of the assembled receptor is 
shown viewed from the top and front. All the subunits are shaded in a different color 
differently to indicate clear boundaries. B. The ligand binding site is present at the 
interface of two adjacent subunits. The binding loops and β-sheets are shown in the 
image. The ligand binds between the loops A, B and C from principal subunit and 
loops D, E and F from the complementary subunit. This leads to opening of the cation 
channel that results in prolonged activation of the excitatory nicotinic acetylcholine 
receptors on nematode muscles leading to spastic paralysis and expulsion of worms 
(Thompson, Lester, and Lummis 2010b; Nasiripourdori et al. 2011). 
 
keratinocytes of the skin; suggesting a broader functional spectrum (Macklin et al. 1998; 
Bruggmann et al. 2002; Wang et al. 2003; Wessler et al. 2003). The nAChRs are widely 
distributed throughout the animal kingdom and a large number of nAChR subunits have 
been identified in both vertebrates and invertebrates (Le Novère and Changeux 1995). 
These subunits co-assemble in various combinations, each arrangement conferring 
different functional and pharmacological properties.  Even the precise order and 




(Le Novère, Corringer, and Changeux 2002; Buxton et al. 2014). Thus, the structural and 
functional diversity within this receptor family has made them potential therapeutic 
targets for a wide variety of medical conditions (Millar and Gotti 2009; Jones and Sattelle 
2004). There is kindled interest in development of subtype-selective ligands for 
management of various neurodegenerative disorders such as Alzheimer’s disease, 
Parkinson’s syndrome and schizophrenia (Leonard and Bertrand 2001). In invertebrates, 
nAChRs are also of considerable interest as they are targets for leading insecticides 
(Millar and Denholm 2007) as well as the antiparasitic drugs levamisole, pyrantel and 
monepantel (Abongwa, Martin, and Robertson 2017; Martin et al. 1991). The nAChRs of 
vertebrates and invertebrates share many structural and functional properties. But there 
are important differences in their physiological roles and pharmacological properties 
(Millar and Denholm 2007). 
2.4.1 Vertebrate nAChRs 
Vertebrates possess 17 nAChR subunits (α1–α10, β1–β4, γ, δ and ε) which are 
classified into two subtypes, the ‘muscle’ and the ‘neuronal’ nAChRs (Le Novère and 
Changeux 1995; Pedersen, Bergqvist, and Larhammar 2019). Of the 17 subunits 
identified so far, the α8 subunit is expressed in avian species but not in mammals. The 
muscular ion channels are heteromeric and have a subunit composition of (α1)2 (β)1εδ 
in adults or (α1)2 (β)1γδ in the fetus (Missias et al. 1996). The acetylcholine binding sites 
are located at the α-δ and α-ε interfaces in the muscle type nAChRs. The adjacent subunit 
(δ or γ/ε) also contribute to the agonist binding site, although occupancy of both binding 
sites is required for effective opening of the channel (Nayak and Auerbach 2013; Karlin 




subunits (β2 – β4) (Galzi and Changeux 1995; Dani 2015; Zoli, Pistillo, and Gotti 
2015).  These receptors can be either homopentamers or heteropentamers consisting of 
two or three types of subunits such as (α4)3(β2)2 or (α4)2(β2)3. This enables greater 
diversity in subunit composition, consequently different biophysical and pharmacological 
properties (Gotti, Zoli, and Clementi 2006; Wu, Liu, et al. 2016; Zoli, Pistillo, and Gotti 
2015; Li et al. 2016). Only α-7, α-8, and α-9 subunits reconstitute functional homomeric 
nAChRs in Xenopus oocytes (Couturier et al. 1990; Elgoyhen et al. 1994; Gerzanich, 
Anand, and Lindstrom 1994). The two agonist binding sites in neuronal receptors (α-β 
and α-α interfaces) have different affinities. The α5 and β3 subunits behave as the 
accessory subunits as they do not directly participate in formation of the binding site 
(Kuryatov, Onksen, and Lindstrom 2008). The vertebrate nAChR subunits have been 
further divided into four subfamilies based on sequence similarities and resemblance of 
gene structures (position of the introns in the coding sequence): subfamily I, epithelial 
α9; subfamily II, neuronal α7, 8; subfamily III, neuronal α2–6 and β2–4; and subfamily 
IV, muscle α1, β1, γ, δ, and ε (Le Novère, Corringer, and Changeux 2002; Le Novère and 
Changeux 1995). The neuronal nAChRs modulate a variety of neuronal functions 
including learning, memory, arousal, cerebral blood flow and metabolism (Cordero-
Erausquin et al. 2000; Levin and Simon 1998). Mutations in nAChR subtypes have been 
linked to myasthenia gravis, congenital myasthenia syndrome and certain epilepsies (Itier 
and Bertrand 2002; Steinlein et al. 1995; Lindstrom 2003). Neuronal nAChRs have also 
been implicated in several neurological disorders including attention deficit disorders, 
Alzheimer’s disease, epilepsy, Parkinson’s disease, schizophrenia and Tourette’s 




Bertrand, and Leonard 2000; Picciotto and Zoli 2002). Additionally, nicotine dependence 
observed with consumption of tobacco and smoking is due to nicotine which acts on 
nAChRs (Greenbaum and Lerer 2009; Mansvelder and McGehee 2002; Dani, Ji, and 
Zhou 2001). Thus, these cy-loop ion channels are the focus of intense 
neuropharmacological research as therapeutic targets for various neurodegenerative 
diseases, as well targets to treat alcohol and nicotine dependence. 
2.4.2 Caenorhabditis elegans nAChRs 
Although C. elegans (Clade V) is one of the simplest organisms to employ 
acetylcholine as a neurotransmitter. It possesses the largest and most diverse nAChR 
gene family described to date. The nAChRs are expressed in nerve and muscle cells as 
well as at both synaptic and non-synaptic sites (Jones and Sattelle 2004; Holden-Dye et 
al. 2013). There are 32 nAChR subunits in C. elegans which are divided into five “core” 
groups based on sequence homology (Jones and Sattelle 2004; Bargmann 1998; Holden-
Dye et al. 2013). The groups are UNC-29 group, UNC-38 group, ACR-8 group, ACR-16 
group and DEG-3 group (Figure 2.7). Each group is named after the first subunit to be 
characterized and majority of the subunit genes are denoted acr 
for acetylcholine receptor (Mongan et al. 1998; Jones et al. 2007). Among the 32 
nAChR subunits, 22 have been classified as α. The members of ACR-16 group are 
highly homologous to vertebrate α7–10 nAChR subunits (Mongan et al. 1998; Ballivet 
et al. 1996). The DEG-3 andACR-8 are unique to nematodes while UNC-38 group 
members most closely resemble insect nAChR subunits (Mongan et al. 2002). The UNC-
29-like subunits show similarity to AChR-like Drosophila protein (ARD; non-α subunit) 




receptor subunits show characteristics common to nAChRs. Although, several subunits 
possess unusual modifications that alter their pharmacological properties (Figure 2.8). 
For example, two members of the DEG-3 group, ACR-24 and ACR-5, contain FxCC in 
loop-C instead of the highly conserved YxCC motif, which decreases the affinity for 
acetylcholine (Galzi et al. 1991). In ACR-10, subunits of ACR-8 group and UNC-38 
the YxCC motif is instead replaced by YxxCC (Mongan et al. 1998). The ACR-8 group 
members are the only subunits in which a basic residue (histidine), instead of the 
highly-conserved acidic residue, flanks the TM2 region. All these modifications and 
diversity in key motifs likely results in receptors with different biophysical and 
pharmacological properties (Jones and Sattelle 2004). C. elegans also possesses 
additional 26 subunits denoted as “orphan” subunits which are homologous to nAChRs 
but do not fall within the core groups. None of these subunits are α subunits and their 
function is unknown, except for CUP-4 and LGC-26 which are involved in endocytosis 
(Jones et al. 2007; Patton et al. 2005).  
Different nAChR subunits can combine into four major types of nAChRs in C. 
elegans, viz, levamisole-sensitive, nicotine-sensitive, DEG-3/DES-2 and EAT-2 nAChRs 
(Figure 2.9). These receptor types are essential for a variety of physiological behaviors 
including: feeding, locomotion, reproduction and development. They vary in their 
expression patterns and pharmacological properties. DEG-3/DES-2 receptors are 
localized to non-synaptic regions and the sensory endings of chemosensory neurons 
(Treinin et al. 1998). Levamisole-sensitive and nicotine-sensitive receptors are expressed 





Figure 2.7 Tree showing the five core groups of nAChR subunits (indicated by the 




Figure 2.8 The unusual sequence features of the C. elegans nAChR subunits (Jones and 
Sattelle 2004). A. Alignment of Loop C from various nAChR subunits highlighting 
alterations in the YxCC motif is shown (Tyrosine residue highlighted in purple and the 
vicinal cysteines highlighted in yellow). B. Alignment of cytoplasmic domain of the 
ACR-8 nAChR subunit with various other subunits. The residue important for ion 





the pharyngeal muscles along with a small transmembrane protein, EAT-18 (McKay et 
al. 2004). 
Levamisole-sensitive (L-type) receptors are the most widely explored nAChRs in 
nematodes. They mediate excitatory neurotransmission at the neuromuscular junctions of 
nematodes and constitute a major target for anthelmintic treatments. Two non-α-subunits 
(LEV-1 and UNC-29) and three α-subunits (LEV-8, UNC-38, UNC-63) have been 
identified as important for levamisole sensitivity (Culetto et al. 2004; Jones and Sattelle 
2004; Towers et al. 2005; Boulin et al. 2008; Fleming et al. 1997). Fleming et al. (1997) 
demonstrated that lev-1, unc-29 and unc-38 mediated levamisole resistance and 
reconstituted the receptor in Xenopus oocytes using the subunits. But the expression was 
low with small current responses to levamisole and the responses were inhibited by 
nicotinic antagonists, mecamylamine and neosurugatoxin. The low expression pointed to 
a possibility of involvement of additional subunit. In vivo recordings from C. elegans 
body wall muscles also confirmed the presence of receptors that were sensitive to 
levamisole and were completely blocked by d-tubocurarine (Richmond and Jorgensen 
1999). The locomotion was impaired in UNC-29 and UNC-38 mutants in C. elegans 
(Richmond and Jorgensen 1999), confirming the role of the levamisole-sensitive nAChRs 
in locomotor behavior. Subsequently, additional genes, unc-63 and lev-8 (also called acr-
13), encoding for nAChR subunits were found to be associated with levamisole resistance 
(Culetto et al. 2004; Towers et al. 2005). Further recombinant expression studies revealed 
the requirement of five nAChR subunits in addition to three ancillary proteins, RIC-3, 
UNC-50 and UNC-74, for successful in vitro expression of the heteromeric receptor 




molecular components of the nAChRs. RIC-3 (Resistance to Inhibitors of Cholinesterase) 
is an endoplasmic reticulum transmembrane protein. It acts as a chaperone to promote 
receptor folding, assembly or maturation (Millar 2008; Halevi et al. 2002). The genes, 
unc-50 and unc-74 (uncoordinated), were identified during mutational screening for 
levamisole resistance and mutants of these genes lack high-affinity levamisole binding 
(Lewis et al. 1980). UNC-50 is a transmembrane protein of the Golgi complex that 
prevents lysosomal targeted destruction of the subunits of levamisole sensitive nAChR 
during intracellular trafficking (Eimer et al. 2007). UNC-74 is a thioredoxin containing 
protein closely related to the human Thioredoxin Related Transmembrane protein, 
TMX3. It is required for trafficking the nAChR subunits to the synapses (Haugstetter, 
Blicher, and Ellgaard 2005). The heterologously expressed levamisole-sensitive nAChR 
was strongly inhibited by d-tubocurarine, methyllycaconitine and hexamethonium. 
Dihydro-β-erythroidine and α-bungarotoxin produced only modest blocking effects on 
the L-type nAChR (Boulin et al. 2008). C. elegans body wall muscles also express the 
ACR-8 subunit (Holden-Dye et al. 2013; Touroutine et al. 2005).  It acts as a spare 
subunit for the levamisole sensitive nAChRs and may replace LEV-8 in its absence 
(Hernando et al. 2012). 
 Richmond and Jorgensen (1999) had identified a rapidly desensitizing nicotine 
and acetylcholine sensitive receptor, in addition to levamisole sensitive nAChRs, in C. 
elegans body wall muscles. unc-29 mutants were responsive to nicotine and this response 
was completely blocked by dihydro-β-erythroidine. In wild type worms, the acetylcholine 
response was only about 50% blocked by dihydro- β-erythroidine. Mutants of unc-29 and 




suggesting an equal contribution of the nicotine-sensitive receptors. In C. elegans, the 
nicotine-sensitive nAChR (N-type nAChR) is a homopentamer formed by co-assembly of 
ACR-16 subunits (initially designated Ce21), which is a closely related homologue of the 
vertebrate α-7 subunit (Raymond, Mongan, and Sattelle 2000; Ballivet et al. 1996). N-
type receptors only required RIC-3 only for successfully assembly into a functional ion 
channel. Levamisole did not act as an agonist on the nicotine-sensitive receptor, but 
rather antagonized the acetylcholine mediated responses. Dihydro-β-erythroidine and d-
tubocurarine produced potent antagonistic effects on C. elegans ACR-16.  The receptor is 
relatively insensitive to methyllycaconitine and α-bungarotoxin, both of which are potent 
antagonists of α-7 nAChRs. The heterologously expressed homomeric receptor 
desensitized rapidly following application of acetylcholine or nicotine. Nicotine is more 
potent agonist than acetylcholine of both vertebrate α-7 nAChRs and C. elegans ACR-16 
receptors. However, it is a full agonist on α-7 cation channels but a partial agonist of the 
ACR-16 receptor (Couturier et al. 1990; Raymond, Mongan, and Sattelle 2000; Ballivet 
et al. 1996). Although, no behavioral phenotype is observed in acr-16 mutants, unc-
63:acr-16  and unc-29:acr-16 double mutants in C. elegans exhibit locomotor defects 
which are more severe than single mutants of either unc-63 or acr-16 alone or unc-29 
single mutants (Touroutine et al. 2005; Li et al. 2014). This shows that ACR-16 in 
combination with UNC-63 and UNC-29, components of levamisole-sensitive nAChR, 
contributes to locomotor behavior in the worms. 
The DEG-3 group of nicotinic acetylcholine receptor subunits is only found in 
nematodes (Brown et al. 2006). DEG-3 (degeneration of certain neurons) and DES-2 





Figure 2.9 Proposed stoichiometry of nAChRs in C. elegans and parasitic nematodes. 
The figure shows possible arrangement and subunit combinations for the various nAChR 
types. This is based on in vivo recordings from body wall muscles and the studies on 
heterologously expressed nAChRs in Xenopus oocytes (Holden-Dye et al. 2013). 
 
adjacent genes that form an operon that regulate the coordinated expression of the two 
subunits (Treinin et al. 1998). Neither of the subunits form homomeric channels in 
Xenopus oocytes but when co-expressed, generate a functional heteromeric receptor that 
has strikingly higher affinity for choline than acetylcholine. DEG-3 and DES-2 are 





mutants display defective chemotaxis towards choline. Thus, DEG-3 and DES-2 possibly 
have an unusual role of regulating chemotaxis behavior (Yassin et al. 2001; Jones and 
Sattelle 2004). An aminoacetonitrile derivative, monepantel (AAD-1566), preferentially 
activates nAChR subunits of DEG-3 group, mainly ACR-23, leading to spastic paralysis 
in the worms (Kaminsky and Rufener 2012; Kaminsky et al. 2008). ACR-23 nAChRs are 
expressed in the C. elegans body wall muscles and unidentified neurons in head and tail 
(Kaminsky and Rufener 2012). ACR-23 homomeric receptors expressed in Xenopus 
oocytes responded to monepantel, choline, nicotine, and acetylcholine, with monepantel 
strongly potentiating choline mediated responses (Rufener et al. 2013). ACR-20, another 
member of the DEG-3 group, co-assembles into homomeric nAChRs when 
heterologously expressed in Xenopus oocytes. At low concentrations (< 1 nM), 
monepantel produced positive allosteric modulatory effects on the C. elegans ACR-20 
nAChR, while at high concentrations (> 0.1 µM) the aminoacetonitrile derivative acted as 
a direct agonist of the receptor. 
C. elegans pharyngeal muscles express a non-alpha nAChR subunit, EAT-2, 
which is required for regulation of pharyngeal pumping. It is localized postsynaptically 
on pharyngeal muscles, between pm4 and pm5, which is also the site of the MC motor 
neuron and its synapse. The nAChR subunit interacts with a small protein, EAT-18, 
which is also expressed in the pharyngeal muscles (McKay et al. 2004; Avery 1993a; 
Raizen, Lee, and Avery 1995). The pharyngeal nAChRs are not a well-exploited target 






2.4.3 Parasitic nematode nAChRs 
The nematode nAChRs on muscle are the target of the cholinergic anthelmintics 
including levamisole, pyrantel, morantel and oxantel.  These compounds activate these 
ligand-gated cation channels, leading to prolonged muscle contraction and spastic 
paralysis of the parasite (Aceves, Erlij, and Martínez‐Marañón 1970; Aubry et al. 1970; 
Martin et al. 1991; Dale and Martin 1995). The nAChR of parasitic nematodes are 
different from the C. elegans receptors in their subunit composition and resulting 
biophysical and pharmacological properties. The parasitic nematode A. suum (Clade III) 
has been extensively used in the characterization studies of the native body wall muscle 
nAChRs, largely due to their large muscle cells. Pennington and Martin (1990) for the 
first time described acetylcholine-activated single channel currents in the Ascaris suum 
muscles. They used inside-out patch clamp recordings and revealed the presence of at 
least two acetylcholine-activated channel types. Using single channel patch-clamp 
recording techniques, Robertson and Martin (1993), examined the levamisole-activated 
channels in A. suum muscle vesicles. Low levamisole concentrations (1–10 µM) caused 
channel opening, while high levamisole concentrations (30 and 90 µM) caused an 
additional flickering channel block. The channel conductance was in the range of 18–50 
pS. Pyrantel and oxantel were also shown to act as agonists and open channel blockers of 
the nAChRs by using patch clamp single-channel recordings from muscle vesicles of 
somatic muscle cells of Ascaris suum (Robertson et al. 1994; Dale and Martin 1995). 
Robertson et al. (2002) and colleagues used paraherquamide and its semisynthetic 
derivative, 2-deoxyparaherquamide or derquantel, to distinguish cholinergic receptor 




compounds on muscle contractions elicited by nicotine, levamisole, pyrantel and 
bephenium, three subtypes of muscle nAChRs were identified. These nAChR types are 
the L-type preferentially activated by levamisole, the N-type preferentially activated by 
nicotine and the B-type preferentially activated by bephenium. The channel conductance 
and mean open times for these nAChR types have been resolved at the single-channel 
level by using various agonists and antagonists (Qian, Martin, and Robertson 2006). The 
single channel conductance and mean open times are respectively, 24 pS and 0.6 ms for 
the N-type, 35 pS and 0.9 ms for the L-type, and 45 pS and 1.3 ms for the B-type (Figure 
2.10A).  The N-subtype was activated by oxantel, methyridine; L-subtype by pyrantel 
and competitively antagonized by paraherquamide; B-subtype was competitively 
antagonized by paraherquamide and derquantel.  Unlike C. elegans, the three types of 
nAChRs in A. suum show subtle differences in agonist pharmacology. For example, 
levamisole not only activates L-type channels but can also stimulate the opening of N- 
and B-type channels to a lesser extent. Similar, bephenium is not just selective for B-type 
channels but also activates some L-type but not N-type channels. A high concentration of 
an nAChR agonist, such as levamisole can lead to activation of all three nAChR types in 
A. suum (Robertson et al. 2002; Qian, Martin, and Robertson 2006; Martin et al. 2004). 
In Oesophagostomum dentatum, a clade V nematode, an additional fourth 
levamisole-activated subtype with a single-channel conductance of 40 pS has been 
revealed (Figure 2.10B) (Robertson, Bjorn, and Martin 1999). The G35 channel, present 
in levamisole-sensitive (SENS) parasites, was not present in levamisole-resistant (LEVR) 
parasites. Thus, like A. suum, the G35 channel is the L-type nAChR in O. dentatum. In 




receptors were present there was reduction in the percentage of active patches and 
probability of channel opening (Po) in anthelmintic resistant worms (Robertson, Bjørn, 
and Martin 2000). Based on single-channel recording, the parasitic nematodes display a 
high level of complexity and heterogeneity in nAChRs. 
 Buxton et al. (2014) characterized the effects of varying subunit composition and 
stoichiometry of four O. dentatum nAChR subunits on the pharmacological profile of the 
cation channel expressed in Xenopus oocytes (Figure 2.10C). The authors identified four 
distinguishable nAChR subtypes based on agonist sensitivities, the pyrantel (Pyr)-nAChR 
composed of UNC-29 and UNC-63 subunits, the pyrantel/tribendimidine (Pyr/Tbd)-
nAChR composed of UNC-29, UNC-63 and UNC-38 subunits, the acetylcholine (ACh)-
nAChR composed of UNC-29, UNC-63 and ACR-8 subunits, and the levamisole (Lev)-
nAChR composed of UNC-29, UNC-63, UNC-38 and ACR-8 subunits. The LEV-8 
subunit has not been detected in any nematode parasite, however, a related subunit, ACR-
8, can be used to reconstitute the receptors. It is plausible the L- and N-type nicotinic 
receptors in the pathogenic clade III nematodes may be different from that found in C. 
elegans. The single channel conductance and mean open times observed for levamisole-
sensitive channels (35 pS and 2.4 ms, respectively) were the same as previously 
identified in vivo. Even varying the subunit stoichiometry of the pyrantel-nAChR from 
1:5 ratio of UNC-29 and UNC-63 subunits to 5:1 produced change in agonist 
pharmacology. The responses to pyrantel and tribendimidine were significantly increased 
with 1:5 stoichiometry, and when the ratio was reversed, the nicotine and levamisole 





Figure 2.10 A. Summary diagram of nAChR subtypes on Ascaris suum somatic muscle 
cell membrane. The single channel and pharmacological properties of each subtype are 
indicated. N-subtype prefers nicotine, L-subtype prefers levamisole and B-subtype 
prefers bephenium. The subtypes show different sensitivities to the competitive 
antagonists paraherquamide (PHQ) and 2-desoxoparaherquamide (2DPHQ) (Qian, 
Martin, and Robertson 2006). B. Frequency histograms of single channel conductance for 
SENS and LEVR parasites (Robertson, Bjorn, and Martin 1999). C. Summary of the four 
O. dentatum nAChR subtypes based on different subunit composition reconstituted in 
Xenopus laevis oocytes. The pyrantel (Pyr)-nAChR is composed of UNC-29 and UNC-63 
subunits, the pyrantel/tribendimidine (Pyr/Tbd)- nAChR is composed of UNC-29, UNC-
63 and UNC-38 subunits, the acetylcholine (ACh)- nAChR is composed of UNC-29, 
UNC-63 and ACR-8 subunits, and the levamisole (Lev)- nAChR is composed of UNC-
29, UNC-63, UNC-38 and ACR-8 subunits (Buxton et al. 2014). 
 
The heteromeric levamisole-sensitive nAChR can be recapitulated by expressing 
A. suum UNC-38 and UNC-29 in Xenopus oocytes (Williamson et al. 2009). Both the 
subunits are colocalized in the body wall muscles of the nematode. The relative 
expression levels of the two subunits, altered the sensitivity of the agonists for the 
receptor. The oocytes injected with 5:1 and 1:5 ratio of UNC-38:UNC-29 produced more 
robust current responses as well a striking differences in agonist pharmacology as 
compared to ratios of 10:1 and 1:10. When the UNC-38:UNC-29 ratio was 5:1, nicotine 




full agonist and nicotine a partial agonist when the ratio was reversed to 1:5. With the 5:1 
ratio, oxantel produced agonistic effect but not pyrantel, while with the 1:5 ratio, oocytes 
responded to pyrantel but not oxantel.  
Haemonchus contortus, a clade V nematode, possesses genes encoding UNC-38, 
UNC-29, UNC-63 and ACR-8 that assemble into the heteromeric L-type nAChRs. No 
orthologue of the C. elegans LEV-8 L-AChR subunit was identified in H. contorus 
(Neveu et al. 2010). ACR-8 nAChR subunit is closely relate to the lev-8 gene and has 
been implicated in the molecular mechanisms leading to levamisole resistance (Boulin et 
al. 2011). Blanchard et al. (2018) have demonstrated the critical role of the ACR-8 
subunit in the levamisole sensitivity of parasitic nematodes using heterologous expression 
systems and gene silencing techniques.  By varying the subunit composition, two types of 
L-AChRs, Hco-L-AChR1 and Hco-L-AChR2, can be functionally reconstituted in vitro 
(Boulin et al. 2011; Charvet et al. 2012). The co-expression of UNC-38, UNC-29, UNC-
63 and ACR-8 constitutes the Hco-L-AChR1. This L-nAChR subtype was more sensitive 
to levamisole than acetylcholine and weakly sensitive to pyrantel, bephenium and 
nicotine. The Hco-L-AChR2 requires only three subunits, UNC-38, UNC-29 and UNC-
63. This subtype was more sensitive to pyrantel and acetylcholine than levamisole and 
insensitive to bephenium. Gene duplication of the unc-29 L-AChR subunit gene has led 
to the expression of four copies of the unc-29 gene (Hco-UNC-29.1, Hco-UNC-29.2, 
Hco-UNC-29.3 and Hco-UNC-29.4) in H. contortus (Duguet et al. 2016; Neveu et al. 
2010). This adds to the complexity and diversity of the nAChRs in the parasitic 
nematodes. Three functional receptor types with different pharmacological profiles were 




receptor. Hco-UNC-29.2 failed to reconstitute a functional receptor. When UNC-29.1 
was used, the L-type nAChR (L-AChR1.1) was more responsive to levamisole than 
acetylcholine and mecamylamine was a potent antagonist of L-AChR1.1. When UNC-
29.3 was used instead of UNC-29.1 (L-AChR1.3), the acetylcholine response was greater 
than the levamisole and mecamylamine was a less potent antagonist. With UNC-29.4 (L-
AChR1.4), levamisole and acetylcholine responses were about equal and mecamylamine 
was more potent. 
Abongwa, Martin, and Robertson (2017) reconstituted a homomeric nAChR, 
ACR-16, from A. suum in the Xenopus oocytes. The ACR-16 nAChR is most closely 
related to α-7 vertebrate receptors. Strikingly, the Asu-ACR-16 was expressed not only 
in the somatic muscle but also in the pharynx, ovijector, head and intestine implying the 
nAChR may have additional tissue-related functions in the worm. Similiar to C. elegans, 
the A. suum channel was most sensitive to nicotine but insensitive to levamisole and 
pyrantel. Unlike the C. elegans ACR-16 homologue, the A. suum channel was highly 
sensitive to mecamylamine but moderately sensitive to hexamethonium and DhβE 
(Briggs, McKenna, and Piattina-kaplan 1995). ACR-16 homologues from both the 
species were nearly insensitive to α-bungarotoxin, but highly sensitive to d-tubocurarine 
(Zhao et al. 2003). In contrast, α-7 vertebrate receptors are highly sensitive to α-
bungarotoxin. The positive allosteric modulators of α-7 (ivermectin, genistein and 
PNU120596) produced inhibitory effects on Asu-ACR-16 (Ballivet et al. 1996). Asu-
ACR-16 has 50 times smaller relative calcium permeability ratio than that of the α7 
receptor (Seguela et al. 1993). In Brugia malayi, a clade V worm, knockdown of acr-16: 




function of the ACR-16 homologue in the filarial worm. ACR-16 homologue distribution 
is more widespread in A. suum. It is plausible that the ACR-16 nAChRs not only 
regulates neurotransmission in A. suum but also serves other tissue-related functions 
including reproduction and digestion.	 
2.4.4 nAChR auxiliary subunits 
Biogenesis of multimeric membrane proteins, including nAChRs, is a complex 
and tightly regulated multistep process. It involves subunit folding, assembly of subunits 
into pentamers, trafficking to the cell surface, and finally, targeting to specific subcellular 
compartments. As mentioned before, ancillary or chaperone proteins, including RIC-3, 
UNC-50 and UNC-74, ensure proper protein folding, subunit assembly, and trafficking of 
the pentameric complexes to the cell surface in a subtype-dependent manner (Halevi et al. 
2002; Haugstetter, Blicher, and Ellgaard 2005; Eimer et al. 2007). Another unique group 
of proteins, known as the auxiliary proteins, existing within the biological matrix of 
multimeric proteins has been identified for ionotropic receptors. These proteins directly 
associate with the ion channels and affect various aspects of biological functions, 
including forward trafficking, surface delivery and gating kinetics. The presence of 
auxiliary proteins has helped in addressing the discrepancies observed when comparing 
recombinant and native biophysical properties and pharmacological sensitivities of the 
ion channels (Isom, De Jongh, and Catterall 1994; Adelman 1995). There are four criteria 
which define the framework for classifying auxiliary proteins (Yan and Tomita 2012): 
i) An auxiliary protein should not be a pore-forming subunit and should not form 




ii) An auxiliary protein should interact with the pore-forming protein in a direct, stable 
and specific manner.  
iii) The natural interaction of auxiliary subunit with the pore-forming subunit must result 
in a functional consequence. Specifically, the auxiliary protein must modulate the 
channel properties and/or assist in the trafficking of the receptor in heterologous cell 
systems. 
iv) An auxiliary subunit must have demonstrable biological impact on certain aspects of 
native channel function in vivo. 
The ancillary and auxiliary proteins have different roles in controlling channel 
functions in vivo. An ancillary or a chaperone assists with folding, assembly and 
trafficking of a protein complex. The interaction of the ancillary protein with the channel 
subunits is transient and not stable. Therefore, these proteins do not meet the criteria of 
an auxiliary subunit. 
The auxiliary proteins were first identified for voltage-gated ion channels in the 
early 1990s (O'Malley and Isom 2015; Adelman 1995; Gurnett and Campbell 1996; 
Isom, De Jongh, and Catterall 1994). However, it was not until 2000s that the first 
auxiliary protein, Stargazin, a small transmembrane AMPA receptor regulatory proteins 
(TARPs), was identified for the glutamate-gated AMPA receptor (Chen et al. 2000; Osten 
and Stern-Bach 2006; Ziff 2007; Vandenberghe, Nicoll, and Bredt 2005). Since then 
various structurally diverse auxiliary proteins have been associated with both AMPA and 
kainate glutamate-gated receptors (Tomita 2010; Greger, Watson, and Cull-Candy 2017; 




In C. elegans the GLR-1 receptor, an AMPA glutamate receptor homologue, is 
required for glutamate-gated current response in a subset of interneurons that control 
avoidance behaviors. C. elegans expresses the evolutionarily conserved TARP proteins, 
STG-1 and STG-2 (stargazin-like protein), that act as auxiliary protein for GLR-1 
receptors. These TARP homologues are required for regulation of only channel 
properties, but not trafficking. A second class of AMPAR auxiliary protein SOL-1 
(Suppressor Of Lurcher movement defect), has also been identified in C. elegans (Zheng 
et al. 2004). It is a type I transmembrane protein with an evolutionarily conserved CUB 
domains in the extracellular domain. SOL-1 mutants lead to loss of GLR-1 activity in C. 
elegans and it has been shown to regulate the rate of GLR-1 desensitization as well as its 
rate of recovery from desensitization. STG-1 and STG-2 with SOL-1, are essential for 
GLR-1 activity in vivo as well as in recombinant systems. SOL-1 can coassemble into a 
tripartite complex with STG-1 and GLR-1 in heterologous cells to reconstitute glutamate-
gated currents, but interestingly, no mammalian homologue of SOL-1 has been identified 
so far (Walker et al. 2006; Wang et al. 2008). Another class of auxiliary protein, SOL-2, 
contributes to the GLR-1 complex and modifies the GLR-1 kinetics and pharmacology 
(Wang et al. 2012). SOL-2 is a transmembrane protein with two CUB-domains and is 
homologous to vertebrate NETO proteins, auxiliary proteins of kainate receptors. 
Overall, GLR-1 along with the associated TARP proteins, STG-1 and STG-2, interacts 
with a protein complex containing SOL-1 and SOL-2 at the plasma membrane. Loss of 
any of the component proteins results in significant alteration of channel properties. 




changes in the relative numbers of auxiliary proteins present at the postsynaptic 
membrane (Wang et al. 2008; Wang et al. 2012; Walker et al. 2006; Zheng et al. 2004). 
In contrast to glutaminergic receptors, only one auxiliary subunit, MOLO-1 
(modulator of levamisole receptor-1), has been identified for the nicotinic acetylcholine 
receptors in C. elegans (Boulin et al. 2012). It is an evolutionarily conserved single-pass 
transmembrane protein with a single extracellular globular domain, the TPM domain. 
The protein regulates the levamisole-sensitive nAChRs function through direct physical 
interaction. Null mutants of the protein results in impaired locomotion and loss of 
sensitivity to levamisole. MOLO-1 affects synaptic transmission in the worms and 
promotes channel opening in the heterologously expressed receptors. The existence of 
auxiliary subunits for nAChRs further amplifies their heterogeneity and pharmacological 
diversity. This also expands the repertoire of potential drug targets for nAChR 
complexes.  
 
2.5 Caenorhabditis elegans  
C. elegans is a small ~1mm long, transparent, free-living rhabditid nematode that 
was first described by Emile Maupus (Maupas 1900). The name has been derived from 
Greek Caeno (recent), rhabditis (rod-like) and Latin elegans (nice). The non-parasitic 
nematode is present in the soil, especially decaying organic material, where it survives by 
feeding on microbes such as bacteria. The wild-type C. elegans are sexually dimorphic; 
worms are either self-fertilizing hermaphrodites or males exhibiting differences in the 
reproductive functions and posterior anatomy (Chalfie 1984). The adult worms are 
bilaterally symmetrical with unsegmented cylindrical body shape that is tapered at the 




pseudocoelomic space.  The body wall consists of cuticle, hypodermis, excretory system, 
neurons, and muscles while the inner tube comprises the pharynx, gut and the 
reproductive system. The adult hermaphrodite has 959 somatic cells, 30% (302) of which 
are neurons. On the other hand, an adult male has 1031 somatic cells and 381 neurons; 
the extra neurons are dedicated mostly to reproductive behavior (White 1988; Sulston et 
al. 1983). Despite its anatomical simplicity, the worm displays a large repertoire of 
behaviors including locomotion, foraging, feeding, defecation, egg laying, sensory 
responses and complex behaviors including mating, social behavior and simple forms of 
learning. Remarkably, all these behaviors are accomplished by the small number of 
neuronal cell nuclei present in the adult nervous system (de Bono 2003; Bargmann 1993). 
C. elegans is an extraordinarily powerful model system. The bacterivorous worm 
was used for the first time in early 1960’s as a simple metazoan model to study 
developmental biology and neurobiology by Sydney Brenner (Brenner 1973). Over time 
this remarkable expression system has addressed many fundamental questions in multiple 
fields of biology concerning both parasites and humans (Leung et al. 2008; Teschendorf 
and Link 2009; Newman et al. 2017; Nussbaum-Krammer and Morimoto 2014; 
Alexander, Marfil, and Li 2014; Ma et al. 2018; Buckingham, Partridge, and Sattelle 
2014; Katiki, Ferreira, et al. 2011; Geary and Thompson 2001). It has a number of 
features that foster its value as a biological research tool and enables experimental use. 
The small size allows large numbers of worms to be easily cultivated in a small space 
including microtiter plates. It can easily thrive on agar plates or in liquid media 
supplemented with a bacterial diet, making it convenient and economical to maintain in 




which can be stored indefinitely in liquid nitrogen making it possible to possess and 
archive an unlimited collection of mutants (Stiernagle 2006). The relatively short life 
cycle (~3.5 days), quick generation time with high progeny number (~300) and short life 
span (~ 2 weeks) renders it amenable to high-throughput manipulations. The transparent 
body of the non-parasitic nematode allows clear observation of all the body cells 
facilitating developmental and cell biology research. (Brenner 1973; John 1988; Sulston 
et al. 1983; Bürglin, Lobos, and Blaxter 1998; Riddle et al. 1997). Studies that utilize 
fluorescent proteins including in vivo electrophysiological recordings, mapping of 
synaptic and cell to cell contacts and optogenetic explorations are greatly aided by this 
physiological property (Kerr 2006; Husson, Gottschalk, and Leifer 2013; Goodman et al. 
2012). The hermaphrodite nematode was the first multicellular organism to have its 
whole genome sequenced (Consortium 1998). The highly accurate, complete and well-
annotated genome sequence and vast library of mutant strains makes C. elegans 
compliant to a plethora of well-established genetic manipulations and alterations 
(Kaletta and Hengartner 2006; Lamitina 2006). It is also possible to raise genetically 
identical populations without the risk of inbreeding depression from C. elegans as they 
reproduce by self-fertilization (Rieckher et al. 2009). Furthermore, the nervous system 
of C. elegans is small and tractable. It provides a unique opportunity to unfold the 
complex behaviors at the levels of neural circuitry and genes without the interference of 
pleiotropic effects that are often seen in other model organisms (Rankin 2002; Corsi 
2006). 
There has been an increased interest in identifying novel anthelmintic targets 




for helminth studies is posed by the complicated life cycles with reliance on host in vivo 
models, wide range of size and diverse activity of parasitic nematodes, lack of in vitro 
culture systems and high expenditure involved in maintenance of in vivo models for 
many parasitic species. The inherent simplicity and extensive toolkit available for C. 
elegans offers great promise for antiparasitic drug discovery. C. elegans not only shares 
morphological similarities with parasitic nematodes but displays sufficient conservation 
of biological characteristics and regulatory processes including protective cuticle, dauer 
stages, biochemical adaptations to extreme conditions, molting and reproduction that are 
divergent from mammalian host species. Parasitic nematodes also share physiological 
and pharmacological characteristics with C. elegans which is an important consideration 
for drug discovery (Holden-Dye and Walker 2014). The majority of the marketed 
anthelmintic drugs are effective against C. elegans which highlights the validity of the 
worm for parasitic nematode research (Burns et al. 2015; Kaminsky et al. 2008; Holden-
Dye and Walker 2014). The value of this free-living nematode for comparative functional 
genomics and transgenesis studies has also been unequivocally demonstrated (Britton and 
Murray 2006).  WormBase, founded in 2000, is an excellent comprehensive source for 
C. elegans biology, proteomics and gene information (http://www.wormbase.org). 
This centralized public online platform helps to prioritize hits for target identification. 
C. elegans has proven instrumental in providing insights into mechanism of action and 
resistance of various anthelmintic agents including cholinergic anthelmintics and 
avermectins (Kaminsky et al. 2008; Driscoll et al. 1989; Kaletta and Hengartner 2006; 
Lewis et al. 1980; Rufener et al. 2013; Dent et al. 2000; Jones, Buckingham, and 




understanding of parasite biology and its utility as a model organism for discovery of 
anthelmintics is undeniable. 
2.5.1 C. elegans pharynx  
C. elegans is a microbivores filter feeder and the feeding motion is under the control of 
the pharynx. It is a prominent feature in the head region that connects the buccal cavity 
and the intestine (Avery and Horvitz 1989; Albertson and Thomson 1976). The pharynx 
is an encapsulated myogenic neuromuscular organ with similarities to the vertebrate and 
invertebrate heart that pumps throughout the life of the worm. It undergoes a rhythmic 
cycle of contraction and relaxation that helps in drawing bacteria into the lumen, grinding 
and transporting them into the intestine. The feeding behavior is tightly regulated by a 
complex interplay of neurotransmitters, neuromodulators and electrically coupled 
muscles (Avery and Horvitz 1990; Albertson and Thomson 1976). Feeding is vital for 
survival and thus targeting this behavior in nematodes has pharmaceutical relevance. 
C. elegans is physiologically and pharmacologically related to many parasitic nematodes 
(Holden-Dye and Walker 2014). Thus, discovery of pharyngeal targets and associated 
drugs that inhibit feeding in this species should generalize to other nematode species of 
clinical importance. 
2.5.2 Anatomy of C. elegans pharynx  
 Albertson and Thomson (1976) performed ultrastructural analysis, using serial 
section electron micrographs, to reconstruct the anatomy of the C. elegans pharyngeal 
cells and their respective neural circuitry. The pharynx is 100µm long tubular, bilobed 
structure with a diameter of approximately 20µm at its widest. It is connected to the 




entire structure is self-contained, encased in specialized basal lamina that isolates it from 
the pseudocoelom. It has a simple anatomy consisting of three functional units, namely, 
the corpus (divided into procorpus and metacorpus/anterior bulb), isthmus and the 
terminal/posterior bulb (Figure 2.11B). The pharyngeal lumen and buccal cavity are lined 
by cuticle and is continuous with the outer cuticle of the body. The lumen of the pharynx 
is triangular anteriorly and in the procorpus it becomes triradiate, with tubular apices. The 
procorpus is completely closed posteriorly while the metacorpus is slightly more open. 
The tubular apices reappear briefly at the anterior of the isthmus. The cuticle forms 
specialized structures that serves as sieves in the anterior of the procorpus and grinder in 
the terminal bulb. The pharynx has its own muscles, nervous system, gland cells and 
structural cells. The mature pharynx is composed 62 cells containing 80 nuclei which 
includes 20 muscle cells of anatomical types (37 nuclei) connected by 8 gap-junction, 9 
marginal cells, 9 epithelial cells, 4 gland cells (5 nuclei) and 20 neurons of 14 anatomical 
types (Hall and Altun 2008).  
The muscle cells are grouped into eight separate segments (pm1-8). These are 
arranged as eight consecutive rings encircling the pharynx. The corpus comprises of pm1 
through pm4 forming the anterior part and its purpose is to draw in and trap the bacteria. 
The isthmus, the muscle pm5, is the middle part and regulates the flow of food from the 
corpus to the terminal bulb. The isthmus is surrounded by the large somatic nerve ring. 
The terminal bulb is formed from muscles pm6 through pm8 and connects to the 
intestine by the pharyngeal-intestinal valve or cardia. Pm6 and pm7 secrete a thick, 
ridged cuticle which forms the grinder which facilitates the breaking up of the bacteria 




The pharyngeal muscle cells of each segment are separated from each other by 
three marginal cells. The nine marginal cells are arranged in sets of three cells (mc1-
mc3). Together, the muscles cells and marginal cells form a single-cell-thick epithelial 
tube with trifold symmetry (two bilateral symmetrical left and right subventral sides, and 
one dorsal side). The muscle cells communicate by a network of desmosomes or gap 
junctions. These exist between muscles and marginal cells, and between neighboring 
marginal cells (Albertson and Thomson 1976). The gap-junctions are made up of 
innexins, pore forming proteins that express hexameric hemichannels. These 
hemichannels confer a high degree of electrical connectivity and are required for 
myogenic excitation and neuronal modulation (Altun et al. 2009; Phelan 2005; Franks et 
al. 2006). The gap-junctions divide the pharyngeal muscle membranes into apical 
surfaces which faces the lumen and the basal surfaces which faces the pseudocoelom. 
The longitudinal pharyngeal nerve cord is located in a deep groove formed by syncytial 
muscle cells on the basal side. The pharynx is not covered by an epithelial sheet but is 
surrounded by a narrow ring formed by nine epithelial cells that connects with the 
mouth opening (Albertson and Thomson 1976). These cells contain filaments that 
anchor the basement membrane to the cuticle. Two sets of gland cells, g1 and g2, 
distinguished by the fine structure of the cytoplasm are found in the second bulb of the 
pharynx. The g1 type have two cells with three nuclei and lamellar cytoplasm while the 
other set, g2, has two cells with two nuclei have clearer cytoplasm with vesicles. These 
cells open into the lumen via a short cuticular duct. The gland cells secrete vesicles just 




contain mucoids (Smit, Schnabel, and Gaudet 2008; Albertson and Thomson 1976; Hall 
and Hedgecock 1991).  
The nervous system of pharynx is a self-contained, nearly autonomous system as 
it makes a connection with only one bilaterally symmetrical pair of extrapharyngeal 
neurons (Albertson and Thomson 1976).  It is composed of 20 neurons, mostly 
unbranched unipolar and bipolar cells, and accounts for all chemical synapses onto 
pharyngeal muscle. Based on their physiological or behavioral functions they have been 
classified into five classes of motor neuron (M1-M5), six classes of interneurons (I1-I6), 
two neurosecretory motor neurons (NSM), a motor interneuron (MI) and a pair of 
neurons which innervate marginal cells (MC) (Figure 2.11C). These neurons are 
contained in folds of the pharyngeal muscle basal membrane, between the muscle and 
the basal lamina. 
2.5.3 Feeding behavior in C. elegans  
Feeding in C. elegans is achieved by a rhythmic pumping motion of the 
pharynx (Avery and Shtonda 2003; Doncaster 1962) (Figure 2.11D). The electrically 
coupled pharyngeal muscle cells pump throughout the life cycle of the worm except 
during molting or dauer larval stage. Normal feeding consists of two stereotyped 
motions: pumping, a contraction-relaxation cycle involving the corpus, anterior half of 
the isthmus and terminal bulb; and the posterior isthmus peristalsis.  A pump represents a 
near-simultaneous contraction of the muscles of the corpus, anterior isthmus and terminal 
bulb followed by near-simultaneous relaxation. The corpus and anterior isthmus have 
two functions, one to trap food and the other to transport food. The pharyngeal lumen 





Figure 2.11 A. Anatomical drawing of a male C. elegans nematode (modified from 
https://en.wikipedia.org/wiki/File:C_elegans_male.svg). B. Graphic representation of the 
pharynx highlighting the corpus, the isthmus and the terminal bulb. Transmission electron 
microscope sections through various parts of the pharyngeal lumen are shown in B.1 along 
with the section levels indicated in the micrograph of the pharynx shown in B.2. The arrows 
in the procorpus section (arrows) indicates the channels seen at the three corners of the 
lumen. In the metacorpus section the two-ventral gland (Gl) openings and M3 cell bodies 
can be seen. Bacteria (arrows) are seen in channels while the rest of the lumen is structured 
as a sieve. The TEM section of the isthmus is shown at the level of the excretory duct. 
Grinder can be seen in the section of the terminal bulb grinder (modified from 
doi:10.3908/wormatlas.1.3). C. The image showing organization of the pharyngeal 
system.  The contraction-relaxation cycle of the pharyngeal muscle is regulated by the 
pharyngeal interneurons and motor neurons. A subset of the 20 pharyngeal neurons is 
depicted along with their major neurotransmitter phenotype. The pharyngeal nervous 
system is connected to the extrapharyngeal system by a gap junction linking RIP 
(ring/pharyngeal interneuron) to I1. The neurotransmitters released from neurons within 
the pharyngeal system are also shown (Dallière et al. 2017). D. A diagram showing 
pumping behavior in C. elegans (anterior end is left). During a pump, food enters via the 
corpus, which is then transferred along the isthmus via posteriorly propagating peristaltic 
waves. The food is broken up by the cuticular grinder in the terminal bulb during the 





pharyngeal muscles are radially oriented; contraction pulls the lumen open to a triangular 
cross-section, sucking in liquid and suspended bacteria from outside. The posterior 
isthmus remains closed during this period of the cycle; it separates the corpus and 
anterior isthmus from the terminal bulb. The contraction of the terminal bulb muscles 
rotates the grinder plates which breaks up the bacteria and the food is returned to the 
lumen.  Following contraction, there is a near-simultaneous relaxation of the muscles and 
the grinder returns to its resting position. This closes the lumen of the corpus and anterior 
isthmus, resulting in expulsion of liquid while retaining bacteria. The corpus contracts 
and relaxes as a unit but the anterior isthmus contracts in a wave that proceeds from 
anterior to posterior. In addition, these motions of the anterior isthmus are slightly 
delayed, resulting in a net posterior transport of the food particles during a pump 
(Seymour, Wright, and Doncaster 1983). During the next contraction and relaxation 
cycle, the trapped bacteria are carried in a posterior direction by the influx of liquid. With 
repeated pumps, the bacteria are transported further posteriorly in the isthmus. The 
second motion, isthmus peristalsis, is a posterior-moving peristaltic wave of contraction 
in the posterior isthmus that carries food accumulated in the anterior isthmus back to the 
terminal bulb and intestine. The isthmus peristalsis typically occurs every third to fourth 
pump following the completion of main relaxation (Avery and Horvitz 1987). 
2.5.4 The pharyngeal muscle action potential 
The pharyngeal pumping behavior is a consequence of a single muscle action 
potential. The pharyngeal muscles generate myogenic rhythm and the pharyngeal 





Figure 2.12 An image of a normal electropharyngeogram (EPG) from C. elegans. 
Different phases of the EPG are indicated (Avery, Raizen, and Lockery 1995). 
 
release (Trojanowski, Raizen, and Fang-Yen 2016). The action potential generated by 
pharyngeal muscles are comparable to the vertebrate ventricular myocardium; they are 
long-lasting and have three phases, called E for excitation, P for plateau, and R for 
repolarization (Figure 2.12). 
 Raizen and Avery (1994) performed the first extracellular recordings, termed 
electropharyngeograms or EPGs; Avery, Raizen, and Lockery (1995) pioneered the 
technique to study pharyngeal excitation in C. elegans. EPGs provide information 
regarding the rate of pharyngeal pumping, duration of each pump and the activity of 
neurons within the pharyngeal nervous system. A typical EPG begins with excitation, 
viewed as a rapid rise in the membrane potential to 30-40 mV from the resting value of -
40 to -50 mV. This E phase is divided into two components; the initial part (E1), which 
is a small excitatory postsynaptic potential associated with activation of MC motoneuron, 
immediately followed by a large depolarizing spike (E2).  This is followed by a plateau 




spike, R1, terminates the plateau phase with a drop in the membrane potential to more 
negative values than resting membrane potential. R1 represents the repolarization of the 
corpus, which is followed by a much smaller repolarizing spike, R2, associated with 
repolarization of the terminal bulb. Between E2 and R1, inhibitory postsynaptic 
potentials (I potentials) of varying amplitudes are often observed. Each contraction-
relaxation cycle corresponds to a single muscle action potential. EPG amplitude and 
shape is dependent on the relative placement of the recording electrode and the resistance 
of the seal making it difficult to compare the magnitude of pharyngeal potentials between 
individual worms (Cook, Franks, and Holden-Dye 2006).  
2.5.5 Role of pharyngeal nervous system in regulation of feeding  
The pharyngeal nervous system is not essential for pumping, but as with the 
heart, serves a modulatory role. Using laser ablation, extensive analysis of mutants and 
electrophysiological recordings, key neurons required for efficient feeding have been 
identified (Figure 2.10C). These include M3, M4, MC, I1, I5 and NSM; physiological or 
behavioral functions have been defined for these neurons (Avery and Horvitz 1989, 1987; 
Avery 1993b; Raizen, Lee, and Avery 1995). 
M3 motoneurons are a bilaterally symmetric pair of motor neurons, which 
primarily synapse onto the pm4 cells. They have free subcuticular endings in the 
metacorpus, suggesting they may be proprioceptive sensory neurons (Albertson and 
Thomson 1976). M3s receive chemical synaptic inputs from I2, I3, I4, I5, M1 and NSM 
but do not appear to have strong synaptic inputs onto any neurons. These motoneurons 
are glutamatergic and generate fast inhibitory post-synaptic potentials (IPSPs) in response 




(Avery 1993b; Raizen and Avery 1994). They regulate the pumping duration by 
triggering the end of a pump by initiating pharyngeal relaxation which is important for 
effective trapping of bacteria (Avery 1993b). These actions are mediated through 
glutamate-gated chloride channels formed by avr-15 (avermectin resistant gene). 
Mutations in avr-15 eliminates both the M3 transmission as well as the responses to 
glutamate. A chloride-dependent depolarizing current dependent on avr-15 was observed 
in response to exogenously applied glutamate during intracellular recordings from 
pharyngeal muscles (Dent et al. 2000; Dent, Davis, and Avery 1997). Heterologously 
expressed avermectin-sensitive glutamate channels from C. elegans were found to be 
irreversibly opened by avermectin (Cully et al. 1994b). 
M4 motorneuron cell bodies lie at the level of nerve ring and they form synapses 
with the posterior part of the isthmus, pm5 and g1 gland cells. M4 receives chemical 
inputs from I3, I5 and I6.  This motorneuron is necessary for posterior isthmus 
peristalsis and regulate the swallowing motion of the isthmus (Albertson and Thomson 
1976). M4 ablated worms fail to grow since they swallow little to no food as the posterior 
isthmus remains relaxed and the lumen closed. However, the worms still continue to 
pump, consequently the anterior isthmus and corpus become stuffed with the 
concentrated bacteria (Avery and Horvitz 1989). M4 are cholinergic as they stain with 
antibodies against UNC-17 (Chiang et al. 2006; Alfonso et al. 1993). However 
cholinergic antagonists and mutations affecting nicotinic ACh receptors only partially 
block M4 function. These motorneurons also contain large dense-core vesicles at 
neuromuscular junctions and also express the 5-HT receptor, SER-7b and the glutamate 




Thomson 1976); this suggests acetylcholine is probably not the only neurotransmitter in 
M4s.  
NSMs are a pair of bipolar neurons with cell bodies at the level of the 
metacorpus. The axons of these motoneurons run in a posterior direction through the 
isthmus but terminate before reaching the terminal bulb, making contact with pm5. 
NSMs make a chemical synaptic contact with I6 and M3 and receive a chemical input 
from I1, I2, I3, I4 and I6. NSMs have putative sensory endings at the boundary between 
the corpus and isthmus. The NSM axons are swollen with varicosities and contain mixed 
sized vesicles and the processes of these neurons run in close apposition to the 
pseudocoelom over most of their length (Albertson and Thomson 1976). NSMs contain 
the neurotransmitter, serotonin (Horvitz et al. 1982). It is possible that these neurons play 
neurosecretory and motor function, communicating the presence of food in the 
pharyngeal lumen (Albertson and Thomson 1976). Exogenous application of the 
neurotransmitter depresses locomotion, stimulates egg laying and pumping in 
hermaphrodite worms (Horvitz et al. 1982; Croll 1975b). All of these responses are 
observed when the bacteria are present in the environment (Croll and Smith 1978; Croll 
1975a), making NSMs a possible candidate for mediating the effects of endogenous 
serotonin. However, laser killing of NSMs produces little measurable effects on 
pharyngeal pumping suggesting these neurons are redundant for this function (Avery, 
Bargmann, and Horvitz 1993). 
MC are excitatory neurons with cell bodies located at the level of the metacorpus. 
Their axons are short, the posterior ones terminating at the very anterior end of the 




from M1 and I1. MCs do not synapse on muscle but onto the marginal cells, mc2, 
suggesting that the signal spreads through gap-junctions (Albertson and Thomson 1976). 
Like M3 motorneurons, MC may be a sensorimotor neuron as their putative free 
subcuticular endings, between the procorpus and metacorpus, might be able to sense 
bacteria (White et al. 1986). MC behaves as a motorneuron, producing a fast 
depolarization of muscle membrane potential (excitatory postsynaptic potential, EPSP), 
which triggers a muscle action potential. Thus, it acts as a neurogenic pacemaker for 
rapid pharyngeal pumping and is the sole neuron responsible for this type of behavior 
(Raizen, Lee, and Avery 1995). MCs are required for maintaining optimal rate and 
frequency of pharyngeal pumping rate. Following MC ablation, the pumping becomes 
irregular, slowing down from around 250 to 50 pumps per minute and resulting in 
starved adults (Avery and Horvitz 1989). MC neurons are cholinergic; mutations 
disrupting acetylcholine synthesis (cha-1) or packaging (unc-17) produce a pumping 
defect similar to MC ablation. Acetylcholine and cholinergic agonists produce excitation 
of the pharyngeal muscles and nicotinic blocker, curare, competitively blocked the MC 
neuromuscular transmission. In addition, genes encoding for nAChR subunit, eat-2, and a 
protein required for nicotine response in pharyngeal muscles, eat-18, mimic the 
phenotype of worms with MC loss (Raizen, Lee, and Avery 1995).  
Interneurons (I1 and I5) have been shown to regulate the functioning of MC, 
M3 and M4, hence influence feeding. The cell bodies of I1s are located immediately 
anterior to the metacorpus and their axons project onto pm1 and pm2. I1 neurons 
receive the gap junctions from the somatic system RIPs (ring/pharynx interneuron), thus 




1997). These interneurons make chemical synapses with MC and affect the rate of 
pumping in the absence of bacteria (Franks et al. 2006; Albertson and Thomson 1976; 
Trojanowski et al. 2014). Trojanowski et al. (2014) demonstrated that I1s endogenously 
excite pumping via both the MCs and the M2s in a state-dependent manner. I5s are 
sensory interneurons and have a large cell body on the ventral side of the terminal bulb. 
It forms synapses on M3 (Albertson and Thomson 1976). In I5 ablated worms, the 
pump duration was decreased due to faster relaxation. Killing both I5 and M3 resulted 
in an increase in pump duration due to delay in relaxation, indistinguishable from that 
caused by M3 ablation alone. Thus, I5 increased the pump duration by inhibiting M3 
motoneuron (Avery 1993b). 
2.5.6 Role of neurotransmitters and biogenic amines in feeding 
The pharyngeal nervous system contains classical neurotransmitters (acetylcholine, 
glutamate) and biogenic amines (serotonins, dopamine, octopamine, tyramine) which 
assist with various aspects of feeding behavior.   
Acetylcholine is contained in at least eight pharyngeal neurons, M1, M2s, M4, 
M5, MCs and I6 (Franks et al. 2006). As discussed above, it is mainly MCs that play 
key roles in the cholinergic stimulation and regulation of pharyngeal functions (Avery 
and Horvitz 1989, 1987). Of the 32 nicotinic acetylcholine receptor subunits identified 
in C. elegans so far, EAT-2 has been identified in the pharynx (Raizen, Lee, and Avery 
1995). It is a non-alpha subunit localized near the junction of pm4 and pm5, also the 
site where MC synapses (McKay et al. 2004). Acetylcholine released from stimulated 
MCs increases the pharyngeal pumping rate by activating EAT-2 containing nAChRs on 




ablated worms (McKay et al. 2004; Raizen, Lee, and Avery 1995). Another protein 
encoded by eat-18 is expressed in pharyngeal muscle and M5. Eat-18 is a small single-
pass protein with no homology to previously characterized proteins. The null mutants of 
this protein also generate a phenotype indistinguishable from the worms which had MC 
motorneurons killed. Another α-7-like nAChR subunit encoded by acr-7 is present in 
the pharyngeal muscles and is sensitive to anti-psychotic drugs (Saur et al. 2013).  
Five pharyngeal neurons, viz, M3, NSM and I5 contain glutamate (Lee et al. 
1999). Invertebrates express unique glutamate-gated chloride channels (GluCls) that 
exhibit fast inhibitory glutamatergic transmission resulting in hyperpolarization. GluCls 
are targets of extremely potent class of anthelmintics agents, macrocyclic lactones which 
includes avermectins (Arena et al. 1992; Cully et al. 1994b). These channels are most 
closely related to mammalian glycine receptors and distantly related to the GABA-gated 
chloride channels (Vassilatis et al. 1997). Out of the 6 genes that encode GluCl subunits 
in C. elegans four, glc-1(encoding GLC-1), glc-2 (encoding GLC-2), avr-14 (GluClα3A 
and GluClα3B) an avr-15 (encoding AVR-15/GluClα2) are present in pharynx. avr-15 is 
localized in the pm4 (metacorpus) and pm5 (isthmus) pharyngeal muscle cells. As 
already mentioned before, the actions of M3 released glutamate are mediated through 
ivermectin-sensitive GluClα2/AVR-15 (Dent, Davis, and Avery 1997). Mutations in avr-
15 renders the pharynx insensitive to ivermectin (Pemberton et al. 2001). Heterologously 
expressed GLC-2, assembled into a homomeric glutamate sensitive and ivermectin 
insensitive channels (Cully et al. 1994b). The expression of this GluCl subunit is limited 
to the pm4 muscle cells in the worms (Laughton, Lunt, and Wolstenholme 1997). GLC-1 




glutamate binds to GLC-1 only after ivermectin has already bound. avr-14 is expressed 
in M1 and M4 but is not present in the pharyngeal muscles. This gene encodes for splice 
variants, GluClα3A and GluClα3B. However,  avr-14 null mutants are still responsive to 
ivermectin and  indistinguishable from wild type worms (Pemberton et al. 2001). In 
terms of function, glutamate regulates the pharyngeal pumping, sensory perception and 
locomotion in the worms (Dent, Davis, and Avery 1997; Dent et al. 2000). AVR-15 
functions to inhibit pharyngeal muscle contractions during pharyngeal pumping (Dent et 
al. 2000; Dent, Davis, and Avery 1997; Cook et al. 2006). Additionally, mutations in or 
knockdown of avr-15 or glc-1 increases the frequency with which worms change 
direction. AVR-15 along with AVR-14 mediates mechanosensory inhibition of 
pharyngeal pumping (Keane and Avery 2003).  
Biogenic amines, serotonin (5-hydroxytryptamine, 5HT), dopamine, octopamine 
and tyramine, function as neurotransmitters or neuromodulators (Sanyal et al. 2004; 
Horvitz et al. 1982; Alkema et al. 2005; Sulston, Dew, and Brenner 1975). They 
modulate a variety of worm behaviors in response to the surrounding environment. 5-HT 
is found in the NSM and I5 neurons (Albertson and Thomson 1976; Horvitz et al. 
1982). Exogenous serotonin stimulates pharyngeal pumping from around 40 pumps per 
minute to over 250 pumps per minute (Avery and Horvitz 1990). Endogenous reduction 
of 5-HT decreases pharyngeal pumping rate (Sze et al. 2000). Mutants of tph-1, a gene 
coding for tryptophan hydroxylase, are viable but deficient in 5-HT synthesis which 
alters the feeding behavior. The worms have low average pumping rate in the presence of 
food (Sze et al. 2000). Hobson et al. (2006) reported that tph-1 mutants can pump at a 




to sustain a fast pump rate. Therefore, 5-HT is required to maintain a sustained high 
pumping rate in the presence of food and not for basal pumping. 5-HT mediates its 
actions through three GPCR coupled (SER-1, SER-4 and SER-7B) and one serotonin-
gated chloride channel (MOD-1) receptors, expressed in pharyngeal neurons and muscles 
(Hamdan et al. 1999; Ranganathan, Cannon, and Horvitz 2000; Hobson et al. 2003). 
Serotonergic transmission through SER-7 is essential for stimulation of pumping as ser-7 
mutants fail to exhibit 5-HT induced feeding. The presence of bacteria can still stimulate 
pumping (Hobson et al. 2006). This shows serotonin is not the only signal required to 
induce feeding and the stimulation of feeding behavior has a complex neuronal basis 
(Franks et al. 2006). Dopamine is another biogenic amine that affects feeding behavior in 
C. elegans. Dopamine signaling assists the worms with efficient food search (Sawin, 
Ranganathan, and Horvitz 2000). Exogenous dopamine application does not affect the 
pumping rate on food (Barros et al. 2014). Both octopamine and tyramine are not 
synthesized in the pharyngeal nervous system, but their exogenous application reduces 
pumping rate (Horvitz et al. 1982; Alkema et al. 2005; Rex et al. 2004; Rogers et al. 
2001), therefore they have a neurohormonal function. Tyrosine is the precursor for 
synthesis of tyramine and tyramine-β-hydroxylase (TBH-1) converts tyramine to 
octopamine. Octopamine mediates its effects through suppression of M3 activity which 
increases the action potential duration. SER-3 is the octopamine receptor found on the 
pharyngeal muscles and ser-3 mutants have a slightly lower pumping rate than wild type 
worms in the absence of food (Carre-Pierrat et al. 2006). Tyramine inhibits pumping 
through SER-2 receptors present on NSM neurons, pm1 and pm6 muscles (Rex et al. 




2.6 Ascaris spp. pharynx 
Similar to C. elegans, the pharynx of Ascaris is essential for feeding and regarded 
as an exploitable target for development of therapeutics. An example is the macrocyclic 
lactones which target pharyngeal ion channels and interrupt pharyngeal processes 
(Brownlee, Holden-Dye, and Walker 1997; Wolstenholme and Rogers 2005). Ascaris 
spp. are parasitic nematodes with a limited glycogen reserve. They feed on the host tissue 
and fluids to meet their energy demands. A functional failure of the pharynx affects the 
survival of the worms as starving and sluggish worms are removed from the host during 
intestinal movements.  
2.6.1 Anatomy of Ascaris spp. pharynx 
The pharynx of Ascaris is thick walled, 8-11 mm long, and up to 1 mm wide 
hollow cylindrical structure, developed from the fusion of about 30 cells (Brownlee et al. 
1995; Goldschmidt 1904). It is a musculo-glandular motile segment of the digestive 
system, externally surrounded by the cuticle along with hypodermis and the somatic 
muscle layer (Figure 2.13A). The lumen of the pharynx is tripartite and derived from the 
cuticle (del Castillo and Morales 1967a). The muscular portion of the pharynx consist of 
two types of fibrillar components, the contractile ordinary muscle fibers and the marginal 
muscle fibers, arranged like the segments of an orange. The marginal muscle fibers are 
heavily concentrated at the apices of the triradiate lumen (Goldschmidt 1904; Hsü 1929; 
Mapes 1965). The muscle fibers are transversely oriented to the long axis of the 
esophagus arranged as bundles of thick and thin filaments (Reger 1966). This 
arrangement suggests that the esophagus function is mechanically analogous to the 




regions of the myoepithelium contain mitochondria, endoplasmic reticulum, and bundles 
of tightly packed, filaments. The glandular cells are interspersed between the 
myoepithelial cells, producing digestive enzymes. There are two one-way valves present 
at both ends, anterior and posterior, ensuring unidirectional flow of the material. The 
function of the tube-shaped pharynx is to pump food against the inner peudocoelomic 
pressure and prevent gut contents from being regurgitated (Bennet-Clark 1976). 
2.6.2 Pharyngeal peristalsis in Ascaris 
Unlike C. elegans, the pharynx of Ascaris is opaque and a simple cylindroid with 
no distinct bulbs. The contraction of the pharyngeal musculature in the parasitic 
nematode undergoes rhythmic peristalsis, rather than two stage pumping seen in C. 
elegans (Mapes 1966; Harris and Crofton 1957b) (Figure 2.13B). The pharyngeal 
peristalsis starts at the anterior tip, considered as the pacemaker, and travels all the way to 
end of the pharynx. The initiation of the rhythmic peristaltic motion is regulated by either 
myogenic or enteric nervous system activity (Brownlee et al. 1995). The depolarization 
of the muscles of the pharynx results in progressive contraction waves which move at an 
average speed of 4 cm/sec. The contraction of the radially oriented muscle fibers, results 
in the expansion of the outer diameter of the cell. This converts the narrow lumen into a 
wide triangular canal with a subsequent decrease in pharyngeal pressure, thus facilitating 
suction of food through a one-way valve near the mouth. Rapid relaxation of the 
contractile fibers due to repolarization closes the lumen and results in increased internal 
pressure sufficient to overcome hydrostatic pseudocoelomic pressure. This forces the 
contents of the lumen to move into the intestine through a second one-way valve. The 





Figure 2.13 A. Photograph (top) of the head region of female A. suum (with cm scale 
above the worm). Image (bottom) showing cross-section of A. suum pharynx. The cuticle 
(1), muscle cells (2), pharynx with triradiate lumen (3), lateral chord (4), pseudocoel (5) 
and nerve chord (6) are indicated (modified from 
https://www.vcbio.science.ru.nl/en/image-gallery/show/labels/print/AN0013/). B. 
Diagram showing various stages and different time points of repeating cycle of 
pharyngeal peristalsis (approximately every 0.32 s) of Ascaris pharynx (Sauders and Burr 
1978). At any point pharynx never opens simultaneously at both anterior and posterior 
ends. 
 
pumps are needed for feed intake and transport in nematodes which is defined as 
pharyngeal pumping behavior. At any stage of pharyngeal peristalsis, the lumen of the 
pharynx never opens fully at both ends (Sauders and Burr 1978).The rate of peristaltic 
cycles in an intact Ascaris pharynx is 4 pumps/sec, while an isolated pharynx shows 2.5 
pumps/sec (Sauders and Burr 1978; Mapes 1966). 
2.6.3 Electrophysiology of the Ascaris pharyngeal muscle 
The Ascaris pharynx behaves as a single tube-shaped cell functionally with no 
appreciable barriers to impede the flow of current within the cytoplasm. 




Morales (1967a, 1967b); Byerly and Masuda (1979) using current-clamp and voltage-
clamp techniques. It has a resting membrane potential of -35 mV which is dependent on 
the extracellular anions and pH fluctuations. Increasing the external pH (7 to 8) increased 
the resting potential by about 4 mV, while lowering the pH (7 to 6) resulted in 
depolarization of about 20 mV. Unlike somatic muscle cells, the pharyngeal action 
potential exhibited two different regenerative, all-or-nothing mechanisms and is 
occasionally spontaneous (del Castillo and Morales 1967a). One of the processes result in 
the positive overshoot (depolarization) caused by the influx of cations which are probably 
sodium and calcium. The potential reaches a plateau and remains depolarized from 150 
msec to several seconds. The depolarization can reach as high as 18 mV and results in the 
long-lasting shortening of the myofibrils associated with the opening of the lumen. The 
second regenerative process results in a unique negative-going action potential (as low as 
-108 mV) caused by a potassium spike. These K+ currents are strikingly analogous to the 
classical Na+ currents of the vertebrate skeletal muscle and nerve, except for inverted 
voltage dependencies. The intense negative spike drives the return from the plateau to the 
resting potential and is a relatively fast process. In the pharyngeal muscles, the negative-
spike is associated with the rapid relaxation of the muscles and closing of the lumen. 
Both the prolonged positive-going action potential which maintains the contractions and 
the rapid termination by the negative-going action potential improve the efficiency of the 
pharynx as a pumping organ. Byerly and Masuda (1979) described a depolarizing 
postsynaptic potential (-10 mV reversal potential) which triggered the positive-going 
spike and a hyperpolarizing postsynaptic potential (-40 mV reversal potential) that 




transition from one regenerative potential to another may be dependent on a transmitter 
and the associated receptor. The pharmacology of the receptor involved has not been 
explored yet but might be a potential target site for future anthelmintics. 
del Castillo and Morales (1967a, 1967b) demonstrated the existence of membrane 
spaces within the cytoplasm of pharyngeal muscle. These spaces were proposed to 
behave as the tubular systems of the muscle cells in vertebrates that spread the action 
potential into the cytoplasm. Electrophysiological investigation using a microelectrode 
revealed that the recorded signals in these spaces resembled extracellular action 
potentials. The large intracellular spikes observed in the pharyngeal muscle cells are 
instead replaced by small transients. Thus, these cytoplasmic spaces are in 
communication with the external solution and separated from the cytoplasm by an active 
membrane which can generate action potentials. It is possible that these spaces are either 
invaginations of the surface membrane or interstices between the cells that originally 
form the pharynx.  
2.6.4 Nervous system of Ascaris pharynx 
The pharyngeal-sympathetic nervous system provides the innervation to the 
Ascaris pharynx. It is formed by the nerve ring located at the posterior end of the 
pharynx. The three longitudinal nerve strands, dorsal and a paired sub-ventral cords, 
extend anteriorly from the nerve ring to innervate the pharyngeal muscle (Sauders and 
Burr 1978; Goldschmidt 1910). The dorsal nerve is shorter and contain two nerve cells 
while the sub-ventral cords have four nerve cells each (Goldschmidt 1910). The 
longitudinal nerve cords are joined together by 2-3 cross-connecting commissures. These 




and in turn, coordinate the muscular and glandular activity of the pharynx. The 
pharyngeal nervous system is chemically complex. It is regulated by cholinergic 
(excitatory), glutamatergic (inhibitory) and serotoninergic (excitatory) systems. In 
addition, sensory neurons of the pharyngeal nervous system have GABAergic 
components (inhibitory) and peptidergic secretory components (Brownlee, Fairweather, 
and Johnston 1993; Brownlee et al. 1996; Brownlee et al. 1995). 
 
2.7 Plant-based compounds therapeutic compounds  
Plants have been a remarkable source of medicinal products for the treatment of a 
wide spectrum of diseases. Various ancient records reveal the importance of the botanical 
compounds in sophisticated traditional pharmacopeia. The earliest records which date 
back to 2600 BCE in Mesopotamia, describes the use of approximately 1000 plant-
derived substances (Borchardt 2002). "Ebers Papyrus" (1500 BCE), the Chinese Materia 
Medica (1100 BCE) (Huang 1998) and the Indian Ayurvedic system (before 1000 BCE, 
Charaka; Sushruta and Samhitas) (Kapoor 1990) also document the medical relevance of 
herbal products. Plant-based systems continue to be indispensable in healthcare even 
today. Natural products are important source of pharmaceutical agents as well as leads to 
bioactive molecules. Many therapeutics, including codeine, quinine, artemisinin, 
digitoxin, morphine, paclitaxel, galantamine, used for various medical conditions in 
modern pharmacotherapy are plant-based (Newman, Cragg, and Snader 2000; Newman 
and Cragg 2016; Samuelsson 2004; Butler 2004). An estimated four billion people living 
in the developing world rely on phytomedicine for primary pharmaceutical care (WHO 
2005). Even in the developed part of the world, herbal remedies in the form of 




Traxler 2011; Calapai 2008). In addition to exhibiting a wide array of medicinal 
properties, plant-based compounds are eco-friendly and affordable. Most of the plants 
and their products are also readily available in the tropical and sub-tropical regions. In 
case of issues with the supply of source material, recent advances and novel scientific 
resources can be used for organic synthesis of phytocompounds.  
Phyotherapeutics have been used by traditional healers to treat parasitic infections 
and improve performance of livestock for eons. Different parts of plants such as garlic, 
onion, mint, walnuts, dill, parsley, male fern Dryopteris filixmas and Artemisia spp. and 
thyme have been used to treat helminth parasitism (Ferrell 1914; Lamson and Ward 
1932; Guarrera 1999). The evidence of antiparasitic activity of phytocompounds is based 
on anecdotal observations and the bioactive compounds have not been fully identified. 
Therefore, controlled scientific experimental studies are ongoing to aim to verify and 
quantify the clinical plant activity, with many reports of research-based validation of the 
anthelmintic activity of several plants (Jaradat et al. 2016; Bissinger et al. 2014; Kaplan 
et al. 2014; Katiki, Chagas, et al. 2011; Trailović et al. 2015). The identification and 
validation of botanical compounds may accelerate the anthelmintic drug discovery and 
development and also mitigate the pressure on the limited classes of anthelmintic drugs 
available. 
2.7.1 Monoterpenoids as potential anthelmintic agents 
Essential oils are the aromatic and volatile organic products of secondary 
metabolism in plants. The term “essential oil” was coined in the 16th century by 
Paracelsus von Hohenheim, a swiss physician and alchemist (Guenther 1948).  It is 




drug’. The composition of essential oils is extremely complex and diverse as they contain 
compounds of several different functional-group classes. The insecticidal and 
nematocidal effects of essential oils and their active principles is well documented 
(Coskun et al. 2008; Camurca-Vasconcelos et al. 2007; Macedo et al. 2009; Cetin et al. 
2009; Enan 2005; Panella et al. 2005; Kim et al. 2008).  Thymol, the principal component 
of thyme (Thymus vulgaris L.) and santonin which is derived from buds of the Artemisia 
spp. were used in the late nineteenth and early twentieth century for the treatment of 
ascarids and hookworms infestations (Ferrell 1914; Kaplan et al. 2014; Lamson and 
Ward 1932). Ascaridol, a peroxide monoterpene, found in wormseed oil (Chenopodium 
ambrosioides), was described as ‘one of the best-known anthelmintic”. It was used for 
the treatment of several roundworm and hookworm infections in man and animals 
(Lamson and Ward 1932). 
Terpene biomolecules, particularly monoterpenes and sesquiterpenes, are the 
major constituents of essential oils. Many of the monoterpenoid compounds have been 
identified as promising anthelmintic compounds (Andrés et al. 2012; Ntalli et al. 2010; 
Avato et al. 2017). Jaradat et al. (2016) demonstrated the anthelmintic effects of Thymus 
bovei essential oil, which is mainly composed of monoterpenoids (~90%), against 
gastrointestinal roundworms. Four monoterpenoid compounds (α-pinene, linalool, p-
cymene, and thymol) exhibited antinematodal activity when used alone and in 
combination (Bissinger et al. 2014). Lei et al. (2010) also reported in vitro nematocidal 
activity of thymol and carvacrol (major components of thyme and oregano essential oils) 
against Caenorhabditis elegans and Ascaris suum. Carvacrol, a phenolic monoterpene 




derivative of carvacrol, exhibited in vitro and in vivo anthelmintic activity against 
Haemonchus contortus (Andre et al. 2016). Trailović et al. (2015) also demonstrated the 
potential anthelmintic effects of carvacrol in A. suum. Monoterpenoids produce the 
anthelmintic effects by targeting the nervous system of nematodes through the 
invertebrate-specific G protein-coupled receptors for octopamine and tyramine, 
acetylcholine esterase, nicotinic acetylcholine receptors and ionotropic gamma amino 
butyric acid (GABA) receptors (Enan 2005; Lei, Leser, and Enan 2010; Trailović et al. 
2015; Enan 2001; Tong et al. 2013; Tong and Coats 2012; Park et al. 2003; Miyazawa, 
Watanabe, and Kameoka 1997; Höld et al. 2000). Additionally, these compounds can 
bind to multiple target sites, which can slow down the development of drug resistance 
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Nematode parasites infect approximately 1.5 billion people globally and are a 
significant public health concern. There is an accepted need for new, more effective 
anthelmintic drugs. Nicotinic acetylcholine receptors on parasite nerve and somatic 
muscle are targets of the cholinomimetic anthelmintics, while glutamate gated chloride 
channels in the pharynx of the nematode are affected by the avermectins. Here we 
describe a novel nicotinic acetylcholine receptor on the nematode pharynx that is a 
potential new drug target. This homomeric receptor is comprised of five non-α EAT-2 
subunits and is not sensitive to existing cholinomimetic anthelmintics. Importantly, this is 
the first report of successful heterologous expression of a non-α nicotinic subunit into a 
functional homomeric ligand-gated cation selective ion-channel. We found that EAT-18, 
a small transmembrane protein, is a novel auxiliary subunit protein essential for 
functional expression of the receptor.  It directly interacts with the mature receptor and 








Nematodes are multicellular organisms that exhibit diverse and complex 
physiological behaviors. These functions are controlled by a neuromuscular system that 
employs a large repertoire of highly regulated transporters, neurotransmitters, peptides 
and ion channels, which all contribute to homeostatic cell-cell communication (White et 
al. 1986; Wolstenholme 2011). Nicotinic acetylcholine receptors (nAChRs) are pore-
forming membrane proteins belonging to the cys-loop ligand-gated ion channel 
superfamily. They are conserved throughout metazoan evolution and characterized by a 
pentameric subunit organization. nAChRs facilitate rapid ionotropic neurotransmission 
thereby controlling various physiological behaviors including reproduction, navigation, 
feeding, and locomotion (Greenberg 2014).  
Nematode nAChRs, especially those found on somatic muscle, are targeted by the 
cholinergic anthelmintic drugs (Robertson, Buxton, and Martin 2013; Robertson, Bjorn, 
and Martin 2000; Buxton et al. 2014; Xiao et al. 2005; Greenberg 2014). These drugs 
help alleviate the nematode parasite burden of the 1.5 billion people affected globally as 
well as mitigate the threat to global food security caused by nematode parasites of 
livestock (WHO 2018; Abongwa, Martin, and Robertson 2017). Nematodes have a 
greater number (≥29) of nAChR subunits than vertebrates (17); variation in stoichiometry 
and subunit composition leads to diverse pharmacological sensitivities which makes them 




Sattelle 2004; Millar 2008). The introduction of recently discovered drugs such as amino-
acetonitrile compounds (monepental) and spiroindoles (derquantel) which target 
nematode nAChRs further highlight their importance in drug discovery (Kaminsky et al. 
2008; Robertson et al. 2002; Little et al. 2011).  
All nAChR ion-channels are composed of five subunits forming a central ion 
conducting pore and can be either homomeric (one α subunit) or heteromeric (multiple 
subunits with at least 2 α subunits). Various chaperone/ancillary proteins, including RIC-
3 (resistance to inhibitors of cholinesterase), UNC-50 (uncoordinated-50) and UNC-74 
(uncoordinated-74), are required for correct folding, assembly of individual subunits into 
pentamers and trafficking of the mature nAChRs in a subtype dependent manner (Millar 
2008; Haugstetter, Blicher, and Ellgaard 2005; Boulin et al. 2008). In addition, several 
structurally unrelated auxiliary subunit proteins have been identified for various 
ionotropic receptors (Schwenk et al. 2010; Tomita and Castillo 2012; Yan and Tomita 
2012; Ben-Yaacov et al. 2017). These proteins are non-pore forming and interact directly 
with the receptor subunits to modulate channel properties. They do not exhibit any 
channel activity on their own and are required for certain aspects of in vivo channel 
function (Yan and Tomita 2012). Boulin et al. (2012) identified the first auxiliary subunit 
for nAChRs, MOLO-1 (modulator of levamisolereceptor-1), that regulates biological and 
biophysical properties of the L-type nAChRs in C. elegans. This demonstrates that 
nAChRs are tractable to regulation by auxiliary proteins contributing to biological and 
pharmacological diversity of nAChR subtypes. 
In nematodes, the pharynx is a neuromuscular organ that undergoes rhythmic 




1983; Albertson and Thomson 1976; Brownlee et al. 1995). Pharyngeal peristalsis is 
under the control of rhythmic activation by excitatory (cholinergic) and inhibitory 
(glutamatergic) motor neurons innervating the pharyngeal muscle (Martin 1996; 
Brownlee, Holden-Dye, and Walker 1997). Glutamate-gated chloride channels in the 
nematode pharynx have been exploited as targets for the avermectins (Tompkins, Stitt, 
and Ardelli 2010; Wolstenholme and Rogers 2005; Cully et al. 1994a), however little is 
known about the cholinergic receptors in this tissue. Through genetic screening Raizen, 
Lee, and Avery (1995) identified eat-2 (encoding a non-α nAChR subunit) and eat-18 
(encoding a single pass transmembrane domain protein with no vertebrate homologue) as 
essential components of pharyngeal cholinergic transmission in Caenorhabditis elegans. 
Here, we have cloned and functionally expressed EAT-2 and EAT-18 from free living (C. 
elegans) and parasitic (Ascaris suum) nematodes. For the first time we find that a non-α 
nicotinic subunit (EAT-2) can form a homomeric ligand-gated cation selective ion-
channel. The functional expression of this noncanonical receptor is dependent on co-
expression with EAT-18. All previously characterized cation selective nAChRs have at 
least two α subunits with the ligand binding sites located at the interface between each α 
and its adjacent subunit (Holden-Dye et al. 2013; Corringer, Novère, and Changeux 
2000). We have used electrophysiological, biochemical and molecular techniques to 
demonstrate that EAT-18 forms part of the mature receptor and functions as an obligate 







3.3.1 Molecular Biology  
Plasmid constructs (GeneArt®) containing C. elegans EAT-2 (Accession 
number: Y48B6.4) & EAT-18 (Accession number: isoform-c - Y105E8A.7c.1 and 
isoform-d -Y105E8A.7d.1) were cloned into XhoI and ApaI restriction sites of the pTB-
207 expression vector using In-Fusion cloning kit (Takara Bio USA, Inc.; EAT-2: 5’ end 
- TGGCGGCCGctcgagATGACCTTGAAAATCGCATTTTTCA and 3’ end - 
ATCAAGCTCgggcccTTATTCAATATCAACAATCGGACTAT; EAT-18: 5’ end – 
TGGCGGCCGctcgagATGCGAAGCCTGGAGCGAAT and 3’ end - 
ATCAAGCTCgggcccTCAAAGTGTTGATCGCATTTCCTCA). For biochemistry and 
immunofluorescence assays, Cel-EAT-2 was tagged with GFP in between the 
transmembrane region 3 and 4 between leucine 377 and 378; EAT-18 was tagged with 
the 6xHis tag at the C-terminal. Full length sequences of A. suum EAT-2 (Accession 
number: GS_09411) and EAT-18 were amplified from total RNA extracted from 
dissected whole pharynx of A. suum. Briefly, TRIzol ReagentTM (InvitrogenTM, 
Carlsbad, CA, USA) was used to extract total RNA from A. suum adult worms. cDNA 
was synthesized by using SuperScript VILO Master Mix (InvitrogenTM, Carlsbad, CA, 
USA) and served as a template for the amplification. Full length product was sub-cloned 
into pTB207 expression vector by adding XhoI and ApaI restriction enzyme sites 
respectively to the forward primer (5’ end: 
TGGCGGCCGctcgagATGCAAATATTTTCTATGGTAATT) and reverse primers (3’ 
end: ATCAAGCTCgggcccTTAATTCCATACGTTTGGGG) using In-Fusion cloning. Z-




of the ligated product. The final cloned constructs of all the plasmids were sequenced 
with pTB207 vector primers (forward, T7) and (reverse, SP6). Only positive clones were 
used for cRNA synthesis using in vitro transcription with the mMessage mMachine T7 
transcription kit (Invitrogen, CA, USA) and the cRNA was aliquoted and stored at -80°C. 
3.3.2 Electrophysiology 
3.3.2.1. Two-electrode voltage-clamp in Xenopus oocytes  
Oocyte injections and two-electrode electrophysiology recordings were performed 
as previously described (Choudhary et al. 2019).  
3.3.2.2. A. suum current clamp recordings from the pharynx 
A. suum pharyngeal dissections and electrophysiology recordings were adapted 
from Martin (Martin 1985). Briefly, pharynx was dissected out from the head region of 
the worm and mounted on Sylgard™-lined in a double jacketed bath chamber maintained 
at 28 °C. The muscle layer surrounding the anterior 3rd of the pharynx was preserved for 
anchoring. The intestine attached to the posterior end of the pharynx was used for 
stretching and pinning down. The preparation was continuously perfused with calcium 
free Ascaris Perienteric Fluid-Ringer (calcium free APF-Ringer) composition (mM): 
NaCl 23, Na-acetate 110, KCl 24, MgCl2 11, glucose 11, and HEPES 5; NaOH or acetic 
acid was added to adjust the pH to 7.6. The experimental compounds were dissolved in 
calcium free APF-Ringer and applied as described in the results. The rate of localized 
perfusion was 3.5–4 ml min−1 through a 20-gauge needle which was placed directly 
above the recording region of pharynx. The pharyngeal preparations with resting 
membrane potentials less than -15 mV and the resting conductances less than 250 µS 




final resistances of 4-7 MΩ for the voltage sensing and 0.5-1 MΩ for the current injecting 
electrode for current clamp recordings. The current-injecting electrode injected 
hyperpolarizing step currents of −1000 nA for 500 ms at 0.3 Hz.  
3.3.2.3. Data analysis 
GraphPad Prism 8.0 software (GraphPad software Inc., CA, USA) was used to 
analyze the data. In two-electrode voltage-clamp recordings, the peak currents were 
measured and normalized to 100 µM acetylcholine response and expressed as mean ± 
S.E.M.  The data for sigmoid concentration-response curves was fitted to the Hill 
equation (Boulin et al. 2008). We used One-way analysis of variance (ANOVA) and 
Extra sum of squares F-test to test statistical differences (statistically different if p<0.05). 
Tukeys multiple comparison was used as post-hoc test.   
In current-clamp recordings, the peak changes in membrane conductance (δGmax) 
in response to drug applications were normalized to δG response to acetylcholine 
application (100 µM ACh, applied for 10s) within each preparation. We constructed the 
sigmoidal concentration response plots by fitting the data by nonlinear regression to 
determine the pEC50 and the maximal response (Rmax). Extra sum of squares F-test was 
used to test statistical differences between pEC50, slope and maximal response. The 
significance levels were set to P<0.05. 
 
3.3.3 Biochemistry 
3.3.3.1. Immunostaining for confocal microscopy 
Oocytes were prepared for confocal imaging following previously published 




paraformaldehyde at 4°C overnight. Fixed oocytes were embedded in 3% low-melting 
point agarose and 50-μm thick slices were cut using a vibratome. The oocyte slices were 
blocked with 0.2% Bovine Serum Albumin (BSA) plus 0.1% Tween 20 in PBS overnight 
at 4°C. This was followed by incubation with the primary antibody (ABfinity™ Histidine 
tag recombinant rabbit oligoclonal antibody at 1:500 dilution for detecting Cel-EAT-18c, 
ThermoFisher#A-710286, and goat  anti-GFP rabbit IgG antibody for detecting Cel-
EAT-2, Abcam # ab6673, 1:1000) over night at 4°C and then incubated with a 
fluorescent secondary antibody (Alexa Fluor® 488 goat anti-rabbit IgG antibody, 1:1000, 
ThermoFisher#A-11008; Alexa Fluor Plus 680 donkey anti-goat IgG secondary antibody, 
ThermoFisher#A-32860, 1:15000) for 1 hour at room temperature. The slices were 
mounted on glass slides using a FluoromountTM mounting medium followed by confocal 
imaging (Leica SP5 X MP confocal/multiphoton microscope system). 
3.3.3.2. Western blot analysis using Xenopus oocytes 
Oocyte protein extraction and western blot analysis protocol were adapted from 
Lin-Moshier & Merchant (Lin-Moshier and Marchant 2013) with the following 
modifications. Ten oocytes with currents ³ 500 nA in response to 100 µM acetylcholine 
were pooled and suspended in 100 µL of homogenization buffer (50 mM HEPES, pH = 
7.5, 150 mM NaCl, 1 mM PMSF, 1 mM EDTA, pH = 8.0 and Protease Inhibitor cocktail, 
Sigma Aldrich, MO, USA). The homogenized sample was centrifuged at 800g for 5 min 
at 4°C and the supernatant was transferred into a clean tube. The centrifugation step was 
repeated twice to ensure complete removal of the yolk particles. Samples were boiled 
with Laemmli buffer for 5 min and then subjected to electrophoresis (4-12% Bis Tris gel 




onto PVDF membranes and blocked with BlockOut® blocking buffer (Rockland 
immunochemicals Inc., PA, USA). The blots were probed with a 1:10000 dilution of 
primary antibody (mouse monoclonal anti-GFP antibody to detect GFP tagged Cel-EAT-
2, Proteintech # 66002-1-Ig; HRP-conjugated anti-His antibody to detect His tagged Cel-
EAT-18, Proteintech # HRP-66005) at 4°C overnight. HRP conjugated anti-mouse 
antibody at 1:10000 dilution was used as secondary antibody (SA00001-1) for GFP 
tagged protein. Immunoreactivity was visualized by enhanced chemiluminescence (GE 
healthcare, IL, USA). 
3.3.3.3. Co-immunoprecipitation using Xenopus oocytes membrane extracts 
Xenopus laevis oocytes were processed as described previously; anti-GFP-Trap-A 
beads (ChromoTek, Germany) were used for immunoprecipitation (Boulin et al. 2012).  
Laemmli buffer was used to recover the immunoprecipitates and eluates were analyzed 
separately using the following primary antibodies: mouse monoclonal anti-GFP antibody 
(Proteintech # 66002-1-Ig, 1:10000), HRP-conjugated anti-His antibody (Proteintech # 
HRP-66005). HRP conjugated anti-mouse antibody was used as secondary antibody 
(1:10000; SA00001-1). Chemiluminescent reagents (GE healthcare, IL, USA) were used 
for detection.  
3.4 Results 
3.4.1 Cel-EAT-2 forms a functional homomeric receptor when co-expressed 
with Cel-EAT-18 
Initiation of the pharyngeal muscle action potential and the frequency of 
excitatory pharyngeal pumping are under the control of the marginal cell (MC) motor 




subunit Cel-EAT-2 which is expressed in pharyngeal muscle (Avery and Horvitz 1990; 
Raizen, Lee, and Avery 1995). In order to reconstitute the post-synaptic pharyngeal 
nAChR, we expressed Cel-EAT-2 in Xenopus laevis oocytes but failed to observe 
electrophysiological evidence for the formation of a functional nAChR. This could be 
attributed to the lack of vicinal cysteines required for agonist binding and pointed to a 
possible requirement for an additional protein or subunit. Raizen, Lee, and Avery (1995) 
have shown that similar to Cel-eat-2, mutations in Cel-eat-18 rendered worms incapable 
of MC neurotransmission and rapid pharyngeal pumping suggesting the protein may act 
as either an ancillary or auxiliary protein for the assembly of a functional nAChR. Cel-
eat-18 is a small, single-pass transmembrane protein. There are two splice variants of the 
protein in C. elegans, EAT-18c (71 aa) and EAT-18d (78 aa), which differ mainly in the 
C-terminal region (Supporting Information S3.0). We co-expressed Cel-EAT-2 with Cel-
EAT-18c or Cel-EAT-18d cRNA and recorded robust responses to 100 µM acetylcholine 
in both cases (Figure 3.0A). The resulting nAChRs produced larger current amplitudes in 
response to acetylcholine application when the Cel-EAT-18c isoform was used. The 
majority of subsequent recordings were done using the Cel-EAT-18c isoform. The ability 
of the non-α EAT-2 to express functionally when co-injected with a non-subunit protein 
makes this cation selective nAChR unique to date.  
3.4.2 Cel-EAT-2 is a non-α nAChR subunit most similar to vertebrate α-7 
subunits 
C. elegans EAT-2 has the typical functional domains of a pentameric ligand-gated 
ion channel subunit: a large extracellular N-terminal domain of ~200 amino acids 




intervening amino acids; four transmembrane (TM) domains that form the ion-conducting 
pore; a cytoplasmic domain between TM3 and TM4 that is involved in modulation of 
channel activity and ion conductance; and a short extracellular C-terminus. EAT-2 is a 
non-α subunit as it lacks the pair of adjacent cysteine residues in loop-C required for 
agonist binding, but overall its sequence is most comparable to the human a-7 subunit 
with 55% similarity in amino acid residues (Supporting Information S3.1). Ligand 
binding occurs in a cleft formed by three loops (A, B, C) of the principal face of one a 
subunit and a series of beta strands from loops (D, E, F) of the complimentary interface 
of the adjacent subunit. All a subunits have either a YXCC or YXXCC motif in loop-C 
and this motif was considered essential for ligand binding and modulating the affinity of 
the receptor binding site (Kao et al. 1984; Karlin 2002; Kao and Karlin 1986). EAT-2 
lacks the YXCC or YXXCC motif but is still able to assemble, with EAT-18, as a 
functional cation selective homomeric channel, which encouraged us to continue to 
explore this interesting and different nAChR. This lack of vicinal cysteines in the EAT-2 
protein subunit suggest that the receptor channel will have different contact residues in 
the ligand binding pocket and a different pharmacology from other nAChRs.   
3.4.3 Pharmacology of the Cel-EAT-2 nAChR 
In order to investigate the potential of EAT-2 as a drug target, we characterized 
the pharmacology of the nAChR by using two-electrode voltage-clamp. Different 
cholinergic agonists and anthelmintic agents were tested on the heterologously expressed 
Cel-EAT-2 receptor. All agonists were used at 100 µM, except tribendimidine which was 
tested at 30 µM (n ≥ 6 for all agonists). Methacholine was the most efficacious 




± 8.0%). Oxantel acted as a weak agonist and produced 11 ± 1.3% of the control 
acetylcholine response.  However, many of the current cholinergic anthelmintic drugs 
such as morantel, levamisole, bephenium, tribendimidine and pyrantel did not activate the 
receptor. Fig. 3.0B shows the rank order potency series for agonists and anthelmintics on 
the Cel-EAT-2 receptor when normalized to control 100 μM acetylcholine (ACh) current 
response: acetylcholine > methacholine > nicotine > carbachol > butyrylcholine > 
epibatidine > oxantel >>> DMPP (Dimethylphenylpiperazinium) = tribendimidine = 
bephenium = cytisine = lobeline = levamisole = SIB 1508Y = 𝛼-cotinine = nornicotine = 
anabasine = pyrantel.  
To further investigate the receptor pharmacology, we examined the concentration-
response relationships of selected agonists (Figure 3.0 C&D and Supporting Information 
S3.2A). 100 μM ACh was used as the internal standard for normalization. Nicotine 
(pEC50 = 4.2 ± 0.1) was the most potent agonist after acetylcholine (pEC50 = 4.8 ± 0.0), 
whereas carbachol was least potent with a pEC50 = 3.4 ± 0.0. The concentration-response 
curves for all the agonists had hill coefficient values greater than 1 indicating positive 
cooperativity, with methacholine having the steepest hill slope (nH = 3.5 ± 1.3). This 
suggests that the Cel-EAT-2 ion channel has multiple ligand binding sites consistent with 
other nAChRs. 
To characterize the antagonist pharmacology, we tested the effects of five 
cholinergic antagonists on the expressed Cel-EAT-2 channel. The antagonists were 𝛼- 
bungarotoxin (10 µM), derquantel (10 µM), paraherquamide (30 µM), d-tubocurarine (30 
µM) and dihydro-β-erythroidine (30 µM, DHβE). Figure 3.0 E&F (and Supporting 




concentration-response relationship for Cel-EAT-2. d-Tubocurarine produced the most 
potent inhibition and almost completely blocked the response mediated by acetylcholine 
(»98% inhibition). Unlike many mammalian nAChRs, sensitivity and efficacy of the 
receptor for acetylcholine was not altered by either a-bungarotoxin or DHβE. The rank 
order potency series based on mean current (%) decrease of the control 100 μM ACh 
current response was: d-tubocurarine > paraherquamide > derquantel >>> 𝛼-
bungarotoxin » DhβE. In conclusion, the pharmacology of the Cel-EAT-2 receptor is 
distinct from previously characterized nematode and vertebrate nAChRs (Buxton et al. 
2014; Abongwa, Baber, et al. 2016; Ballivet et al. 1996; Raymond, Mongan, and Sattelle 
2000; Chen and Patrick 1997; Decker et al. 1995). 
3.4.4 Characterization of the acetylcholine response in the A. suum pharynx 
Although C. elegans is a powerful model, it is not a parasitic nematode of medical 
importance. In order to validate pharyngeal nicotinic acetylcholine ion channels as 
potential anthelmintic drug targets, it is crucial to identify and establish the presence and 
in turn the pharmacology of such nAChRs in the pharynx of parasitic worms. We 
therefore characterized the pharmacology of the A. suum pharynx for comparison with 
the Cel-EAT-2 receptor. We employed the current-clamp technique to understand the 
pharmacology of the postsynaptic nAChR response. Application of 100 µM acetylcholine 
on the pharyngeal preparation produced a large depolarization accompanied by an 
increase in membrane conductance. The acetylcholine response was inhibited by 






Figure 3.0 Pharmacology of the Cel-EAT-2 nicotinic acetylcholine receptor. A. Bar graph 
showing current sizes (mean±S.E.M, %) produced in response to 100 μM acetylcholine 
for various mixtures of Cel-EAT-18c & d and Cel-EAT-2. B. Bar graph (expressed as 
mean±SEM, %, n≥6) showing rank order potency for nAChR agonists and anthelmintics 
when normalized to the control 100 μM ACh current: acetylcholine (ACh) > 
methacholine (methCho; 73.0±5.3) > nicotine (nic; 55.0±8.0) > butyrylcholine (butCho; 
50.0±5.0) > carbachol (carCho; 37.0±3.4) > epibatidine (epi; 25.0±1.5) > oxantel (oxa; 
11.0±1.3) >>> dimethylphenylpiperazine (DMPP; 0.0±0.0) = tribendimidine (tri; 
0.0±0.0) = bephenium (bep; 0.0±0.0) =  cytisine (cyt; 0.0±0.0) = lobeline (lob; 0.0±0.0) = 
levamisole (lev; 0.0±0.0) = SIB 1508Y (0.0±0.0) = 𝛼-cotinine (𝛼-cot; 0.0±0.0)= 
nornicotine (nor; 0.0±0.0) = anabasine (ana; 0.0±0.0) = pyrantel (pyr; 0.0±0.0). C. 
Sample traces for acetylcholine, nicotine and carbachol concentration–response 
relationships. D. Concentration-response plots of selected agonists (n≥6). pEC50 
(mean±SEM) and hill slope (nH, mean±SEM) values were respectively: 4.8±0.0 and 
1.9±0.3 for ACh; 4.2±0.1 and 2.4±0.4 for nic; 4.1±0.0 and 3.5±1.3 for methCho, 3.9±0.1 
and 2.8±1.8 for butCho; 3.4±0.0 and 2.1±0.3 for carbCho. E. Sample traces for 
acetylcholine concentration–response relationships in the presence of 10 μM α-
bungarotoxin (α-BTX), 30 μM DHβE (Dihydro-β-erythroidine) and 30 μM d-
tubocurarine (d-TC). F. Acetylcholine concentration-response curves in the presence of 
α-BTX (n=7), DHβE (n=6) and d-TC (n=6). d-TC caused »98% reduction in the mean 
acetylcholine response. α-BTX (pEC50 = 5.0±0.0 and Imax = 86.0±2.4%) and DHβE 
(pEC50 = 4.6±0.0 μM and Imax = 91.1±4.1%) failed to show any significant antagonistic 





agonists (Supporting Information Data S3.0).  This confirmed the presence of a nicotinic 
acetylcholine receptor (nAChR) in the pharynx of the parasite.  
We next quantified the effects of selected nicotinic agonists to determine whether 
the pharyngeal nAChRs are pharmacologically distinct from those of somatic muscle. 
Our pharyngeal preparations in this group had a mean resting membrane potential of -
21.3 ± 1.3 mV and a mean resting conductance (G) of 136.4 ± 14.9 µS (n=17). The 
change in conductance (dG) responses to test applications of selected nicotinic agonists 
were normalized to the ACh dG. Nicotine was the most potent agonist after acetylcholine 
with mean dG of 92.0 ± 6.2%. Cytisine also produced a large conductance change in the 
A. suum pharynx (mean dG = 71.2 ± 5.0). The rank order potency series for vertebrate 
nicotinic agonists on the A. suum pharynx was: ACh > nicotine > cytisine > epibatidine > 
DMPP >> choline (Figure 3.1A). The rank order potency series of selected vertebrate 
nicotinic agonists on the pharynx differs from that of somatic muscle nAChRs and 
vertebrate host nAChRs (Supporting Information Table S3.0). We also tested nine 
cholinergic anthelmintics on the receptor to study their effect. Our pharyngeal 
preparations in these experiments had a mean resting membrane potential of -19.3 ± 1.1 
mV and a mean resting conductance of 150.5 ± 11.9 µS (n=21). The dG responses to test 
applications of selected cholinergic anthelmintic agents were normalized to the ACh dG. 
Figure 3.1B shows the rank order potency series on the A. suum pharynx: ACh >> 
bephenium > thenium > levamisole » morantel » pyrantel » oxantel » methyridine » 
tribendimidine. In contrast to somatic muscle nAChRs, none of the cholinergic 
anthelmintics tested on the pharynx produced >7% of the acetylcholine response 




To further investigate the receptor, we used selected nicotinic antagonists (30µM) 
to study their inhibitory effects on 100µM ACh responses. Our pharyngeal preparations 
in this group had a mean resting membrane potential of -20.2 ± 1.1 mV and a mean 
resting conductance of 129.2 ± 6.8 µS (n=34). The dG produced by a control application 
of ACh was set as 100%. We calculated the % inhibition of the dG response to ACh by 
nicotinic antagonists to determine a rank order potency series (mean ± SEM, Supporting 
Information S3.3): d-tubocurarine > mecamylamine > methyllycaconitine > 
paraherquamide > derquantel > hexamethonium > DHbE. The rank order potency series 
of nicotinic receptor antagonists on the pharynx differs from that of vertebrate nAChRs 
(Supporting Information Table S3.0).  
We also determined concentration response curves by plotting the concentration 
of agonists (1-1000µM, applied for 10s) against the response (dG) produced. The dG 
produced during the increasing concentration of agonist was normalized to the dG 
produced by 100 µM ACh (applied for 10s) within each experiment. Figure 3.1C shows 
the concentration response curves for ACh and nicotine. The pEC50 of ACh and nicotine 
were 5.0 ± 0.0 and 5.0 ± 0.1. The maximal response of ACh was 105.3 ± 2.5 µS and 
nicotine was 79.3 ± 4.3 µS. We determined the ACh concentration-response relationships 
in the presence of nicotinic receptor antagonists: d-tubocurarine (10µM), 
methyllycaconitine (10µM), paraherquamide (10µM) and dihydro-b-erythroidine (30µM) 
(Figure 3.1D). The pEC50 of the ACh concentration response curve did not significantly 
differ in the presence of methyllycaconitine, dihydro-b-erythroidine, d-tubocurarine  or 
paraherquamide but the maximal response for ACh was inhibited. This suggests that 






Figure 3.1 Pharmacology of the A. suum pharynx. A. Bar graph showing the rank 
order potency of selected vertebrate nAChR agonists producing % change in membrane 
conductance (dG; expressed as mean±SEM,%, n³4): ACh (100.0±0.0) > nicotine (nic; 
92.0±6.2) > cytisine (cyt; 71.0±5.0) > epibatidine (epi; 31.0±3.0) > 
dimethylphenylpiperazine (DMPP; 12.0±2.9) >> choline (cho; 0.0±0.0). B. Bar graph 
showing the rank order potency series of selected cholinergic anthelmintics producing % 
change in membrane conductance (dG; expressed as mean±SEM,%): bephenium (bep; 
7.2±3.5) > thenium (the; 6.1±1.5) > levamisole (lev; 1.8±0.61) >>> morantel (mor; 
0.3±0.3) > pyrantel (pyr; 0.0±0.0) = oxantel (oxa; 0.0±0.0) = methyridine (met; 0.0±0.0) 
= tribendimidine (tri; 0.0±0.0). C. Concentration-conductance curves for ACh and 
nicotine plotting % change in conductance vs log molar concentration of the drugs. pEC50 
(mean±SEM) and hill slope (nH, mean±SEM) values were respectively: 5.0±0.0 and 
1.8±0.3 for acetylcholine (n=6) and 5.0±0.1 and 1.7±0.6 for nicotine (n=8). D. 
Concentration-conductance plots of ACh in the presence of nAChR antagonists: 
paraherquamide (para; 10µM), methyllycaconitine (MLA; 10µM), d-tubocurarine (d-TC; 
10µM) and Dihydro-β-erythroidine (DHbE; 30µM). The pEC50 values were 5.0±0.1 in 
the presence of MLA (n = 8); 4.9±0.2 in the presence of d-TC (n = 3); 5.1±0.1 in the 
presence of para (n = 3) and 4.8±0.0 in the presence of DHbE (n = 7). The maximal 
response (dG) (mean±SE, µS) values were: 57.0±4.6 in the presence of MLA; 23.0±3.0 





3.4.5 Functional expression of Asu-EAT-2 requires Asu-EAT-18 and Asu-
RIC-3 
After characterizing the A. suum pharyngeal nicotinic response, we were interested in 
identifying the subunits which constitute these ion channels. We used Cel-EAT-2 and 
Cel-EAT-18 sequences as queries in BLASTP homology searches and identified 
homologues for EAT-2 and EAT-18 in the pig parasite. Comparison of Asu-EAT-2 with 
Cel-EAT-2 sequences revealed 80% similarity in amino acid composition, with 
differences among some of the ligand binding residues from various loops (Supporting 
Information S3.1). This suggested that the receptor channel could have different contact 
residues in the ligand binding pocket and possibly a different pharmacology. The proteins 
were expressed in vitro in Xenopus oocytes to recapitulate the pharyngeal ligand-gated 
cation channel. Unlike Cel-EAT-2 nAChRs, Asu-EAT-2 not only required Asu-EAT-18 
but also Asu-RIC-3 for robust expression. However, addition of Asu-UNC-50 or Asu-
UNC-74 did not produce any significant increase in current amplitude. The most robust 
responses were observed from oocytes injected with 30 ng each of Asu-EAT-2 and Asu-
EAT-18 plus 20 ng of Asu-RIC-3 (Supporting Information S3.4), and so these cRNA 
amounts were used for all subsequent injections. 
3.4.6 Pharmacological profile of the Asu-EAT-2 nAChR 
To determine the agonist pharmacology of the Asu-EAT-2 receptor we tested various 
cholinergic agonists and anthelmintic agents. The rank order potency series based on 
maximum current response (Figure 3.2A) for the receptor was: nicotine > acetylcholine > 
cytisine > epibatidine > DMPP > oxantel. As with the A. suum pharynx, cholinomimetic 




activate the receptor. We also constructed a concentration-response curve for 
acetylcholine and found it to be » 9 times more potent on the Asu-EAT-2 nAChR 
compared to Cel-EAT-2 with a pEC50 = 5.7 ± 0.0 (Figure 3.2B). We tested the 
antagonistic effects of derquantel, mecamylamine, d-tubocurarine, DHbE, 
hexamethonium and methyllycaconitine on the Asu-EAT-2 receptor. The mean % 
inhibition of the 100 μM acetylcholine current response was used to determine the rank 
order potency of the antagonists. Mecamylamine and d-tubocurarine produced almost 
100% inhibition of the acetylcholine currents and DhβE was the least potent antagonist 
(inhibition, 66 ± 8.4%). The rank order potency series for the antagonists (Figure 3.2C) 
was: d-tubocurarine ~ mecamylamine > hexamethonium > methyllycaconitine > 
deraquantel > DhβE. The rank order potency series of cholinomimetic anthelmintics, 
nicotinic agonists and antagonists on the Asu-EAT-2 receptor differs from that of the A. 
suum somatic muscle nAChRs as well as the vertebrate nAChRs (Supplementary 
Information S3.0). In conclusion, the Asu-EAT-2 receptor has a distinct pharmacology 
and is therefore likely suitable to be exploited as a therapeutic target. 
3.4.7 Tissue expression of eat-2 and eat-18 in A. suum  
In C. elegans, EAT-2 expression is restricted to pharyngeal muscle, while EAT-
18 is found in both pharyngeal muscle and some neurons (McKay et al. 2004). We used 
RT-PCR to examine the distribution of Asu-eat-2 and Asu-eat-18 mRNA in various 
dissected adult A. suum tissues and single somatic muscle cells (n≥ 5; Figure 3.2D). We 
determined that Asu-eat-2 was transcribed in the pharynx, sections of the reproductive 





Figure 3.2: Effect of selected cholinergic agonists, anthelmintics and antagonists on the 
Asu-EAT-2 receptor. A. Bar graph showing the rank order potency (mean ± SEM, %, 
n³5) of cholinergic agonists and anthelmintics when normalized to the control 100 μM 
ACh current: nicotine (nic; 105.0±5.7) » acetylcholine (ACh; 100±0.0, n=9) > cytisine 
(cyt; 81.0±5.2) > epibatidine (epi; 77.0±4.2) > dimethylphenylpiperazinium (DMPP; 
6.6±1.9) > oxantel (oxa; 3.0±1.3) >>> bephenium (bep; 0.1±0.1, n=9) = tribendimidine 
(tri; 0.0±0.0) = levamisole (lev; 0.0±0.0) = pyrantel (pyr; 0.0±0.0) = choline (cho; 
0.0±0.0) = thenium (the; 0.0±0.0). B. Comparison of concentration-response plots to 
acetylcholine for the Cel-EAT-2 (black curve) and Asu-EAT-2 (maroon curve) receptor. 
pEC50 (mean ± SEM) and hill slope (nH, mean ± SEM) values were respectively: 4.8 ± 
0.0 and 1.9 ± 0.2 for Cel-EAT-2 (n=9); 5.8 ± 0.1 and 3.5 ± 1.1 for Asu-EAT-2 (n=6). C. 
Bar graph showing the rank order potency of selected vertebrate nAChR antagonists. 
Results were expressed as mean ± SEM (%, n=6), inhibition of currents elicited by 100 
μM ACh. d-Tubocurarine (d-TC, 10µM; 97±1.0) and mecamylamine (mec, 10µM; 
95±1.1) almost completely blocked the acetylcholine response. Mean current inhibition 
were 83.0±5.1 for hexamethonium (hex, 10µM), 78.0±8.1 for methyllycaconitine (MLA, 
10µM), 72.0±3.4 for derquantel and 66±8.4 for DHβE (30µM, Dihydro-β-erythroidine). 
D. Localization of Asu-eat-2 and Asu-eat-18 mRNA in different body tissues of the A. 
suum worm (n = 5). RT-PCR analysis of Asu-eat-2 (lanes 2, 5, 8,11) and Asu-eat-18 
(lanes 3, 9, 9,12) and gapdh control (lanes 4, 7, 10, 13) in pharynx, ovijector, head, and 
gut region. The PCR product sizes for eat-2, eat-18 and gapdh were 949, 213 and 411 bp 




the same tissues, as well as gut tissue. We found no evidence of expression of Asu-eat-2 
or Asu-eat-18 in somatic muscle cells (Supplementary Information S3.5). The widespread 
expression of both the proteins in body tissues other than pharynx was unexpected. It is 
plausible that Asu-EAT-2 not only assists in feeding but also plays a role in other 
physiological processes such as reproduction. It also raises the possibility that EAT-18 is 
interacting with other nAChR subunits in different tissues. 
3.4.8 Comparative pharmacological profile reveals EAT-2 constitutes the 
pharyngeal nAChR in A. suum  
Figure 3.3A shows the pharmacological comparison between in vitro Cel-EAT-2, 
Asu-EAT-2 and in vivo A. suum pharyngeal recordings. The agonist rank order potency 
series acquired from both in vivo and in vitro recordings in A. suum revealed a similar 
pharmacological profile. Both nicotine and cytisine were highly efficacious in in vivo and 
in vitro recordings in A. suum, while DMPP acted as a weak agonist. In comparison, the 
Cel-EAT-2 channel failed to respond to cytisine and DMPP application but was activated 
by oxantel (Imax = 11.0 ± 1.3 % of acetylcholine response) albeit weakly. Importantly, the 
comparable pharmacological profile observed for Ascaris in vivo and in vitro recordings  
suggests it is likely that EAT-2 and EAT-18 constitute the pharyngeal nicotinic response 
in the parasitic nematode. 
3.4.9 Different EAT-18 homologues affect the pharmacology of the EAT-2 
nAChR 
We expected to see differences in nAChR pharmacology between A. suum and C. 
elegans due to differences in the amino acid residues of the EAT-2 protein sequences. 




the pharmacological relevance of EAT-18, we expressed Cel-EAT-2 with Asu-EAT-18. 
We tested five agonists on the expressed channel: acetylcholine, nicotine, cytisine, 
levamisole, tribendimidine and pyrantel (data not shown). No significant differences were 
observed in the rank order potency series.  Interestingly, the nicotine sensitivity was 
affected illustrating a change in the pharmacology (Figure 3.3B). Substitution of Asu-
EAT-18 for Cel-EAT-18c shifted the concentration-response curve to the left and 
increased the efficacy of nicotine on the receptor. The EC50 = 18.7 µM (pEC50 = 4.7 ± 
0.0) for nicotine was approximately 3.5 times lower than before 64.2 µM (pEC50 = 4.2 ± 
0.0). We also observed a significant increase in Imax (96.5 ± 2.3% from 54.6 ± 2.6%) 
when replacing Cel-EAT-18c with Asu-EAT-18. Sensitivity of the pharyngeal receptor to 
acetylcholine was also altered significantly but there was no effect on the agonist efficacy 
(Supplementary Information S3.6A and B). The significant shift in acetylcholine and 
nicotine pEC50 establishes the electrophysiological evidence of modulation of the 
receptor by EAT-18 and points to an interaction between the proteins. 
3.4.10 EAT-18 colocalizes with EAT-2 on the oocyte surface membrane  
EAT-18 is required for functional in vitro expression of EAT-2 and modulates its 
pharmacological properties. McKay et al. (2004) have shown that Cel-EAT-18 is not 
required for trafficking of Cel-EAT-2 to the oocyte membrane. It is possible that Cel-
EAT-18 functions as an auxiliary subunit rather than an ancillary chaperone protein. To 
test this hypothesis, we performed confocal imaging experiments on oocytes expressing 
GFP tagged Cel-EAT-2 and His tagged Cel-EAT-18c constructs. These experiments 
revealed that both Cel-EAT-2 and Cel-EAT-18c were co-localized on the oocyte surface 




Figure 3.3 A. Bar graph showing comparative pharmacology of agonists for Cel-EAT-2 
receptor expressed in vitro, Asu-EAT-2 receptor expressed in vitro and in vivo pharyngeal 
recording in A. suum. Inset: Images of source nematode (C. elegans and A. suum) and 
corresponding recording techniques (TEVC recordings from X. laevis oocytes and 
current-clamp recordings from intact A. suum pharynx). B. Effect of different EAT-18 
homologues on pharmacology of the Cel-EAT-2 receptor. Concentration-response curves 
showing comparison for nicotine application on Cel-EAT-2 + Cel-EAT-18c mix (black 
curve), Cel-EAT-2 + Cel-EAT-18c + Asu-RIC-3 (blue curve) and Cel-EAT-2 + Asu-
EAT-18 + Asu-RIC-3 mix (green curve). Bar graphs showing significant effect of using 
different EAT-18 proteins with Cel-eat-2 on pEC50 (top graph) and on maximum 
response (bottom graph) produced by application of 300 µM nicotine. ***P < 0.001, ****P 
< 0.0001; significantly different as indicated; Tukey’s multiple comparison tests.  
 
injected and un-injected oocytes. Cel-EAT-18c is not a typical nAChR subunit protein 
and its co-localization with Cel-EAT-2 suggests the possibility of an association between 
both proteins. Cel-EAT-2-GFP, when expressed alone, localizes to the oocyte surface 
membrane suggesting that Cel-EAT-18c does not function as an ancillary protein (Figure 




analysis of oocyte protein extracts. Using antibodies that recognize GFP and His tags, we 
detected Cel-EAT-2-GFP as a 62 kDa and Cel-EAT-18c-His as a 10kDa protein (Figure 
3.4E and Supplementary Information S3.9A). We were able to detect Cel-EAT-2 in 
membrane extracts prepared from oocytes co-injected with Cel-EAT-2 and Cel-EAT-18c 
as well as oocytes injected with Cel-EAT-2 alone. In contrast, Cel-EAT-18c was only 
present in membrane extracts prepared from oocytes co-injected with both Cel-EAT-2 
and Cel-EAT- 18c. We did detect Cel-EAT-18c in whole oocyte extracts when Cel-EAT-
18c was injected alone. It is plausible that EAT-18 requires EAT-2 for trafficking to the 
surface membrane and its role is more complex than a simple ancillary protein; perhaps 
related to the functionality of the mature receptor. 
3.4.11 EAT-18 forms a part of the EAT-2 nAChR complex  
Although Cel-EAT-18c was co-localized with Cel-EAT-2 on the surface membrane of 
the oocytes and modulated the pharmacology of pharyngeal nAChR, it did not define the 
molecular interaction. Therefore, we performed co-immunoprecipitation experiments in 
order to explore a possible, direct interaction between Cel-EAT-18c and Cel-EAT-2 
(Figure 3.4F and Supplementary Information S3.9B). We were able to demonstrate that 
Cel-EAT-18c-His co-immunoprecipitated with Cel-EAT-2-GFP, which shows that EAT-







Figure 3.4 EAT-2 and EAT-18 form a receptor complex. A. Immunostained oocyte 
sections showing expression of Cel-EAT-2-GFP (red fluorescence; n=4) on the surface 
membrane when injected alone. B. Cel-EAT-18-His (n=4) fails to localize on the surface 
membrane when injected alone. C. Double immunostained sections of Xenopus laevis 
oocytes showing Cel-EAT-2-GFP and Cel-EAT-18-His (n=6) on the surface membrane. 
The overlay image (yellow fluorescence) shows the co-localization of both the proteins. D. 
Double immunostained sections of un-injected (negative control; n=6) Xenopus laevis 
oocytes. E. Western blot analysis of Xenopus oocyte extracts. Un-injected oocytes served 
as negative control. Cel-EAT-2-GFP was immunostained with anti-GFP antibodies and 
was present in the extracts prepared from oocytes co-injected with Cel-EAT-18-His as well 
as oocytes injected with Cel-EAT-2-GFP alone. Cel-EAT-18-His was immunostained with 
anti-His antibodies and was present in the extracts prepared from oocytes co-injected with 
Cel-EAT-2-GFP. ✶, ✣: non-specific interacting protein bands labelled by anti-GFP and 
anti-his antibodies respectively, served as positive control. F. Co-immunoprecipitation 
experiments revealed Cel-EAT-18 directly interacts with EAT-2 and constitutes part of the 
receptor complex. Cel-EAT-2-GFP was immunoprecipitated using anti-GFP followed by 
western blot analysis of Cel-EAT-18-His using anti-His antibodies. Un-injected oocytes 
and oocytes injected with Cel-EAT-2-GFP alone served as negative controls for co-
immunoprecipitation experiments. ✶: non-specific interacting protein bands labelled by 
anti-GFP and anti-his antibodies respectively, served as positive control. G. Schematic 








nAChRs are key components of the metazoan neuromuscular junction and 
important targets for anti-parasitic interventions. They typically are composed of 5 
subunits including at least 2 α subunits. Here we describe for the first time a non-α 
nAChR subunit can form a functional homomeric cation selective receptor. Cel-EAT-18 
functions as an obligate auxiliary protein and modifies the pharmacological properties of 
this cys-loop ion channel. A number of previously characterized nAChRs require 
ancillary proteins, either RIC-3 alone or in combination with UNC-50 and UNC-74, for 
successful in vitro expression (Abongwa, Buxton, et al. 2016; Boulin et al. 2008; Millar 
2008; Haugstetter, Blicher, and Ellgaard 2005; Buxton et al. 2014). The Cel-EAT-2 
receptor instead only required co-expression with EAT-18, which has no similarity to 
other ancillary proteins, for in vitro expression. Both proteins are localized in the 
pharyngeal muscles and mutations in Cel-eat-18 caused pharyngeal pumping defects 
similar to Cel-eat-2 mutations (McKay et al. 2004; Raizen, Lee, and Avery 1995). Based 
on our confocal imaging studies, Cel-EAT-18c is localized on the oocyte surface only 
when injected with Cel-EAT-2. This supports our hypothesis that EAT-18 interacts with 
EAT-2 and likely requires the pore forming subunit protein for trafficking to the surface 
membrane. Other evidence of interaction is provided by the pharmacological modulation 
of the acetylcholine and nicotine responses by using EAT-18 proteins from different 
nematode species with Cel-EAT-2. The co-immunoprecipitation experiments have 
provided more concrete evidence of direct physical interaction between Cel-EAT-2 and 
Cel-EAT-18. EAT-18 modifies the pharmacological properties of the EAT-2 nAChR and 




pumping. Therefore EAT-18 meets the criteria of an auxiliary protein. However, unlike 
other auxiliary proteins, successful expression of a functioning channel requires the 
presence of EAT-18. Various auxiliary subunits have been discovered for the ionotropic 
glutamate-gated (kainate and AMPA) and GABAB receptors that modulate their 
properties or functional expression levels (Yan and Tomita 2012; Ben-Yaacov et al. 
2017; Schwenk et al. 2010; Tomita and Castillo 2012). The interaction of these auxiliary 
subunits with the receptor complex holds a physiological relevance. MOLO-1 (modulator 
of levamisole receptor-1) is the first example of an auxiliary subunit for levamisole 
sensitive acetylcholine receptors in C. elegans (Boulin et al. 2012). Like MOLO-1, null 
mutants of EAT-18 result in significant physiological defects and many of the nematode 
species express highly conserved orthologues of EAT-18 (Supplementary Information 
S3.8) suggesting evolutionary conservation of function. In contrast to EAT-18, MOLO-1 
is not required for the functional expression of the somatic levamisole nAChR but only 
regulated the trafficking, localization or gating kinetics; instead EAT-18 is essential for 
EAT-2 to form a functional receptor in vitro. This implies that EAT-18 not only meets 
the criteria for an auxiliary protein but may belong to a novel class of proteins not 
previously described, adding to the types of auxiliary subunits identified for the cys-loop 
cation channels. 
Identification of a suitable target and its validation is one of the most important 
steps in developing a new drug. An ideal anthelmintic target should meet certain criteria 
in order to be considered relevant for pharmacological intervention; important 
physiological function, conservation across parasite species and pharmacological 




as popular targets because they contribute to vital physiological functions. Additionally, 
their diversity, conserved structure among various species of nematodes and distinct 
pharmacology from mammalian orthologues makes them “druggable”. The pharynx is a 
muscular organ required for feeding in nematodes. While the nematode pharynx has been 
exploited as a target tissue for the avermectins (GluCl- channels) (Cully et al. 1994a; 
Martin 1996; Brownlee, Holden-Dye, and Walker 1997; Pemberton et al. 2001) less is 
known about the nAChRs in this tissue. In C. elegans two genes, eat-2 and eat-18, were 
required for MC neurotransmission. Cel-EAT-2 and Cel-EAT-18 are both localized in the 
pharyngeal muscles and mutations in these genes caused defects in feeding behavior in 
the worms (Raizen, Lee, and Avery 1995; McKay et al. 2004). We hypothesize that 
activation of the pharyngeal nAChR formed by the EAT-2 subunit and EAT-18 auxiliary 
protein will lead to an effect similar to levamisole in somatic muscle and cause 
pharyngeal paralysis in nematodes. We were able to successfully co-express EAT-2 and 
EAT-18 from C. elegans, a model nematode, and A. suum, a parasitic species, in Xenopus 
oocytes and characterize the pharmacology of this conserved receptor. 
3.5.1 The pharyngeal nAChR composed of EAT-2 and EAT-18 as a novel 
drug target  
The pharyngeal cys-loop ligand-gated ion channel formed by EAT-2 meets the 
criteria for a suitable anthelmintic drug target (Wever, Farrington, and Dent 2015): 1) it 
performs a neuromuscular function essential for parasite biology; 2) this receptor is 
druggable, it has distinct pharmacology from somatic muscle receptors and is insensitive 
to many of the currently used cholinergic anthelmintic including morantel, tribendimidine 




species (Supplementary Information S3.7 and S3.8) and the protein sequences are highly 
conserved; 4) Cel-EAT-2 is only 36% identical to human α-7 nAChR subunit and there 
are no mammalian homologues for EAT-18 providing potential for selectivity; it is also 
pharmacologically distinct from vertebrate nAChRs.  In order to identify novel drug 
targets for anthelmintic agents, it is important to understand the properties and function of 
the target proteins. We have successfully elucidated the components and pharmacological 
profile of the pharyngeal nAChR by employing various molecular, biochemical and 
electrophysiology techniques.  
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3.10 Supporting information 
 
Supporting Figure S3.0 Amino acid sequence alignment of Asu-EAT-18, Cel-EAT-18c, 
and Cel-EAT-18d. Predicted transmembrane domain is highlighted in blue.  
 
Supporting Figure S3.1 Amino acid sequence alignment of Cel-EAT-2, Asu-EAT-2 and 
human-α7 nAChR subunits. The signal peptide (olive green), ACh-binding loops A–C 
(purple), cys-loop (orange) and transmembrane regions TM1–TM4 (light blue) are 
indicated. The vicinal cysteines (grey box) are absent in the C-binding loop of the 
EAT-2 protein. The conserved ligand binding residues of human-α7 subunits are 
highlighted in blue color in loops A-C and in maroon color in loops D-F. The residues 
Asu-EAT-18    MRTLERVVETRIDMLEFEEGDQIKEDCPFCRSLDCDIIFALLFTFVIACLLVLIMVFWLK 60
Cel-EAT-18c   MRSLERIVETRIELLEWDSK-ETKEDCARCRALDCDIIFALLFTIVIACLLVLIMVFWLK 59
Cel-EAT-18d   MRSLERIVETRIELLEWDSK-ETKEDCARCRALDCDIIFALLFTIVIACLLVLIMVFWLK 59
**:***:*****::**::.  : ****  **:************:***************
Asu-EAT-18    GVLQYEDVYTRLSRGQGNV 79
Cel-EAT-18c   GVLQYEEMRSTL------- 71
Cel-EAT-18d   GVLQYEDVYTRLLRDRGSV 78
******:: : *       
Intracellular N-terminal Transmembrane domain
Extracellular C-terminal
Fig. S1: Amino acid sequence alignment of  Asu-EAT-18, Cel-EAT-18c, and Cel-EAT-18d. 





not conserved in EAT-2 proteins are in grey boxes in the loops. The negatively 
charged acid residues flanking the transmembrane-2 region are highlighted in orange. 
 
 
Supporting Figure S3.2 Pharmacology of the Cel-EAT-2 nicotinic acetylcholine 
receptor. A. Representative traces for methacholine and butyrylcholine concentration-
response relationships for Cel-EAT-2 receptor. B. Representative traces & 
acetylcholine concentration-response curves for Cel-EAT-2 receptor in the presence of 
10 μM derquantel (der, n=6) and 30 μM paraherquamide (para, n=6). The pEC50 and 
Imax values (expressed as mean±SEM) were: 4.9±0.0 and 68.4±2.1% in the presence of 
derquantel; 4.7±0.1 and 40.2±2.7% in the presence of 30 μM paraherquamide. Both 
the antagonists did not produce a shift in pEC50 but reduced the efficacy of the 
acetylcholine on the Cel-EAT-2 receptor significantly (****P < 0.0001, Extra sum of 
squares F-test).  
 
Supporting Figure S3.3 Bar graph showing the rank order potency of selected 
vertebrate nAChR antagonists (30µM) producing % inhibition of 100µM ACh 
membrane conductance (dG; expressed as mean ± SEM, %) in the A. suum pharynx: d-
Tubocurarine (d-TC; 94.6±0.2) > mecamylamine (mec; 92.2±1.9) > 




(der; 30.6±7.0) > hexamethonium (hexa; 26.8±1.9) > dihydro-b-erythroidine (DHbE; 
17.9±5.0). 
 
Supporting Figure S3.4 Bar chart showing current sizes (mean ± S.E.M) produced in 
response to 100 μM acetylcholine on Asu-EAT-2 nAChR. Black bar: Asu-EAT-2 + 
Asu-EAT-18 + Asu-RIC-3 (n=11). Olive green bar: Asu-EAT-2 + Asu-EAT-18 + Asu-
RIC-3 + Asu-UNC-50 + Asu-UNC-74 (n=6). Asu-EAT-2 and Asu-EAT-18 did not 




Supporting Figure S3.5 Single-cell RT-PCR of Asu-eat-2 (lanes 2, 6), Asu-eat-18 (lanes 
3, 7) and gapdh control (lanes 4,8) in somatic muscle cells (n=10). Lane 1, FastRuler 
High Range DNA ladder; negative control- no-template controls for Asu-eat-2 (lane-






Supporting Figure S3.6 A. Concentration response curves for acetylcholine application 
on Cel-EAT-2 + Cel-EAT-18c mix (black curve), Cel-EAT-2 + Cel-EAT-18c + Asu-
RIC-3 (blue curve) and Cel-EAT-2 + Asu-EAT-18 + Asu-RIC-3 mix (green curve). B. 
Bar graphs showing significant effect of using different EAT-18 proteins with Cel-eat-
2 on pEC50.**P < 0.01, ***P < 0.001; significantly different as indicated; based on 
Extra sum of squares F-test.  
 
 
Supporting Figure S3.6 Protein sequence alignment of EAT-2 subunit from multiple 
parasitic nematode species. The signal peptide (olive green), ACh-binding loops A–C 
(pink), loops D-F (green), cys-loop (grey) and transmembrane regions TM1–TM4 
(blue) are indicated. The conserved ligand binding residues are highlighted in blue 




Supporting Figure S3.7 Amino acid sequence alignment of EAT-18 from multiple 
parasitic nematode species. Transmembrane domain highlighted in blue. 
 
 
Supporting Figure S3.8: A. Uncropped western blots corresponding to Figure 3.4E. B. 
Uncropped western blots corresponding to Figure 3.4f. Dashed blue regions represent 







Supplementary Table 1: Rank order potencies of nAChR agonists, antagonists and 
cholinergic anthelmintics in A. suum pharyngeal nAChRs observed from our study, A. 
suum somatic muscle nAChRs and nAChRs of the vertebrate hosts. ACh 
(acetylcholine), nic (nicotine), cyt (cytisine), epi (epibaditine), DMPP 
(dimethylphenylpiperazine), chol (choline), pyr (pyrantel), oxa (oxantel), bep 
(bephenium), the (thenium), lev (levamisole), met (methyridine), d-TC (d-
tubocurarine), mec (mecamylamine),  MLA (methyllycaconitine), para 
(paraherquamide), der (derquantel), hexa (hexamethonium) and DHβE (Dihydro-β-
erythroidine). 
1 Colquhoun, L., Holden-Dye, L. & Walker, R.J. J Exp Biol 158, 509-530 (1991). 
2 Martin, R.J., Clark, C.L., Trailovic, S.M. & Robertson, A.P. Int J Parasitol 34, 1083-
1090 (2004). 
3 Trailovic, S.M., Verma, S., Clark, C.L., Robertson, A.P. & Martin, R.J. Int J 
Parasitol 38, 945-957 (2008).  
4 Yost, C.S. & Winegar, B.D. Cell Mol Neurobiol 17, 35-50 (1997) .  
5 Wonnacot, S. & Barik, J. Tocris Bioscience scientific review series 28,1-20 (2007). 
6 Virginio, C., Giacometti, A., Aldegheri, L., Rimland, J.M. & Terstappen, G.C. Eur J 
Pharmacol 445, 153-161 (2002).  









Supplementary Data 1: Acetylcholine is a known agonist at nicotinic and muscarinic 
receptors in vertebrates. The rank order potency of muscarinic agonists (all used at 
100µM) observed for an A. suum muscarinic receptor expressed in yeast was ACh 
(100%) > carbachol (80%) ≅ arecoline (76%) > oxotremorine (61%) ≅ bethanechol 
(58%) > pilocarpine (14%)1. Here we tested the hypothesis that the observed change in 
membrane conductance response (δG) to ACh on the pharynx is produced by activation 
of nAChRs and mAChRs (GARs). Our pharyngeal preparations in this group had a 
resting membrane potential (RMP) of -17.6±1.3 mV and a resting conductance of 
147.8±13.1 µS (n=8, mean±SE). We tested responses to the muscarinic agonists ACh, 5-
methylfurmethiodide (MFI), oxotremorine, arecoline, pilocarpine (all 100µM, 10s 
application). In applications containing arecoline and pilocarpine, we used 
mecamylamine, a nAChR antagonist (30µM) to inhibit nAChRs and to allow only 
mAChR activation. A control application of ACh (100 µM, 10s) in the presence of 
mecamylamine was used for comparison of response to nAChR activation. We 
normalized the conductance change (δG) produced by the control ACh application (100 
µM, 10s) to 100% in order compare the relative responses to other muscarinic agonists. 
The normalized responses to muscarinic agonists (mean ± SE, %, n=4) were MFI 
(4.0±0.6), oxotremorine (1.8±0.8), arecoline (2.6±2.0), pilocarpine (0.7±0.7). 
Mecamylamine inhibited 92% of the ACh δG response suggesting nicotinic receptor 
activation rather than the muscarinic receptor activation was responsible for the observed 
changes. Our results demonstrate the contribution of mAChRs to the acetylcholine 
induced conductance changes is negligible. Therefore, it was unnecessary to further use 
muscarinic receptor antagonists in our experiments to characterize the nAChRs. Other 
work has documented the phenomenon of concentration dependent reversible channel 
block produced by atropine (IC50 = 4-10µM) on α3β4, α3β2, α4β4 and α4β2 vertebrate 
nAChRs2.  
1 Kimber M.J. et al. Int J Parasitol 39: 1215-1222 (2009). 
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4.1 Abstract 
Parasitic nematode infections are treated using anthelmintic drugs, some of which 
target nicotinic acetylcholine receptors (nAChRs) located in different parasite tissues. 
The limited arsenal of anthelmintic agents and the prevalence of drug resistance implies 
that future defense against parasitic infections will depend on the discovery of novel 
targets and therapeutics. Previous studies have suggested that Ascaris suum ACR-16 
nAChRs are a suitable target for the development of antinematodal drugs. In this study 
we characterized the pharmacology of the Ancylostoma caninum ACR-16 receptor using 
two-electrode voltage-clamp electrophysiology. This technique allowed us to study the 
effects of cholinergic agonists and antagonists on the nematode nAChRs expressed in 
Xenopus laevis oocytes. Aca-ACR-16 was not sensitive to many of the existing 
cholinomimetic anthelmintics (levamisole, oxantel, pyrantel and tribendimidine). 3-
Bromocytisine was the most potent agonist (>130% of the control acetylcholine current) 




receptor. The mean time constants of desensitization for agonists on Aca-ACR-16 were 
longer than the rates observed in Asu-ACR-16. In contrast to Asu-ACR-16, the A. 
caninum receptor was completely inhibited by DhβE and moderately inhibited by α-BTX. 
In conclusion, we have successfully reconstituted a fully functional homomeric nAChR, 
ACR-16, from A. caninum, a model for human hookworm infections. The pharmacology 
of the receptor is distinct from levamisole sensitive nematode receptors. The ACR-16 
homologue also displayed some pharmacological differences from Asu-ACR-16. Hence, 
A. caninum ACR-16 may be a valid target site for the development of anthelmintics 
against hookworm infections.  
Keywords 
nAChR, hookworms, Aca-ACR-16, anthelmintic, Xenopus oocyte 
 
4.2 Introduction 
 Infections caused by hookworms (mainly Necator americanus and Ancylostoma 
duodenale) are one of the leading neglected tropical disease, affecting approximately 500 
million people worldwide; especially in the developing regions of Asia, Africa, Latin 
America and the Caribbean (Pullan et al. 2014; Loukas et al. 2016; Hotez 2008). These 
infections account for >4 million disability adjusted life years (DALYs) lost annually and 
an estimated global economic loss of over US $100 billion (Loukas et al. 2016; 
Bartsch et al. 2016). These blood feeding nematodes do not directly account for 
substantial mortality; instead the major clinical manifestations of hookworm infection are 
the consequences of chronic intestinal blood loss.  Severe infection can result in iron 




al. 2006; Hotez and Pritchard 1995). Hookworm infections pose a major health threat to 
adolescent girls, women of reproductive age and children (Menzies et al. 2014; Brooker, 
Hotez, and Bundy 2008). Heavy worm burdens can result in retarded physical and 
cognitive development in children and poor outcomes for pregnant women and their 
newborns (Guyatt et al. 2000; de Silva et al. 2003a; Hotez et al. 2014).  
Current hookworm control strategies are limited to deworming of infected people 
using anthelmintic drugs combined with ancillary strategies such as improvement of 
water quality, sanitation and hygiene (WASH) in endemic regions (WHO 2015; 
Campbell et al. 2018; Albonico et al. 2003). At this time, there is no effective vaccine for 
human use in medical circulation (Hewitson and Maizels 2014; Diemert, Bethony, and 
Hotez 2008), and only a limited number of drug options. Unfortunately, there have been 
failures of mass drug administration in endemic regions due to diminished efficacy and 
potential resistance to anthelmintic agents (Albonico et al. 2003; Krücken et al. 2017; 
Flohr et al. 2007; De Clercq et al. 1997; Reynoldson et al. 1997). The rapid reinfection 
rate of the worm combined with the ability of adult hookworms to survive up to 7 years 
in the human gut producing thousands of ova per day further complicates the issue 
(Albonico et al. 1995; Bennett and Guyatt 2000; Knopp et al. 2012). Due to all of these 
contributing factors, novel drug targets and drugs are required for efficient control of 
these parasitic infections. 
Research has focused on several different parasite ion channels because they are 
major target sites of many classes of antinematodal agents (Wolstenholme 2011; 
Abongwa, Martin, and Robertson 2017). Ion channels are essential for fundamental 




(nAChRs) which belong to the cys-loop ligand gated ion channel family serve as synaptic 
transmission proteins and mediate fast transduction of signals by opening an intrinsic ion 
channel (Jones et al. 2007; Thompson, Lester, and Lummis 2010a). They are pentameric 
channels which can be homomeric or heteromeric around a central pore. Nicotinic 
anthelmintics such as pyrantel and levamisole selectively paralyze nematodes by 
activating cholinergic ion-channels (nAChRs) in their body wall muscle (Abongwa, 
Martin, and Robertson 2017; Aceves, Erlij, and Martínez-Marañón 1970; Harrow and 
Gration 1985; Aubry et al. 1970; Martin et al. 2005). The significance of nematode 
nAChRs as drug targets has been emphasized by the recent development of novel amino-
acetonitrile compounds (Kaminsky et al. 2008).  
Ancylostoma caninum is the most widespread and pathogenic hookworm of dogs 
(Nemzek et al. 2015). Infestation typically results in anemia with bloody diarrhea, 
hemorrhagic enteritis, vomiting, anorexia, dehydration and poor weight gain, sometimes 
leading to death (Epe 2009; Dias et al. 2013). Zoonotic infection with A. caninum in 
humans has been associated with eosinophilic enteritis, localized myositis and cutaneous 
larva migrans (Prociv and Croese 1996; Bowman et al. 2010; Landmann and Prociv 
2003; Traversa 2012). Ancylostoma caninum is the most accessible of all hookworms for 
research and is closely related to human hookworm species, A. duodenale and N. 
americanus. Therefore, they are used as a model for human hookworm (Nemzek et al. 
2015; Prociv and Croese 1996; Blaxter 2000).  
In this study, we have cloned and expressed a homologue of ACR-16 from A. 
caninum, a clade V nematode parasite. The receptors were expressed in Xenopus laevis 




pharmacology. ACR-16 has been suggested as a druggable target in the parasitic clade III 
roundworm, Ascaris suum by Abongwa, Buxton, et al. (2016). The focus of this study 
was to generate a comparative pharmacological analysis of the homomeric channel and 
establish ACR-16 as a potential target in the hookworm parasites. 
 
4.3 Materials and Methods 
4.3.1 Ethical concerns 
No vertebrate animals were used directly in this study. Defolliculated Xenopus 
laevis oocytes were obtained from Ecocyte Bioscience (Austin, TX, USA).  
4.3.2 Parasites 
Ancylostoma caninum were obtained opportunistically from a naturally infected 
dog. Feces containing eggs was mixed with vermiculite and stored in a humidified 
container for 8 days.  The mixture was overlaid with cheesecloth and was placed under a 
desktop lamp at room temperature for 8 hours. L3 larvae were then concentrated and 
collected by the Baermann method (Hawdon 1991).   
4.3.3 Sequence analysis 
Database searches for A. caninum ACR-16 were performed by BLAST search 
(WormBase Parasite), using the BLASTP algorithms (Altschul et al. 1997). Signal peptide 
predictions were done using the SignalP 4.1 server (Petersen et al. 2011), and membrane-
spanning regions were identified using TMpred (Hofmann and Stoffel 1993). Alignment 
of the full-length amino acid sequences with Ascaris suum ACR-16 was carried out using 





4.3.4 Cloning of Aca-ACR-16  
TRIzol ReagentTM (InvitrogenTM, Carlsbad, CA, USA) was used to extract total 
RNA from homogenized A. caninum larvae. cDNA was synthesized by using SuperScript 
VILO Master Mix (InvitrogenTM, Carlsbad, CA, USA) according to the manufacturer’s 
instructions and served as a template for Aca-ACR-16 amplification (WormBase Parasite 
Gene ID: ANCCAN_01899). We used the Gibson assembly protocol to assemble the 
amplified fragments into the full length Aca-ACR-16 sequence (Gibson et al. 2009). Full 
length product was subcloned into pTB207 expression vector by adding XhoI and ApaI 
restriction enzyme sites respectively to the forward primer (5’ end: 
TGGCGGCCGctcgagATGCGTTCGTTGGTCGTCTG) and reverse primers (3’ end: 
ATCAAGCTCgggcccTTAGGCGACGAGATATGGAGC) using In-Fusion cloning 
(Takara Bio USA, Inc.).  Z-competent E. coli JM109 cells (Zymo Research, Irvine, CA) 
were used for transformation of the ligated product. The final cloned constructs were 
sequenced with pTB207 vector primers (forward, T7) and (reverse, SP6). Only positive 
clones were used for cRNA synthesis using in vitro transcription with the mMessage 
mMachine T7 transcription kit (Invitrogen, CA, USA) and the cRNA was aliquoted and 
stored at -80°C. 
4.3.5 Oocyte microinjection and electrophysiology 
Xenopus laevis oocyte injections and two-electrode voltage-clamp 
electrophysiology recordings were performed as previously described in Choudhary et al. 
(2019). The oocytes were injected with 25-50 ng of Aca-ACR‐16 cRNA either alone or in 
combination with 15-25 ng of each ancillary protein cRNA (Asu-RIC‐3, Asu-UNC‐50, 




4.3.6 Drug applications 
All drugs used, except tribendimidine and derquantel, were purchased from Sigma 
Aldrich (St Louis, MO, USA). The drugs were solubilized in recording solution or 
DMSO (final working concentration did not exceed 0.1%). Derquantel and 
tribendimidine were a generous gift from Zoetis (Kalamazoo, MI, USA) and Prof Shu 
Hua Xiao (National Institute of Parasitic Diseases, China) respectively. 
Agonists of interest were used at a final concentration of 100 µM except 
tribendimidine (30 µM) due to solubility issues. In all experiments, 100 µM acetylcholine 
(ACh) was applied first and all the responses were normalized to this control response. 
Each agonist was applied for 10s followed by 3 minutes perfusion with recording 
solution. The sequence for application of agonists for determining the rank order potency 
series was random and not predetermined. The concertation-response studies were 
conducted by application of the drug in ascending order of concentrations in order to 
minimize any potential desensitization by high concentrations. In each experiment the 
drug was applied for 10s followed by 3 minutes wash off with the recording solution.  
All the antagonists in our study were used at a final concentration of 10 µM. For 
generating rank order potency series, a control application of 100 μM ACh (30 s) was 
first applied followed by 3 minutes wash off. Thereafter, 100 μM acetylcholine was 
applied for 10 s, immediately followed by 10 s application of the antagonist in the 
continued presence of 100 μM ACh and then a final 10 s application of 100 μM ACh. At 
least 3 min drug wash off interval was allowed between applications in order to minimize 
desensitization. Note that, due to short time of drug application in this protocol, it is 




4.3.7 Data and statistical analysis 
Clampfit 10.3 (Molecular Devices, Sunnyvale, CA, USA) and GraphPad Prism 
8.0 (GraphPad Software Inc., La Jolla, CA, USA) were used to analyze data. The peak 
currents in response to the applied agonists were measured and normalized to the control 
current (100 µM acetylcholine). The results were expressed as mean ± SEM. The Hill 
equation was used to analyze the concentration-response relationships by fitting log 
concentration-response data points as described in (Boulin et al. 2008). Desensitization 
kinetics in response to the agonists were fitted using a single exponential decay fit:  
 
Where n is the number of components, A is the amplitude, t is time, τ is the time constant, 
and C is the constant y-offset for each i component. The mean % inhibition produced by 
the antagonists on currents elicited by 100 μM acetylcholine were calculated using the 
equation previously described (Zheng et al. 2016). One-way ANOVA and extra sum of 
squares F-tests were used to test statistical differences between desensitization rate and 
pEC50 respectively. The significance levels were set to P < 0.05.  
 
4.4 Results 
4.4.1 Sequence comparison of Aca-ACR-16 with Asu-ACR-16  
We were able to identify the putative complete coding sequence of the homologue 
of ACR-16 in the translated Ancylostoma caninum genome (Gene ID: ANCCAN_01899) 
by using the Asu-ACR-16 protein sequence (GenBank: KP756901) as a query in a 
BLASTP search in the nematode protein database, WormBase Parasite. When amplified, 
the Aca-ACR-16 was shorter than ANCCAN_01899 and lacked 19 amino acids between  








Figure 4.0 Amino acid sequence alignment of Aca-ACR-16 and Asu-ACR-16. The signal 
peptide (light brown), ligand binding loops (A to F; maroon) transmembrane regions 
TM1-4 (blue), and cys-loop (green) are indicated. The adjacent cysteines (in the Y-X-C-C 
motif) in Loop-C are indicated in the black box. The negatively charge amino acids (E: 
Glutamic acid and D: Aspartic acid) flanking the TM2 domain are highlighted in orange. 
Note: The sequence of Aca-ACR-16 amplified from A. caninum larval total RNA is 
shorter than the WormBase sequence ANCCAN_01899 and lacks 19 amino acids 
(KVKEPNLFGPWENFHGDLF) between the cys-loop and Loop-B. These amino acid 
residues are also lacking in the A. suum ACR-16 homologue. 
 
the cys-loop and loop-B; these amino acids are also missing in the published sequence of 
Asu-ACR-16. Aca-ACR-16 has all the structural characteristics of a nicotinic 




~200 amino acids involved in correct nAChR assembly, a Cys-loop motif separated by 13 
intervening amino acids, four transmembrane (TM) domains that form the ion-conducting 
pore, a cytoplasmic domain inserted between TM3 and TM4, six loops (A-F) and most 
importantly the presence of vicinal cysteines (a Y-x-C-C motif) in the C-loop making it 
an alpha subunit. Figure 4.0 shows the protein sequence alignment of Aca-ACR-16 with 
Asu-ACR-16. The two worm species belong to different clades of nematode, but their 
amino acid residues were highly conserved with an identity of 78% (87% similarity). 
There was a lack of conservation in Aca-ACR-16 loops E and F (involved in agonist 
binding) which encouraged us to characterize the pharmacology of the ion channel. 
4.4.2 The ancillary factor RIC-3 is required for the functional expression of 
Aca-ACR-16  
For the heterologous expression of the Aca-ACR-16, we expressed the subunit 
protein cRNA with different ancillary proteins (RIC-3, UNC-50 and UNC-74 from A. 
suum and RIC-3 from X. laevis; Figure 4.1). None of the combinations, except Aca-ACR-
16 with Asu-ric-3, gave robust responses to control 100 μM ACh.  In order to optimize 
the expressed receptor, we varied the amount of cRNA of Aca-ACR-16 (25-50 ng) and 
Asu-ric-3 (15-25 ng). We obtained the largest response from oocytes injected with 50 ng 
Aca-ACR-16 and 25 ng Asu-ric-3 and this mix was used for all subsequent recordings. 
4.4.3 Aca-ACR-16 forms 3-bromocytisine sensitive nAChR 
We tested a selection of nicotinic agonists including cholinergic anthelmintics on 
the expressed A. caninum ACR-16 ligand gated ion channel. Figure 4.2A shows the rank 
order potency series for the agonists on the expressed Aca-ACR-16 receptor. 3- 





Figure 4.1 Bar chart showing the effects of ancillary proteins on the expression of Aca-
ACR-16 nAChR. The receptor was able to express functionally only when co-injected 
with Asu-RIC-3.  
 
Epibatidine, cytisine, nicotine and DMPP also activated the receptor. Interestingly the 
cholinergic anthelmintics including levamisole, oxantel, pyrantel, morantel, bephenium, 
and tribendimidine were not active on the expressed nAChR. The rank order potency 
series on Aca-ACR-16 when normalized to the control 100 µM acetylcholine current was: 
3-bromocytisine > ACh > epibatidine > cytisine > nicotine > DMPP >> levamisole = 
oxantel = pyrantel = morantel = choline = bephenium = tribendimidine. None of 
cholinomimetic anthelmintics currently used in the field activated the homomeric receptor 
which shows that this channel is distinct from the other somatic nAChRs of nematodes.  
4.4.4 Comparative pharmacology of acetylcholine and 3-bromocytisine  
Figure 4.2B shows the concentration-response relationships of acetylcholine and 3- 
bromocytisine for the A. caninum homomeric channel. The sigmoidal plots were 
constructed by application of drugs in ascending order (0.3-300 µM depending on the 




(EC50 = 50.0 µM) on the receptor. The curves for both the nicotinic agonists were steep 
with the hillslope (nH) values greater than 1. This suggests that the ligands are binding to 
more than one site in the receptor and exhibit positive cooperativity as expected of a 
homomeric ligand-gated ion channel. 
 
Figure 4.2 The effects of nAChR agonists and antiparasitic drugs on the Aca-ACh-16 
receptor. A. Bar graph (mean ± SEM, %, n = 4) along with sample traces showing the 
effect of agonists and anthelmintics on the nAChR. The rank order potency series when 
normalized to the control 100 μM ACh current was as follows: 3-bromocytisine (3-BC; 
131.0 ± 18.0) > ACh (100.0 ± 0.0) > epibatidine (epi; 85.0 ± 4.0) > cytisine (cyt; 48.0 ± 
9.5) > nicotine (nic; 37.0 ± 8.7) > DMPP (Dimethyl-4-phenylpiperazinium; 27.0 ± 6.4) 
>>> levamisole (lev; 0.0 ± 0.0) = oxantel (oxan; 0.0 ± 0.0) = pyrantel (pyr; 0.0 ± 0.0) = 
morantel (mor; 0.0 ± 0.0) = choline (cho; 0.0 ± 0.0) = bephenium (beph; 0.0 ± 0.0) = 
tribendimidine (tbd; 0.0 ± 0.0). B. Sample traces and concentration-response relationships 
of 3-Bromocytisine and ACh for Ancylostoma caninum ACR-16. The pEC50 and hill 
slope (nH) values, expressed as mean ± SEM, were respectively 4.3 ± 0.0 and 2.5 ± 0.3 






4.4.5 Aca-ACR-16 desensitization 
Desensitization is defined as decrease or loss of biological response following 
prolonged or repetitive stimulation. It is a common feature of many nAChRs including a-
7 homomeric nAChRs (Giniatullin, Nistri, and Yakel 2005; Picciotto et al. 2008; Quick 
and Lester 2002). In the case of A. suum ACR-16, all the potent agonists exhibited 
desensitization (Abongwa, Buxton, et al. 2016). We observed a similar trend characterized 
by peak and then waning current responses observed during maintained (10 s) agonist 
applications with Aca-ACR-16 as shown in Figure 4.3. The time constant for 
desensitization was highest for epibatidine and lowest for 3-bromocytisine. The mean time 
constants for desensitization rates ranged between 1.5 and 4.8 s for the Aca-ACR-16 and 
were less than the rates observed in the Asu-ACR-16 (Abongwa, Buxton, et al. 2016).  
 
Figure 4.3 Bar graph showing desensitization time constants of the Ancylostoma caninum 
ACR-16 nAChR in response to agonists (100 µM, n=4). The rank order of time constants 
of desensitization (mean ± SEM, s) was as follows: epi (4.8 ± 0.2) > nic (4.3 ± 0.5) > cyt 
(3.9 ± 0.5) > ACh (3.3 ± 1.0) > 3-BC (1.5 ± 0.3). *P < 0.05, **P < 0.01; significantly 
different as indicated; Tukey’s multiple comparison test. 
 
 
4.4.6. Antagonist pharmacology 
Six nAChR antagonists (10 µM each) were tested on the expressed cation selective 




dihydro-β-erythroidine (DHβE), derquantel, hexamethonium, and α-bungarotoxin (α-
BTX). α-BTX produced least inhibition of the acetylcholine mediated current while d-TC 
and mecamylamine produced  ~100% inhibition of the control current. DHβE, a selective 
antagonist for α4β2 receptors (Levin 2002), interestingly also produced almost complete 
inhibition of acetylcholine currents. The complete rank order potency for antagonists 
(Figure 4.4) was: dTC ≈ mecamylamine ≈ DHβE > derquantel > hexamethonium > α-
BTX. 
 
Figure 4.4 Effects of selected nAChR antagonists on the Aca-ACR-16. Sample trace and 
bar chart showing inhibition (mean ± SEM, %) of acetylcholine mediated currents by the 
selected antagonists (10 µM). d-tubocurarine (d-TC), mecamylamine (mec) and dihydro-
β-erythroidine (DhβE) produced almost complete inhibition of ACh mediated responses. 
Derquantel (der) and hexamethonium (hexa) produced moderate blockade of Aca-ACR-
16 mediated ACh responses and α-BTX was the least potent antagonist. The rank order 
potency series for nAChR antagonists is as follows: d-TC (100.0 ± 0.1) ≈ mec (98.8 ± 
0.6) ≈ DHβE (98.8 ± 0.4) > der (72.0 ± 5.6) > hexa (52.2 ± 5.6) > α-BTX (49.3 ± 5.2). 
Inset: magnified view of current trace showing predicted acetylcholine response in the 
absence of DHβE (dotted line) and inhibition of acetylcholine mediated response in the 






4.5 Discussion  
4.5.1 Comparison of pharmacology of Aca-ACR-16 with homologues from 
other nematodes 
In this study we have shown that ACR-16 from Ancylostoma caninum, a Clade V 
nematode and model for human hookworm infections, expresses as a homomeric channel 
in Xenopus oocytes. Abongwa, Buxton, et al. (2016) successfully recapitulated and 
characterized the ACR-16 homologue from Ascaris suum, a clade III gastrointestinal 
parasite. Ballivet et al. (1996) characterized the pharmacology of ACR-16 nAChR from 
Caenorhabditis elegans, a clade V free-living nematode. Similar to the A. suum and C. 
elegans channel, Aca-ACR-16 was not sensitive to many of the currently used 
cholinomimetic anthelmintics including levamisole, pyrantel and tribendimidine. 
However, the A. caninum nAChR was most sensitive to 3-bromocytisine while nicotine 
was the most potent agonist for the A. suum and C. elegans ACR-16 receptors. The 
acetylcholine concentration-response curve for Aca-ACR-16 (nH = 2.5 ± 0.3) had 
comparable slope factor to Cel-ACR-16 (nH = 2.1) but was shallower in comparison to 
the Asu-ACR-16 (nH = 3.9 ± 0.3). This may account for the higher sensitivity to 
acetylcholine for the A. suum α nAChR (EC50 = 5.9 µM) and the similar sensitivity to the 
agonist for A. caninum (EC50 = 50.0 µM) and C. elegans (EC50 = 55.4 µM) ACR-16 
receptors. In terms of antagonist pharmacology, the A. caninum cation channel was 
moderately inhibited by α-BTX (mean ± SEM = 49.3 ± 5. 2 %) while Asu-ACR-16 and 
Cel-ACR-16 nAChRs were nearly insensitive. DhβE produced complete inhibition of 
acetylcholine mediated responses on the Aca-ACR-16 and Cel-ACR-16 nAChRs while 




ACR-16 receptor was highly sensitive to mecamylamine and d-TC; moderately sensitive 
to derquantel and hexamethonium. The protein sequence of the ACR-16 homologues 
from all the nematode parasites is highly conserved; Aca-ACR-16 shares 78 % identity 
with A. suum and C. elegans homologues. There are variable amino acids residues in the 
loops E and F which can account for  differences in the pharmacological properties 
(Corringer, Novère, and Changeux 2000).  
4.5.2 Consideration of the Aca-ACR-16 as a drug target 
Hookworm infections affect approximately 500 million people globally, with 5.1 
billion at risk of acquiring infections (Global Burden of Disease Study 2015; Pullan and 
Brooker 2012). Despite decades of strong research efforts and identification of promising 
candidate antigens, there are still no commercially available vaccines for human 
hookworm infections. Consequently, identification of novel drug targets and 
development of associated therapeutic agents is a logical approach for future defense 
against these infections. In parasitic nematodes nicotinic acetylcholine receptors are 
required for various physiological functions. These ligand-gated ion channels are targets 
of important cholinergic antinematodal drugs such as levamisole and pyrantel. Recently 
introduced “novel” anthelmintics including tribendimidine and derquantel also target 
nematode nAChRs (Abongwa, Martin, and Robertson 2017; Wolstenholme 2011). acr-16 
encodes for nicotine-sensitive nAChRs that are expressed in body wall muscles in C. 
elegans and contribute to the fast synaptic cholinergic neurotransmission in these muscles 
(Francis et al. 2005; Touroutine et al. 2005; Richmond and Jorgensen 1999). The unc-
63:acr-16 double mutants in C. elegans exhibit locomotor defects which are more severe 




double mutants also display far greater movement impairment than either unc-29 or acr-
16 single mutants (Li et al. 2014). This demonstrates that ACR-16 in combination with 
UNC-63 and UNC-29, components of levamisole-sensitive nAChR, contributes 
to locomotor behavior in the worms. In Brugia malayi, a clade V worm, knockdown of 
acr-16:acr-26 had no effect on motility (Verma et al. 2017) possibly suggesting a 
different physiological function of the ACR-16 homologue in the filarial worm. In A. 
suum, the ACR-16 homologue was detected in the ovijector and digestive tract tissues in 
addition to the body wall muscles. It is plausible that the ACR-16 nAChRs not only 
regulates neurotransmission in A. suum but also serve other tissue-related functions 
including reproduction and digestion. The ACR-16 homologue from A. suum has been 
suggested as a drug target (Abongwa, Buxton, et al. 2016). We have successfully 
reconstituted a fully functional homomeric nAChR, ACR-16, in the Xenopus oocyte 
expression system from A. caninum, a model for human hookworm infections. The 
pharmacology of the receptor is distinct from the levamisole sensitive nematode receptors 
(Martin et al. 2012; Boulin et al. 2008; Richmond and Jorgensen 1999). The A. caninum 
ACR-16 homologue also displayed some pharmacological differences from Asu-ACR-16. 
Benzimidazoles are the commonly used antiparasitic drugs for treatment of hookworm 
infections but there have been multiple reports of resistance in veterinary medicine 
(Kaplan 2004; Wolstenholme et al. 2004) and decreased cure rates in humans (Geerts and 
Gryseels 2000; De Clercq et al. 1997; Keiser and Utzinger 2008; Conder and Campbell 
1995). There is a need for new drugs against hookworms and ACR-16 may be a valid 
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5.1 Abstract 
 The ongoing and widespread emergence of resistance to the existing anti-
nematodal pharmacopeia has made it imperative to develop new anthelminthic agents. 
Historically, plants have been important sources of therapeutic compounds and offer an 
alternative to synthetic drugs. Monoterpenoids are phytochemicals that have been shown 
to produce acute toxic effects in insects and nematodes. Previous studies have shown 
nicotinic acetylcholine receptors (nAChRs) to be possible targets for naturally occurring 
plant metabolites such as carvacrol and carveol. In this study we examined the effects of 
monoterpenoid compounds on a levamisole sensitive nAChR from Oesophagostomum 
dentatum and a nicotine sensitive nAChR from Ascaris suum. We expressed the receptors 
in Xenopus laevis oocytes and used two-electrode voltage-clamp electrophysiology 




100 µM the majority of these compounds acted as antagonists. Interestingly, further 
experiments revealed that both 0.1 µM and 10 µM menthol potentiated acetylcholine and 
levamisole responses in the levamisole sensitive receptor but not the nicotine sensitive 
receptor. We also investigated the effects of 0.1 µM menthol on the contractility of A. 
suum somatic muscle strips. Menthol produced significant potentiation of peak 
contractions at each concentration of acetylcholine. The positive allosteric modulatory 
effects of menthol in both in vivo and in vitro experiments suggest menthol as a 
promising candidate for combination therapy with cholinergic anthelmintics.  
Keywords 
Menthol, allosteric modulation, nAChR, monoterpenoid, nematode 
 
5.2 Abbreviations  
 Asu, Ascaris suum; BAPTA-AM, 1,2-bis(2-aminophenoxy)ethane-
N,N,N′,N′-tetraacetic acid tetrakis (acetoxymethyl ester); cRNA, complementary RNA; 
DMSO, dimethyl sulfoxide; Hco, Haemonchus contortus; nAChR, nicotinic 
acetylcholine receptor; Ode, Oesophagustomum dentatum; PAM, positive allosteric 
modulator; STHs, soil transmitted helminths.  
 
5.3 Introduction 
Parasitic nematode infections are a threat to health and have significant socio-
economic consequences. Among the different classes of nematodes, soil transmitted 
helminths (STHs) are major contributors to the global parasite burden. According to 




infected with at least one species of soil transmitted helminth, which mainly include 
Ascaris lumbricoides, Trichuris trichiura and hookworms (Necator 
americanus and Ancylostoma duodenale). These infections are most commonly found in 
tropical and sub-tropical countries due to suboptimal sanitation, lack of access to clean 
water and favorable climatic conditions for the parasites (Bethony et al. 2006; Brooker, 
Clements, and Bundy 2006; Savioli and Albonico 2004; Hotez et al. 2008). Although 
mortality is rare, high morbidity is a common feature of intestinal helminthiasis. The 
disease manifestations include weight loss, anemia, diarrhea, abdominal pain, 
malnutrition, general malaise, weakness, as well as impaired growth and physical 
development (Bethony et al. 2006). Children bear the highest burden of these infections 
which profoundly affect their physical growth, cognitive development and cause 
educational deficits (Brooker 2010; Stephenson, Latham, and Ottesen 2000; Alum, 
Rubino, and Ijaz 2010). STH infections such as Ascariasis have also been reported to 
exacerbate other diseases such as malaria, tuberculosis and HIV/AIDS (Fincham, 
Markus, and Adams 2003; Le Hesran et al. 2004).  In addition, production losses caused 
by intestinal nematodes of livestock have adverse effects on nutritional status and the 
food economy especially in poverty-stricken regions (Morgan et al. 2013). 
Effective vaccines are the most desirable approach but even after almost 30 years 
of dedicated research, a licensed vaccine against human parasites remains elusive. 
Current control strategies for treatment and prevention of helminth infections rely heavily 
on chemotherapy. Unfortunately, there are a limited number of classes of anthelmintic 
agents, which include benzimidazoles, macrocyclic lactones and nicotinic agonists 




Moreover, widespread and indiscriminate administration combined with genetic factors 
has led to the development of resistance in animals (Taman and Azab 2014; Albonico et 
al. 2003). There have also been reports of reduced therapeutic efficacy to anti-nematodal 
drugs in humans. De Clercq et al. (1997) and Flohr et al. (2007) reported poor efficacy of 
benzimidazoles against human hookworm infections. There is a need to focus research on 
drug discovery and development to overcome the issue of increasing resistance and 
reduced efficacy against existing drugs.  
The use of phytotherapeutics for parasitic infections has emerged as an attractive 
alternative. Plants have dominated the human pharmacopoeia for thousands of years 
(Balick and Cox 1996; Raskin and Ripoll 2004; Newman and Cragg 2016). Many 
therapeutic products, including codeine, quinine, artemisinin, digitoxin, morphine, 
paclitaxel, galantamine, currently used in modern pharmacotherapy are of plant origin 
(Newman and Cragg 2016; Newman, Cragg, and Snader 2000; Butler 2004; Heinrich and 
Lee Teoh 2004; Pirttila et al. 2004; Samuelsson 2004; Petrovska 2012). Plant based 
therapeutic compounds are environment-friendly and exhibit a wide array of medicinal 
properties (Coats 1994; Hu and Coats 2008; Balunas and Kinghorn 2005; Harvey, 
Edrada-Ebel, and Quinn 2015; Dias, Urban, and Roessner 2012). Interestingly, an 
estimated four billion people living in the developing world rely on medicinal plants for 
their primary pharmaceutical care (WHO 2005). Herbal remedies in the form of 
complementary and alternative medicine (CAM) are also being widely embraced in many 
developed countries (Committee on the Use of Complementary 2005; Calapai 2008; 
Anquez-Traxler 2011). Among phytochemicals, essential oils and their active principles 




nematocidal activities (Enan 2005; Panella et al. 2005; Camurca-Vasconcelos et al. 2007; 
Coskun et al. 2008; Macedo et al. 2009; Cetin et al. 2009). Historically, thymol (found in 
oil of thyme), santonin (derived from buds of the local Artemisia spp.) and ascaridol 
(isolated from Chenopodium oil) were used in the late nineteenth and early twentieth 
century for the treatment of ascarids and hookworms in humans (Ferrell 1914; Lamson 
and Ward 1932; Kaplan et al. 2014). Terpene and terpenoid biomolecules, particularly 
monoterpenes and sesquiterpenes, found in essential oils have been identified as 
promising anthelmintic compounds and are of great pharmaceutical interest (Lei, Leser, 
and Enan 2010; Pessoa et al. 2002; Squires et al. 2010; Jaradat et al. 2016; Katiki, 
Chagas, et al. 2011). Lei, Leser, and Enan (2010) reported in vitro nematocidal activity of 
thymol and carvacrol (major components of thyme and oregano essential oils) 
against Caenorhabditis elegans and Ascaris suum. Trailović et al. (2015) also 
demonstrated the potential anthelmintic effects of carvacrol in A. suum.   
In the present study, we tested the activity of monoterpenoid compounds on two 
different nematode nAChR types: levamisole sensitive (L-type) nAChRs from 
Oesophagostomum dentatum and a nicotine sensitive (N-type) nAChR (ACR-16) from A. 
suum. The receptors were expressed in Xenopus laevis oocytes and we used two-
electrode voltage-clamp to study the pharmacological effects of the compounds. We also 
investigated the effects of menthol on the contractility of A. suum somatic muscle strips. 
The focus of this study was to evaluate the effects produced by monoterpenoid 
compounds to identify potential alternatives to current chemotherapeutic agents. 
  




5.4.1 cRNA preparation and X. laevis oocyte expression 
All nAChR subunit and ancillary factor cRNAs from O. dentatum (Ode-unc-
29, Ode-unc-38, Ode-unc-63 and Ode-acr-8), A. suum (Asu-acr-16 and Asu-ric-3) and 
Haemonchus contortus (Hco-ric-3, Hco-unc-50 and Hco-unc-74) were prepared as 
previously described (Abongwa, Buxton, et al. 2016; Buxton et al. 2014). The receptors 
were expressed in defolliculated X. laevis oocytes purchased from Ecocyte Bioscience 
(Austin, Texas, USA). N-type (nicotine sensitive) nAChRs from A. suum were expressed 
by co-injecting 25 ng of Asu-acr-16 with 5 ng of Asu-ric-3 in a total volume of 50 nL in 
nuclease-free water. Heteromeric (levamisole sensitive) nAChRs from O. dentatum were 
expressed by co-injecting 1.8 ng of each subunit cRNA (Ode-unc-29, Ode-unc-38, Ode-
unc-68 and Ode-acr-8) with 1.8 ng of each H. contortus ancillary factor (Hco-ric-3, Hco-
unc-50 and Hco-unc-74) in a total volume of 36 nL in nuclease-free water. The injections 
were made in the animal pole of the oocytes using a nanoject II microinjector 
(Drummond Scientific, Broomall, PA, USA). The injected oocytes were separated into 
96-well plates containing 200 µL incubation solution (100 mM NaCl, 2 mM KCl, 
1.8 mM CaCl2.2H20, 1 mM MgCl2.6H20, 5 mM HEPES, 2.5 mM Na pyruvate, 
100 U·mL−1 penicillin and 100 μg·mL−1 streptomycin, pH 7.5); each well contained one 
oocyte. The solution was changed daily to maintain oocytes in optimal conditions. The 








We used two-electrode voltage-clamp electrophysiology to record the inward 
current generated by the activation of expressed receptors in X. laevis oocytes. The 
oocytes were incubated with 100 µM BAPTA-AM (an intracellular calcium chelator) for 
∼3 hours prior to recordings to prevent activation of endogenous calcium-
activated chloride currents. The oocytes were clamped at -60mV for all the experiments 
with an Axoclamp 2B amplifier; all data were acquired on a desktop computer with 
Clampex 10.2 (Molecular Devices Inc., CA, USA). The microelectrodes used to impale 
oocytes were pulled using a Flaming/Brown horizontal micropipette puller (model P-97, 
Sutter Instruments Co., USA) and filled with 3 M KCl. The tips of the microelectrodes 
were carefully broken with a tissue paper to achieve a resistance of 2-5 MΩ in recording 
solution (100 mM NaCl, 2.5 mM KCl, 1 mM CaCl2·2H2O and 5 mM HEPES, pH 7.3). 
The low resistance allowed passage of large currents required to maintain adequate 
voltage-clamp of the oocyte. Oocytes were placed into a tiny groove of the narrow 
oocyte-recording chamber. The Digidata 1322A (Molecular Devices, CA, USA) was 
used to control the switches that controlled the perfusion of the chamber at a speed of ~6 
mL/min. Un-injected oocytes served as the negative control. 
5.4.3 A. suum muscle flap contraction measurements 
The adult female A. suum worms were collected from the slaughterhouse at 
Surčin, Belgrade, Serbia and maintained at 32 °C in Locke’s solution (NaCl 155 mM, 
KCl 5 mM, CaCl2 2 mM, NaHCO3 1.5 mM and glucose 5 mM). The Locke’s solution 
was changed twice daily. Each batch of worms was used within 4 days of collection. For 
contraction studies, A. suum muscle flaps were prepared as described in Trailović et al. 




prepare a 1 cm muscle flap and the lateral line was removed from the edge of the flaps. 
Each muscle flap was attached to a force transducer in an experimental bath maintained 
at 37 °C, containing 20 mL Ascaris Perienteric Fluid Ringer (23 mM NaCl, 110 mM Na 
acetate, 24 mM KCl, 6 mM CaCl2, 5 mM MgCl2, 11 mM glucose, 5 mM HEPES, pH 7.6) 
and bubbled with room air. The isometric contractions were monitored on a PC computer 
using a BioSmart interface with eLAB software (EIUnit, Belgrade). The preparations 
were allowed to equilibrate for 15 min under an initial tension of 0.5 g following 
which acetylcholine (1–100 μM) in the absence and presence of menthol (0.1 μM) was 
applied to the preparation. The responses for each concentration were expressed in grams 
(g).  
5.4.4 Drug Applications 
Acetylcholine chloride, L-menthol, (-)-menthone, eugenol, (S)-(-)-β-citronellol, 
(+)-limonene oxide, carvacrol, ((R)-(-))-carvone, geraniol, menthyl acetate, phenethyl 
propionate, trans-cinnamaldehyde and BAPTA-AM were purchased from Sigma-Aldrich 
(St Louis, MO, USA). (+)-Pulegone was purchased from Kodak (Rochester, NY, USA) 
and geraniol from Berje (Carteret, NJ, USA). Acetylcholine was dissolved in recording 
solution while monoterpenoid compounds (Figure 4.0) were dissolved in DMSO such 
that the final working concentration did not exceed 0.1%. 
Oocytes were perfused with drugs by an 8-channel system (VC-8 valve controller) 
(Warner Instruments, USA) at a flow rate of ~6 mL/min.  For the agonist experiments, all 
the essential oils were used at a concentration of 100 μM. All the responses were 
normalized to the control (100 μM acetylcholine) response. Each drug was applied for 




agonists for determining the potency series was random and not predetermined. The 
concentration-response relationship for acetylcholine was generated by applying 
increasing concentrations of acetylcholine (0.1-300 μM) for 10 s. For positive allosteric 
modulator experiments, we tested the effects of menthol (0.1 and 10 μM) on 
acetylcholine and levamisole concentration-response relationships. Control 
concentration-responses were obtained by applying ascending concentrations of the 
agonist for 10 s. Concentration-response relationships in the presence of 0.1 μM and 10 
μM menthol were generated by first applying a control 100 μM acetylcholine for 10 s, 
followed by a two min application of menthol, and 10 s applications of increasing 
concentrations of the agonist in the continued presence of menthol. Between each drug 
application a 2 min wash off time was allowed, and the responses were normalized to 
the control 100 μM acetylcholine current.  
In order to characterize the antagonist properties of the phytocompounds, a 
control concentration of 100 μM ACh was first applied for 30 s followed by a 2 min wash 
with recording solution. Thereafter, 100 μM acetylcholine was applied for 10 s, 
immediately followed by 10 s application of the antagonist (100 μM) in the continued 
presence of 100 μM ACh and then a final 10 s application of 100 μM ACh. At least 2 min 
drug wash off interval was allowed between applications in order to minimize 
desensitization. Note that, the potency for each antagonist is likely to be slightly 
underestimated due to the short time of drug application with this approach (Abongwa, 
Buxton, et al. 2016). Acetylcholine concentration-response relationships in the presence 





Figure 5.0 Chemical structures of monoterpenoid compounds used in the present study. 
 
control 100 μM acetylcholine for 10 s, followed by a 2-min application of the 
antagonist, and 10 s applications of 3, 10, 30, 100 and 300 μM acetylcholine in the 
continued presence of antagonist. The responses were normalized to the control 100 μM 
acetylcholine current. 
5.4.5 Data and statistical analysis  
Data acquired from electrophysiological recordings were analyzed with Clampfit 
10.3 (Molecular Devices, Sunnyvale, CA, USA) and GraphPad Prism 7.0 (Graphpad 




drugs were normalized to the 100 μM ACh control current (unless otherwise indicated) 
and expressed as mean ± SEM. All completed drug application sequences on the oocytes 
were used for analysis without exclusion. If the recording became unstable, indicated by 
a change in the baseline holding current, all of that recording was rejected for analysis. 
The mean % inhibition produced by monoterpenoid compounds on currents elicited by 
100 μM acetylcholine were calculated as previously described (Zheng et al. 2016). For A. 
suum contraction experiments, mean contraction responses in grams (g) to each 
concentration of acetylcholine in the absence and presence of menthol was determined. 
The sigmoidal concentration-responses for the oocyte experiments and isometric 
contraction studies were described using the following equation:  
% response= 1/1+[EC50/Xa]nH 
where EC50 is the concentration of agonist (Xa) producing 50% of the maximum 
response and nH is the Hill coefficient (slope). Differences in pEC50 and Imax were 
assessed using extra sum of squares F-test. Two-way ANOVA and paired t-tests were 
used to test differences between control contractions and test contractions on the same 
muscle flap. The difference was considered significant if P<0.05. 
 
5.5 Results 
5.5.1 Pharmacology of monoterpenoids on Ode (29-38-63-8) receptor 
5.5.1.1. Agonist pharmacology 
The agonist properties of 12 monoterpenoid compounds were investigated on the 
levamisole sensitive Ode-unc-29∶Ode-unc-38∶Ode-unc-63∶Ode-acr-8 nAChR (Figure 




(<1.0% of control acetylcholine current) on the expressed levamisole sensitive channel. 
Menthol was the only compound tested that produced an agonist effect, showing only » 
6.5% of the control acetylcholine currents.  
 
Figure 5.1 Agonist effects of monoterpenoid compounds on levamisole sensitive O. 
dentatum nAChR. A. Sample traces for the agonist experiment. B. Bar chart (expressed 
as mean ± SEM%) showing agonistic effects of the monoterpenoid compounds: menthol 
(6.5 ± 2.4%, n = 6), geraniol (0.9 ± 0.2%, n = 6), cinnamaldehyde (0.6 ± 0.2%, n = 6), 
citronellol (0.4 ± 0.2%, n = 6), menthyl acetate (0.3 ± 0.1%, n = 6), eugenol (0.3 ± 0.2%, 
n = 6), phenethyl propionate (0.3 ± 0.1%, n = 6), limonene oxide (0.3 ± 0.2%, n = 6), 
carvacrol (0.2 ± 0.2%, n = 6), menthone (0.2 ± 0.1%, n = 6), pulegone (0.1 ± 0.1%, n = 6) 
and carvone (0.0 ± 0.0%, n = 6).  
 
5.5.1.2. Antagonist pharmacology 
We tested potential antagonistic effects of the same 12 monoterpenoids on the 
levamisole sensitive receptor (Figure 5.2). Among all the phytocompounds tested 




acetylcholine response. Limonene oxide was the most potent inhibitor (mean inhibition% 
= 36.0 ± 3.2%). The rank order potency of inhibition was: limonene oxide > citronellol > 
carvone > carvacrol = pulegone = eugenol (Figure 5.2A). Interestingly, monoterpenoids 
including menthol, menthone, menthyl acetate and geraniol increased the amplitude of 
currents produced by acetylcholine instead of inhibiting them (data not shown). Menthol 
produced the most potent positive allosteric modulation and increased the response by 3.1 
± 0.7% (mean ± SEM) with a maximum potentiation of 6.3%. 
5.5.1.3. Antagonistic effects of limonene oxide and carvacrol on acetylcholine 
concentration-response relationship 
The concentration-response relationship for acetylcholine was examined by 
applying increasing concentrations of acetylcholine 0.3–300 μM to oocytes expressing 
the levamisole sensitive nAChR (Figure 5.2 B&C). The sigmoidal concentration-
response fit gave pEC50 = 5.3 ± 0.0 (EC50 = 5.3 μM), a hillslope (nH) of 2.0 ± 0.2 and Imax 
value of 104.6 ± 1.6%. We investigated the effects of limonene oxide (100 μM) and 
carvacrol (100 μM) on the acetylcholine concentration-response relationship. Imax for 
acetylcholine in the presence of limonene oxide and carvacrol were 62.8 ± 7.0% and 74.1 
± 3.2%, respectively. Both the monoterpenoid compounds produced a statistically 
significant reduction in the maximum response (P<0.001 for limonene oxide; P<0.0001 
for carvacrol; Figure 5.2 B&C). Neither carvacrol, pEC50 = 5.7 ± 0.1 (EC50 = 2.0 μM) nor 
limonene oxide, pEC50 = 5.4 ± 0.2 (EC50 = 4.0 μM) increased the EC50 values c.f. control. 
This indicates limonene oxide and carvacrol both produced non-competitive inhibition 




Figure 5.2: Effect of monoterpenoid compounds as antagonists on levamisole sensitive O. 
dentatum receptor acetylcholine mediated responses. A. Bar graph showing the rank 
order potency of monoterpenoid compounds as antagonists. Results were expressed as % 
mean inhibition ± SEM of currents elicited by 100 μM ACh: limonene oxide (36.0 ± 
3.2%, n = 6) > citronellol (18.0 ± 1.6%, n = 6) > carvone (14.0 ± 0.6%, n = 6) > carvacrol 
(11.0 ± 1.6%, n = 6) = pulegone (11.0 ± 2.6%, n = 6) = eugenol (11.0 ± 1.0 %, n = 6).  
Inset: image showing predicted acetylcholine response in the absence of limonene oxide 
(dotted line) and inhibition of acetylcholine mediated response in the presence of 
limonene oxide (highlighted in green).  B. Acetylcholine current responses, recorded 
from the Xenopus oocyte expressing the levamisole sensitive channel, alone and in the 
presence of 100μM carvacrol (n=6) & 100 μM limonene oxide (n = 5). C. Concentration-
response plots for acetylcholine alone (n = 6, black) and acetylcholine in the presence of 
100 μM carvacrol (n = 6, maroon) & 100 μM limonene oxide (n = 5, green). pEC50 (mean 
± SEM), EC50 (mean, μM), Hill slope (nH) (mean ± SEM) and Imax (mean ± SEM%) 
values were respectively: 5.3 ± 0.0, 5.3 μM, 2.0 ± 0.2 and 104.6 ± 1.6 for acetylcholine 
alone; 5.4 ± 0.2, 4.0 μM, 2.2 ± 1.7 and 62.8 ± 7.0 in the presence of limonene oxide; 5.7 
± 0.1, 2.0 μM, 1.7 ± 1.1 and 74.1 ± 3.2 in the presence of carvacrol. Bottom was 
constrained to zero for curve fitting. 
 
5.5.1.4. Menthol as positive allosteric modulator  
Menthol was a weak agonist on the expressed levamisole sensitive receptor. However, it 
appeared to potentiate acetylcholine responses in our antagonist experiments (data not 
shown). To investigate positive allosteric modulation further, we analyzed the effect of 
menthol on acetylcholine and levamisole concentration-response relationships (Figure 5.3 
and Figure 5.4). We observed a left shift in the sigmoidal concentration-response curves 
for both levamisole and acetylcholine in the presence of menthol. Sensitivity of the 
receptor was increased significantly for acetylcholine, pEC50 = 5.3 ± 0.0 (EC50 = 5.0 µM); 




in the presence of 0.1 µM menthol, pEC50 = 6.4 ± 0.1 (EC50 = 0.4 µM) and with 10 µM 
menthol, pEC50 = 6.5 ± 0.1 (EC50 = 0.3 µM). 
For levamisole alone, pEC50 and EC50 values were 6.3 ± 0.1 and 0.5 µM 
respectively. In the presence of 0.1 µM menthol pEC50 and EC50 values were 6.5 ± 0.1 and 
0.3 µM respectively. In the presence of 10 µM menthol the pEC50 and EC50 values were 
6.8 ± 0.2 and 0.2 µM. Only 10 µM menthol produced a significant left shift in the 
levamisole concentration-response curve (P<0.05; Figure 5.4C). The positive allosteric 
modulation produced by menthol was more pronounced with acetylcholine as an agonist 
in comparison to levamisole. In conclusion, menthol not only acts as an agonist on the 
levamisole sensitive receptor but also displays significant PAM activity on this nAChR.  
 
Figure 5.3: Effects of menthol as a PAM on levamisole sensitive O. dentatum nAChR 
acetylcholine responses. A. Sample traces for two-electrode voltage-clamp recording 
showing inward currents in response to ascending concentrations of acetylcholine alone, 
acetylcholine in the presence of 0.1 μM and 10 μM menthol. B. Concentration-response 
relationships for acetylcholine alone (n = 7, black), acetylcholine in the presence of 0.1 
μM (n = 6, blue) and 10 μM menthol (n=7, purple). pEC50 (mean ± SEM), EC50 (mean, 
μM), Hill slope (nH) (mean ± SEM) and Imax (mean ± SEM%) values were respectively: 
5.3 ± 0.0, 5.0 μM, 1.4 ± 0.1 and 107.5 ± 2.6 for acetylcholine alone; 6.4 ± 0.1, 0.4 μM, 
1.0 ± 0.1 and 109.0 ± 3.6 in the presence of 0.1 μM menthol; 6.5 ± 0.1, 0.3 μM, 1.0 ± 0.1 
and 110.5 ± 3.7 in the presence of 10 μM menthol. Bottom was constrained to zero for 
curve fitting. C. Bar chart showing comparison of pEC50 (expressed as mean ± SEM) for 
acetylcholine in the presence and absence of menthol. ****P<0.0001; significantly 





Figure 5.4: Effects of menthol on levamisole sensitive nAChR levamisole responses. A. 
Representative current traces for two-electrode voltage-clamp recording showing inward 
currents in response to ascending application of levamisole alone, levamisole in the 
presence of 0.1 μM and 10 μM menthol. B. Concentration-response relationships for 
levamisole alone (n = 7, steel gray) and in the presence of 0.1 μM (n = 6, light green) and 
10 μM menthol (n=7, dark green). pEC50 (mean ± SEM), EC50 (mean, μM), Hill slope 
(nH) (mean ± SEM) and Imax (mean ± SEM%) values were respectively: 6.3 ± 0.1, 0.5 
μM, 1.0 ± 0.2 and 96.3 ± 5.2 for levamisole alone; 6.5 ± 0.1, 0.3 μM, 1.1 ± 0.2 and 94.6 ± 
5.0 in the presence of 0.1 µM menthol; 6.8 ± 0.2, 0.2 μM, 1.0 ± 0.2 and 89.2 ± 6.0 in the 
presence of 10 µM menthol. Bottom was constrained to zero for curve fitting. C. Bar 
chart summarizing the results showing comparison of pEC50 (expressed as mean ± SEM) 
for levamisole in the presence and absence of menthol. *P<0.05; significantly different as 
indicated; extra sum of squares F-test. 
 
5.5.2 Effects of menthol and carvacrol on A. suum ACR-16 nAChR 
Figure 5.5 shows the concentration-response relationship for acetylcholine on the 
expressed Asu-ACR-16 nicotine sensitive nAChR. The sigmoidal concentration-response 
fit gave pEC50 = 5.0 ± 0.1 (EC50 = 11.1 μM), Imax = 109.1 ± 6.6% and a hillslope (nH) of 
1.6 ± 0.3. We investigated the effects of menthol (10 μM) and carvacrol (10 μM and 100 
μM) on the acetylcholine response. There was no significant change in the sensitivity or 
efficacy of acetylcholine on the N-type receptor in the presence of menthol (pEC50 = 5.0 
± 0.1 and I max =101.6 ± 7.5%). The concentration-response fits (Figure 5.5C) show that 
100 μM carvacrol decreased the maximum response while 10 μM carvacrol failed to 




EC50 and Imax values were 5.1 ± 0.1, 8.1 μM and 94.6 ± 5.9% respectively. Carvacrol 
produced a significant reduction in Imax (55.8 ± 4.4%; P<0.05) when applied at 100 μM 
concentration but did not produce a significant right shift in the pEC50 (5.1 ± 0.1). This 
indicates carvacrol at 100 μM produced non-competitive inhibition. 
Figure 5.5 Effects of menthol and carvacrol on nicotine sensitive A. suum ACR-16 
nAChR acetylcholine responses. A. Representative current traces for two-electrode 
voltage-clamp recording showing inward currents in response to increasing acetylcholine 
concentrations in the presence of menthol (10 μM) and carvacrol (10 μM and 100 μM) B. 
Concentration-response plot for acetylcholine alone (n = 7, black) and acetylcholine in 
the presence of menthol (n = 6, red). pEC50 (mean ± SEM) and EC50 (mean, μM) values 
were respectively: 5.0 ± 0.1 and 11.1 μM for acetylcholine alone, 5.0 ± 0.1 and 9.5 μM in 
the presence of 10 μM menthol. Hill slope (nH) (mean ± SEM) values were: 1.6 ± 0.3 for 
acetylcholine alone; 2.5 ± 1.2 in the presence of 10 μM menthol. Imax (mean ± SEM%) 
values were: 109.1 ± 6.6 for acetylcholine alone; 101.6 ± 7.5 in the presence of 10 μM 
menthol. Bottom was constrained to zero for curve fitting. C. Concentration-response 
plots for acetylcholine alone (n = 7, black) and in the presence of carvacrol (n=6, blue). 
pEC50 (mean ± SEM), EC50 (mean, μM), Hill slope (nH) (mean ± SEM) and Imax (mean ± 
SEM%) values were respectively: 5.1 ± 0.1, 8.1 μM, 2.5 ± 0.8 and 94.6 ± 5.9 in the 
presence of 10 μM carvacrol; 5.1 ± 0.1, 8.2 μM, 2.0 ± 0.7 and 55.8 ± 4.4 in the presence 
of 100 μM carvacrol. Bottom was constrained to zero for curve fitting.   
 
5.5.3 Effect of menthol on A. suum muscle  
We examined the effect of menthol on the A. suum muscle flap contractions 
induced by increasing concentrations of acetylcholine. Figure 5.6A shows the 
representative trace for acetylcholine, in the absence and presence of 0.1 μM menthol in 





Figure 5.6: A. Sample trace for the A. suum muscle flap contraction experiments. Inset: 
concentration-response plots for acetylcholine alone (n = 6, black) and in the presence of 
0.1 μM menthol (n = 6, red). pEC50 (mean ± SEM) and EC50 (mean, μM) values were 
respectively: 5.2 ± 0.2 and 7.0 μM for acetylcholine alone; 5.2 ± 0.2 and 6.5 μM in the 
presence of 0.1 μM menthol. Rmax (mean ± SEM, g) values were: 1.7 ± 0.2 g for 
acetylcholine alone and 2.0 ± 0.2 g in the presence of 0.1 μM menthol. Hill slope (nH) 
(mean ± SEM) values were: 0.8 ± 0.2 for acetylcholine alone and 0.8 ± 0.1 in the 
presence of 0.1 μM menthol. Bottom was constrained to zero for curve fitting.  B. Bar 
chart summarizing the results showing significant potentiation in amplitude of 
acetylcholine mediated contractions in the presence of 0.1 μM menthol. *P<0.05, 
***P<0.001; significantly different as indicated; paired t-tests. 
 
contractions with a pEC50 of 5.2 ± 0.2 (EC50 = 7.0 μM) and Rmax = 1.7 ± 0.2 g. We did not 
observe a significant left shift in pEC50 (5.2 ± 0.2) or change in Rmax (2.0 ± 0.2 g) in the 
presence of menthol. As expected, based on two-way ANOVA, acetylcholine 
concentration had a significant effect on muscle contraction (P<0.0001). Importantly the 
presence of menthol also had a significant effect on muscle contraction (P<0.0001). 
Further analysis revealed a significant potentiation of contractions at each concentration 
of acetylcholine in the presence of menthol (paired t-tests, P<0.05, Figure 5.6B for 
examples). This modulatory effect of menthol is similar to our observed effects on the 





Monoterpenoids are a group of plant secondary metabolites that have been shown to 
modulate the function of nicotinic acetylcholine receptors of mammals and insects 
(Lozon et al. 2016; Tong et al. 2013; Park et al. 2003; Park et al. 2001). We were 
interested in finding possible agonists, antagonists or modulators for these cys-loop 
receptors of parasitic nematodes. In this study, we provide evidence of significant 
modulatory effects of several monoterpenoid compounds on the levamisole sensitive O. 
dentatum receptor and nicotine sensitive A. suum nAChR. We chose to use the 
levamisole sensitive nAChR from O. dentatum due to unreliable expression of the 
levamisole sensitive nAChR from A. suum in our hands. 
The majority of the phytocompounds tested failed to exhibit agonist properties on the 
nAChRs but we were able to identify inhibitors of the levamisole sensitive nematode 
receptor with a rank order: limonene oxide > citronellol > carvone > carvacrol = 
pulegone = eugenol. 
Limonene oxide and carvacrol produced significant non-competitive inhibition 
suggesting neither compound acts at the ligand binding sites. Limonene oxide is a 
monoterpene found in essential oils of various citrus fruits and is an odorous component 
of some types of mushrooms (Breheret et al. 1997; Lemes et al. 2018; Lota et al. 2002; 
Vieira et al. 2018; Rapior et al. 1997); it has been reported to stimulate TRPA1 cation 
channels (Kaimoto et al. 2016). There are limited data available on the effects of 
limonene oxide on nAChRs and this is the first example of an antagonistic effect of the 
compound on a levamisole sensitive nematode nAChR. According to a study done by 




and thus could be used in combination with other nicotinic inhibitors for anti-nematodal 
therapy. Carvacrol, found in many plants including thyme, oregano and Alaska yellow 
cedar (Bouchra et al. 2003; De Vincenzi et al. 2004), acted as a non-competitive inhibitor 
on both levamisole sensitive and nicotine sensitive nematode receptors. Various studies 
have shown alpha-7 homomeric nAChRs, GABA (gamma amino-butyric acid) and 
tyramine receptors as target sites for carvacrol (Lozon et al. 2016; Tong et al. 2013; Tong 
and Coats 2012). In addition, carvacrol was shown to produce significant inhibitory 
effects on acetylcholine induced muscle contractions in A. suum (Trailović et al. 2015). 
This polypharmacological effect of carvacrol might make it efficacious as an 
anthelmintic phytotherapeutic, although it may be best considered as an adjunct to other 
anti-nematodal compounds to increase efficacy due to toxicity considerations when used 
alone at high concentrations (Bimczok et al. 2008; Roselli et al. 2007; Stammati et al. 
1999). 
The most interesting finding was the positive allosteric modulatory activity of 
menthol on the levamisole sensitive nematode nAChR. Menthol is a monocyclic terpene 
alcohol extracted from peppermint plants, Mentha spp. and regulates somatosensory 
sensations such as warmth, pain and irritation (Cliff and Green 1994; Eccles 1994; Farco 
and Grundmann 2013). Menthol showed very mild agonist activity but produced 
statistically significant potentiation of acetylcholine induced inward currents at 
concentrations as low as 0.1 μM and of levamisole induced currents at 10 μM on the 
levamisole sensitive cation channel. PAM compounds exhibit potentiation of the agonist-
activation effects by binding to a site distinct from the ligand binding sites. This property 




selectivity more easily in comparison to compounds binding to orthosteric sites 
(Chatzidaki and Millar 2015; Williams, Wang, and Papke 2011) as all the nAChRs have 
highly conserved acetylcholine binding sites. In comparison, the conservation for amino 
acid composition for other sites is less which makes PAMs preferable in terms of 
selectivity and reduced potential off target effects (Chatzidaki and Millar 2015; Williams, 
Wang, and Papke 2011).  Menthol modulates the pharmacological properties and 
expression of vertebrate nicotinic acetylcholine receptors; it inhibits the effect of nicotine 
on α7-nACh receptors in neural cells in a non-competitive manner (Ashoor et al. 2013; 
Hans, Wilhelm, and Swandulla 2012; Ton et al. 2015). However, it is worth noting that 
these negative allosteric modulatory and inhibitory effects of menthol on α7-nACh 
receptors were produced by much higher concentrations (30-300 µM) in comparison to 
our study. In addition, menthol at 10 µM had no significant effect on the nematode 
nicotine sensitive nAChR (the closest ortholog to vertebrate α7-nAChRs in the 
nematodes). This makes menthol an interesting candidate that can potentiate the effects 
of cholinergic agonist anthelmintics acting on levamisole sensitive nAChRs. Importantly, 
0.1 µM menthol produced significant potentiation of contractions produced by 
acetylcholine on A. suum muscle flaps.  The presence of positive allosteric modulation in 
the somatic muscle flap preparation can be attributed to the presence of levamisole 
receptors and is important in vivo confirmation of our findings from the in vitro 








Natural products have formed the basis of sophisticated traditional therapies and 
they continue to play essential roles in modern healthcare. Phytocompounds, with their 
complex chemistry and structural diversity, offer the potential for discovery and 
development of new pharmaceuticals. Botanical anthelmintics may reduce the need for 
chemical drug treatment and alleviate the pressure on the limited group of anthelmintics 
available. Carvacrol produced significant antagonism on the acetylcholine induced 
inward currents on both levamisole sensitive and nicotine sensitive nematode ligand-
gated ion channels. This illustrates a multifaceted mode of action with involvement of 
multiple target subtypes that can help ameliorate the issue of drug resistance. It may be 
possible to combine these compounds with the nAChR antagonist derquantel or perhaps 
with a macrocyclic lactone as with Startect® (derquantel + abamectin). 
Our results provide promising evidence of positive allosteric modulation by 
menthol which could be used in combination therapy with cholinomimetic drugs like 
pyrantel or levamisole to increase efficacy. For future investigations menthol could be 
used as the starting point in structure activity relationship studies to find new potent PAM 
compounds suitable for stand-alone use as anthelmintics.  In summary, the use of plant 
derived compounds, either alone or in combination, could facilitate sustainable control of 
parasitic nematodes. The results of the present study are encouraging and suggest 
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CHAPTER 6. GENERAL DISCUSSION 
Anthelmintic chemotherapy relies heavily on a limited collection of antinematodal drugs. 
In veterinary field, multi-drug resistant nematodes that withstand all available classes of 
anthelmintics are increasingly common (Kaplan 2004; Wolstenholme et al. 2004; Taman 
and Azab 2014). This has raised concerns of drug resistance in human therapy and 
underscores the need for new strategies to combat these debilitating infections (Prichard 
et al. 2012; Geerts and Gryseels 2000). My doctoral research has identified different 
strategies to address the concerns of a depleted drug-discovery pipeline and drug 
resistance. We have described new anthelmintic drug targets and identified plant-based 
compounds that can be used in combination with current cholinomimetic drugs. 
We have expressed and characterized a first of its kind, non-canonical homomeric 
nAChR formed by a non-alpha subunit, EAT-2, from the pharynx of C. elegans. In the 
free-living nematode, the receptor is required for cholinergic neurotransmission and 
regulates pharyngeal pumping, hence feeding behavior. We also characterized the 
homologous EAT-2 receptor from A. suum that had similar pharmacological profile to the 
cholinergic component of the A. suum pharynx. The pharyngeal nAChR from both the 
species has different pharmacological sensitivities from previously characterized 
nematode somatic muscle and vertebrate nAChRs. This receptor is “druggable” as it was 
not sensitive to existing cholinomimetic anthelmintics. A selective compound targeting 
this cation selective channel should lead to pharyngeal paralysis in worms, resulting in 
starvation or sluggish behavior in worms, and faster expulsion from the host. Thus, the 




the worms, is conserved across species, and is pharmacologically diverse from the 
mammalian orthologues.  
A novel approach towards antinematodal target discovery would be identification 
and validation of receptor-associated proteins in addition to new receptor targets (Maher 
et al. 2017). In the case of ionotropic receptors various auxiliary subunit proteins have 
been identified. These subunits physically associate with the ion channels and modulate 
their biological activity (Yan and Tomita 2012; Boulin et al. 2012; Greger, Watson, and 
Cull-Candy 2017). The association of auxiliary proteins with the receptor complex offers 
additional drug binding sites. Thus, targeting these interacting components can provide a 
new dimension for drug discovery. We have identified a novel auxiliary protein, EAT-18, 
which is required for the functional in vitro expression of the EAT-2 cation selective 
channels. We have demonstrated that EAT-18 physically interacts with the mature 
receptor and different homologues of the protein alter the pharmacological properties. As 
with eat-2, eat-18 null mutants also result in pharyngeal defects. Thus, discovery of 
compounds that target EAT-18 should produce paralyzing effects on pharyngeal pumping 
behavior. 
We have also characterized a homologue of the nematode ACR-16 nAChR 
subunit from A. caninum. Earlier studies have reported A. suum ACR-16 nAChRs to be a 
suitable target for the development of antinematodal drugs. In C. elegans acr-16 is 
expressed in body wall muscles and encodes for nicotine-sensitive nAChRs (Touroutine 
et al. 2005; Richmond and Jorgensen 1999). Genetic screening in C. elegans has shown 
that the receptor regulates the locomotor behavior in combination with levamisole 




A. suum other tissue-related functions, including reproduction and digestion, have been 
suggested for the ACR-16 nAChR (Abongwa, Buxton, et al. 2016; Verma et al. 2017). 
Aca-ACR-16 shares 78 % identity with A. suum and C. elegans homologues. Based on 
our electrophysiology findings, the Aca-ACR-16 nAChR was not activated by many of 
the existing cholinomimetic anthelmintics (levamisole, pyrantel, morantel, bephenium 
and tribendimidine). Thus, the pharmacology of the receptor is distinct from the somatic 
muscle nematode nAChRs. Even though the protein sequence of the ACR-16 
homologues is highly conserved, the ACR-16 homologue from A. caninum displayed 
some pharmacological differences from Asu-ACR-16. This can be attributed to variation 
of amino acids residues in the loops E and F. There is a need for new drug targets for 
hookworm infections. A. caninum ACR-16 is pharmacologically distinct from the 
previously characterized nematode nAChRs and may serve as a valid target site.  
We have demonstrated the potential of three monoterpenoid compounds, namely, 
menthol, limonene oxide, and carvacrol for antinematodal therapy in combination with 
existing cholinergic compounds. Earlier studies have shown that carvacrol can act on 
GABA (gamma amino-butyric acid) and tyramine receptors. In our studies, carvacrol 
produced significant non-competitive inhibition on the levamisole sensitive nAChR from 
O. dentatum and nicotine sensitive nAChR from A. suum. Thus, this monoterpenoid 
phytocompound has the capability to bind to multiple types of pharmacological receptor 
which can impede the development of resistance. Limonene oxide produced non-
competitive inhibition of the levamisole sensitive nAChRs and thus binds to a site 
distinct from ligand binding site. It may be possible to combine these compounds with an 




potentiated acetylcholine and levamisole mediated responses in the levamisole sensitive 
nAChR. 0.1 µM menthol significantly potentiated the peak contractions produced by 
acetylcholine on A. suum somatic muscle strips. Positive allosteric modulators bind to a 
site distinct from the highly conserved ligand binding sites, which helps with better 
selectivity profile and reduced potential for development of resistance.  Menthol behaves 
as a positive allosteric modulator of the levamisole sensitive nAChRs. Combination of 
menthol with cholinomimetic drugs like pyrantel or levamisole may produce a more 
potent anthelmintic effect.   
6.1 Future directions 
There are a number of experiments that can be done to further validate the EAT-2 
nAChR and associated auxiliary protein, EAT-18, as a potential drug target.  We would 
recommend expressing the EAT-2 nAChR in cell lines or yeast cells which will facilitate 
high-throughput drug screening. This will allow target-based screening of chemical 
libraries to identify selective drugs for the receptor. These experiments will also assist 
with confirming the pharmacological diversity of the receptor by screening for 
compounds that are specific for mammalian orthologues. Additionally, development of 
three-dimensional models for the protein will help in structure-based virtual screening of 
potential anthelmintic compounds. We also recommend identification and cloning of 
putative homologues from EAT-2 and EAT-18 from parasites of human medical 
relevance for further validation across nematode species.  
We would recommend similar expression and drug screening experiments for A. 
caninum ACR-16 nAChRs to identify selective anthelmintics for hookworm infections. 




the ACR-16 homologue in the hookworms. RT-PCR analysis of various hookworm 
tissues will also help in determining the expression pattern and physiological relevance of 
the nAChR. 
The potential antinematodal monoterpenoid compounds identified should be 
evaluated for their efficacy and toxicity through various in vitro and in vivo assays. The 
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A1.0 Abstract 
‘The best way to predict the future is to create it.’ When we look at drugs that are used to 
control parasites, we see that new knowledge has been created (discovered) about their 
modes of action. This knowledge will allow us to predict combinations of drugs which 
can be used together rationally to increase the spectrum of action and to slow the 
development of anthelmintic resistance. In this paper we comment on some recent 
observations of ours on the modes of action of emodepside, diethylcarbamazine and 
tribendimidine. Emodepside increases the activation of a SLO-1 K+ current inhibiting 
movement, and diethylcarbamazine has a synergistic effect on the effect of emodepside 
on the SLO-1 K+ current, increasing the size of the response. The combination may be 
considered for further testing for therapeutic use. Tribendimidine is a selective 
cholinergic nematode B-subtype nAChR agonist, producing muscle depolarization and 
contraction. It has different subtype selectivity to levamisole and may be effective in the 
presence of some types of levamisole resistance. The new information about the modes of 
action may aid the design of rational drug combinations designed to slow the 
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A2.0 Introduction 
‘The best way to predict the future is to create it.’ This quote is usually ascribed to 
Abraham Lincoln and leads to some interesting thoughts when applied to different 
research fields including our own field of study, that is, anthelmintics. What are we 
creating and what can we see for the future for anti-parasitic drugs? We are creating new 
techniques for the screening of anthelmintic drugs, we are creating new methods for 
studying the modes of actions of anthelmintics and we are creating new ways for 
detecting anthelmintic resistance (Gilleard and Beech, 2007 and Lanusse et al., 2014). 
We are also creating better awareness of the ‘neglected tropical diseases’ (Hotez et al., 
2008) of humans which include ascariasis, hookworm and trichuriasis and better 
awareness of the link between human and animal medicine, the ‘One Health’ concept. 
Our western economic system has also produced a more favorable economic environment 
for the development of animal anthelmintics, than anthelmintics for humans. Currently, 
we limit the damage done by nematode parasites of animals with pasture management, 
and improved targeted metaphylactic and therapeutic use of anthelmintics; for humans, 
clean water and sanitation are limiting factors (like clean pasture for animals) while mass 
drug administration (MDA) has similarities to the regular metaphylactic use of 
anthelmintics for animals. Vaccinations against parasites for both humans and animals 
are very desirable but so far they have limited efficacy.  
The advances and creations listed above lead to a number of logical predictions 




development and better understanding of anthelmintic properties will continue, at a 
steady but modest pace, driven by economic, human and animal needs. We think that the 
economic pressures associated with animal medicine will remain greater than for human 
medicine and focused on the development of novel ‘resistance-busting’ anthelmintics. 
Success in research can be limited by funding as was said by the father of modern drug 
development, Paul Ehrlich, Figure 1 (1854–1915), who recognized success required the 
four Gs: Gluck, Geduld, Geshcick und Geld (luck, patience, skill and money) (Perutz, 
1988). The ‘money’ for animal anthelmintics comes from the market for anti-parasitic 
drugs and chemicals for small animals and livestock which was estimated at $11 billion 
(Evans and Chapple, 2002). This contrasts with the market for human anthelmintics 
which is only $0.5 billion despite some 2 billion humans being infected in developing 
countries, around 25 cents per person annually! Given that the out of pocket costs of new 
human drugs may be $403 million (at year 2000 valuations (DiMasi et al., 2003) or more, 
we can see that the commercial development of human anthelmintic drugs is not 
favorable. It seems more likely that the economics of animal health will drive the 
development and advance of the knowledge base of animal anthelmintics and that these 
developments will be applied and adapted for human use (ivermectin and perhaps 
emodepside) unless private charities, governments and foundations overcome the 
financial limitations. In addition to the gradual development of resistance-busting 
anthelmintics we see: developments in our understanding of the modes of action of 





Fig. 1. Paul Erlich in his Frankfurt office, circa 1900, the father of modern chemotherapy, who 
worked on trypanosome diseases and popularized the concept of the ‘magic bullet’ (magische 
Kugel, the perfect therapeutic agent). 
 
counter the development of resistance and; also new methods for detecting anthelmintic 
resistance. 
Our lab has focused on understanding of the modes of action of anthelmintics and 
in this paper we illustrate some of our recent observations and developments in our 
understanding of the actions of emodepside, diethylcarbamazine and tribendimidine. The 
mode of action of these anthelmintics involves effects on membrane ion-channels and has 
required us to use electrophysiological techniques for their study (Martin et al., 1996b). 
We think that better knowledge of the mode of action of these compounds will allow 
rational combination with other anthelmintics to increase potency, spectra and allow a 
slowing of the speed of development of resistance in animal and human parasites. This 
paper is based on a lecture given to the World Association for the Advancement of 
Veterinary Parasitology (WAAVP) in Liverpool, 2015 and covers: (1) emodepside, an 
anthelmintic used for small animals, which has the potential for being used for human use 




for the control of filariasis in humans and; (3) tribendimidine, a recent anthelmintic 
developed by China for human use. 
 
A3.0 Emodepside 
Emodepside is a cyclooctadepsipeptide developed by Bayer, Fig. 2, which is related 
to its parent compound, PF1022A (Martin et al., 1996a) which has broad-spectrum 
anthelmintic activity. Emodepside has an inhibitory effect on locomotion that allowed 
(Guest et al., 2007) to use a C. elegans mutagenesis screen to find that slo-1 (a Ca2+-
dependent K+ channel) mutant alleles were resistant to the inhibitory effects of 
emodepside. Crisford et al. (2011) also described transgenic experiments in which C. 
elegans SLO-1a channels were swapped for KCNMA1, the human orthologue of SLO-1 
channels. These studies found that the sensitivity to emodepside in the rescues depended 
upon the origin of the SLO-1 channel: the human KCNMA1 channel was 10–100 times 
less sensitive to emodepside than the rescues expressing C. elegans SLO-1a channel. 
These experiments suggested that SLO-1 Ca2+-dependent K+ channels of nematodes are a 
major part of the target site of emodepside. Expression of C. elegans SLO-1a channels in 
Xenopus oocytes have revealed that emodepside can directly open these channels (Kulke 
et al., 2014) and that emodepside action on this splice variant of the channel does not 
require the presence of additional receptors like the latrophilin receptors for an 
emodepside effect (Willson et al., 2004). It does not however, rule out a contribution of 
latrophilin receptors to the overall mode of action of emodepside in parasites as indicated 




SLO-1 K+ channels have large (∼200 pS) single-channel conductances and are 
also known as ‘big’ potassium (BK) channels. These channels serve to clamp the 
membrane potential near the potassium reversal potential and inhibit electrical 
excitability. The SLO-1 K+ channel, has a different function to the high conductance 
Ca2+-dependent Cl− channel (Thorn and Martin, 1987) which is associated with the 
transport of carboxylic acids from anaerobic metabolism of glucose (Valkanov and 
Martin, 1995). Subunits homologous to the vertebrate SLO-1 K+ channels are found in C. 
elegans and Ascaris suum (Buxton et al., 2011). The SLO-1 K+ channels are composed of 
4 α-subunits; α-subunits have seven (S0–S6) transmembrane regions, a P-loop between 
S5 and S6, a large intracellular domain (S7-S-10) and a well conserved ‘calcium bowl’ 
between domains S9 and S10, Fig. 2. In addition, the regulator of the K+ channel 
conductance (RCK) domains (S7, S8) contains high and low affinity calcium binding 
sites. The SLO-1 α-subunits show alternative splicing, producing channels with different 
calcium sensitivities; in C. elegans there are up to 15 splice variants (including SLO-1a, 
SLO-1b and SLO-1c (Kulke et al., 2014 and Wang et al., 2001)). Each α-subunit of the 
channel has at least two high affinity calcium binding sites and one low affinity 
calcium/magnesium binding site. The channel also combines with secondary, regulatory 
β-subunits in vertebrates (Knaus et al., 1994) but these subunits have not yet been 
identified in C. elegans. However, Drosophila, which also lacks β subunits, has SLOb 
proteins, which appear to carry out similar functions to the vertebrate β-subunits and 
these may be present in nematodes (Claridge-Chang et al., 2001).  






Fig. 2. Summary diagrams of emodepside structure, SLO-1 subunit and a model of the 
mode action of emodepside on nematode body muscle. A: Emodepside. B: Line diagram 
of structure of one SLO-1 subunit; each SLO-1 K+ channel is made up of 4 of these 
subunits. C. Putative mode of action of emodepside on SLO- 1K+ channels in the 
muscle: act directly (1) or indirectly by stimulating latrophilin-like receptors (2) and 
signaling cascades that may involve NO, protein Kinase C and/or calcium. It is unlikely 
that emodepside acts at the extracellular surface of the SLO-1 K+ channel because of the 
slow time course of its action. It is very lipophilic and could act in the lipid membrane 
phase on the SLO-1 K+ channel or move into the cytoplasm and act intracellularly. A 
SLO-1 K+ channel (C) is shown composed of 4 subunits along with the ‘RCK’ 
cytoplasmic regulatory region of the channel. (Martin et al., 2012). 
 
membrane potential of electrically excitable cells and adjust the level of excitability, up 
or down, and so affect the response to other inputs. The opening of the SLO-1 K+ 
channel, Fig. 2, is regulated by at least ten factors including: (1) membrane potential; (2) 
calcium; (3) magnesium; (4) NO; (5) CO; (6) arachidonic acid; (7) prostaglandins; (8) 
phosphorylation by cAMP-dependent protein kinase A; (9) phosphorylation by 
diacylgycerol/Ca2+-dependent protein kinase C; and (10) phosphorylation by cGMP-
dependent protein kinase G (Salkoff et al., 2006). The kinases allow SLO-1 to be coupled 
to multiple and quite diverse signaling cascades permitting different ways of adjusting the 




cGMP levels (e.g., AF1, AP2, and PF1 and PF2) could then affect SLO-1 channels 
(Muhlfeld et al., 2009, Verma et al., 2007 and Verma et al., 2009). A selective agonist for 
the PF1 and/or a selective antagonist of the AF1 receptor would activate a SLO-1 K+-like 
current and increase the efficacy of emodepside. The neuropeptides AF1, AF10 and PF2 
also bind with low affinity to the latrophilin-like receptor, HC110-R of Haemonchus 
contortus, suggesting that emodepside could also have an indirect mode of action on 
SLO-1 K+ channels through these latrophilin-like receptors (Fig. 2) that are neuropeptide 
receptors (Muhlfeld et al., 2009).  
We found (Buxton et al., 2011 and Martin et al., 2012)  that Asu-slo-1 is an 
evolutionarily conserved homologue of the slo-1 genes, expressed in adult A. suum body 
muscle flaps. Using a two-micro-electrode current-clamp and voltage-clamp technique, 
Fig. 3A, we found in the nematode parasite A. suum, that emodepside activates SLO-1-
like K+ channels to produce hyperpolarization under current-clamp, Fig. 3B1, and an 
outward current when under voltage-clamp, Fig. 3B2. We also found that emodepside 
increased voltage activated K+ currents, Fig. 3C and D, in a time dependent manner. 
Emodepside, Fig. 3C, unlike PF1 did not decrease calcium currents and so emodepside 
does not work by releasing PF1 as has been hypothesized. We found that the effects of 
emodepside on the voltage activated K+ channels is Ca2+-dependent and were inhibited by 
5 mM 4-aminopyridine, Fig. 4A. The membrane hyperpolarization and increase in 
voltage-activated K+ current produced by emodepside, Fig. 3B, are very slow in onset and 
increase over a period of more than 10 min (Buxton et al., 2011); the slow onset effect of 
emodepside might be due to its very lipophilic nature and a membrane partitioning effect. 





Fig. 3. Electrophysiological techniques (two micropipette current-clamp and voltage-
clamps) for recording from Ascaris suum. A: A. suum muscle bag showing the current (I) 
and voltage (V) micropipettes in the bag, and the perfusion needle (P). B1: 
Representative current-clamp trace showing the slow hyperpolarizing membrane 
potential during and after 10 min application of 1 μM emodepside. B2: Outward current 
response to 1 μM emodepside at higher time resolution. Holding potential −35 mV. 
Notice that emodepside produces a gradually increasing current after a delay of some 30 
seconds. The response does not plateau in the time period of this recording. C: Voltage-
clamp traces of control K+ current and the time-dependent effects of 1 μM emodepside 
on the K+ currents, all to a step potential of 0 mV from a holding potential of −35 mV. D: 
Bar chart (mean ± S.E.) of 1 μM emodepside effect on steady state (LK) currents. 
Comparison was made between the control 0 mV step current at 30−40 ms and the 
corresponding current increased by emodepside at 10, 20 and 30 min. Emodepside 
increased LK currents at 10 min (p < 0.01, n = 4, paired t-test), 20 min (p < 0.01, n = 4, 
paired t-test) and 30 min (p < 0.05, n = 4, paired t-test). (Martin et al., 2012). 
 
of a slow signaling cascade. Fig. 4B and C shows that the effects of emodepside are 
potentiated by sodium nitroprusside (a NO donor), antagonized by iNOS inhibitors 





Fig. 4. Effect of 1 μM emodepside on membrane potential. A: Comparison was made 
between membrane potential before and during emodepside application. 1 μM 
emodepside caused a significant membrane hyperpolarization (p < 0.001, n = 10, paired 
t-test) which was reduced in the presence of 5 mM 4-aminopyridine (p < 0.01, n = 8, 
unpaired t-test). 10 μM emodepside caused an increased hyperpolarization in comparison 
to 1 μM emodepside (p < 0.05, unpaired t-test). B: Bar chart (mean ± s.e) of NO 
influence on emodepside-induced hyperpolarization. In the presence of 1 mM SNP, 1 μM 
emodepside caused an increased hyperpolarization (p < 0.01, n = 4, paired t-test). 100 μM 
NNLA decreased the hyperpolarization caused by 1 μM emodepside (p < 0.01, unpaired 
t-test). C: Bar chart (mean ± s.e) of effect of protein kinase modulators on emodepside 
induced hyperpolarization. 10 μM PMA had no significant effects on the 
hyperpolarization caused by 1 μM emodepside. However, 1 μM staurosporine decreased 
the hyperpolarization caused by 1 μM emodepside (p < 0.05, unpaired t-test). (Martin et 
al., 2012). 
 
al., 2011). Interestingly, these signaling molecules are known as activators of SLO-1 in 
other cells (Bolotina et al., 1994b, Holden-Dye et al., 2007, Mistry and Garland, 1998 
and Wang et al., 1999) and therefore encourage the view that emodepside could act 
through either or both of these signaling cascades and the signaling cascades may be in 
series or parallel, Fig. 2C. A number of studies on the mammalian orthologues of SLO-1 
show that they are directly and alternately regulated by complex, multiple signaling 




Salkoff et al., 2006). It is pointed out that NO signaling pathways in mammals may not 
be conserved in all species of nematode. 
Thus emodepside appears to selectively activate the SLO-1 K+ current that is 
present in nematodes but has less effect on the SLO-1 K+ currents of vertebrates. This can 
explain the selective toxicity of the drug. The existence and mechanisms of resistance to 
emodepside in nematode parasites remain to be studied but could involve several 
different mechanisms including changes in the splice forms of the SLO-1 K+ channel or 
its regulation by different signaling cascades. However, such resistance, depending on the 
specific mechanism, might be countered (Verma et al., 2007 and Verma et al., 2009) by a 
selective agonist for the FMRFamide PF1 receptor and/or a selective antagonist of the 
FMRFamide AF1 receptor which would activate a SLO-1 K+-like current and increase 
the efficacy of emodepside. An increased knowledge of the physiology of target site of 
emodepside provides a new way of designing drug combinations. The complex nature of 
SLO-1 K+ regulation suggests that if there were resistance to emodepside it would be 
complex in nature and therefore likely to be polygenic involving multiple mechanisms. 
 
A4.0 Diethylcarbamazine 
Diethylcarbamazine, Fig. 5A, is an antifilarial drug that has been used since 1947 
against lymphatic filariasis and loiasis. It is still an important and effective antifilarial 
drug but its mode of action is not fully described. Diethylcarbamazine has been suggested 
to have an indirect, host mediated mode of action: it appears to alter host arachidonic 
acid, nitric oxide metabolic pathways and inhibits NF-κB, which together in an unknown 





Fig 5. The combined effect of emodepside and diethylcarbamazine is greater than the 
effect of emodepside alone on A. suum membrane potential. A: Chemical structure of 
diethylcarbamazine. B: Representative current-clamp traces showing the membrane 
potential before, during 1 μM emodepside application (top trace) and during application 
of 1 μM emodepside plus 100 μM diethylcarbamazine (lower trace). The time delay 
between the end of the application of 100 μM diethylcarbamazine and 1 μM emodepside 
plus 100 μM diethylcarbamazine was 10 min. The change in membrane potential between 
the beginning of the 100 μM diethylcarbamazine and application of 1 μM emodepside 
plus 100 μM diethylcarbamazine was a hyperpolarization of 1.5 mV. C: Bar chart (mean 
± i.e.) of diethylcarbamazine effect on emodepside-induced hyperpolarization. 100 μM 
diethylcarbamazine increased the hyperpolarization caused by 1 μM emodepside (p < 
0.01, n = 5, unpaired t-test. (Buxton et al., 2014a). 
 
1992 and Peixoto and Silva, 2014). Diethylcarbamazine activity against B. malayi 
microfilariae is abolished in inducible nitric oxide synthase knockout mice (iNOS−/−), 
suggesting that diethylcarbamazine activity is dependent on host inducible nitric oxide 
synthase (iNOS) and nitric oxide (McGarry et al., 2005). 
We were interested to determine how diethylcarbamazine would affect calcium 




diethylcarbamazine interacts with emodepside. The interest was prompted by 
observations in vertebrates (Bolotina et al., 1994a) which show that nitric oxide activates 
SLO-1 K+ channels and observations on A. suum indicating the presence of nitric oxide 
synthase and of SLO-1 K+ channels which show positive modulation by a nitric oxide 
pathway (Buxton et al., 2011). We hypothesized that diethylcarbamazine, with effects on 
arachidonic acid and nitric oxide pathways, would increase activation of SLO-1 K+ 
currents in A. suum muscle and potentiate effects of emodepside on membrane potential 
(Buxton et al., 2014a). We conducted current-clamp and voltage-clamp 
electrophysiological experiments, using A. suum body muscle in the presence of 
sufficient calcium to allow activation of the SLO-1 K+ currents. We found that indeed 
diethylcarbamazine, by itself, can increase activation of SLO-1 K+ currents and potentiate 
the hyperpolarizing effects of emodepside. This to us was very interesting since it showed 
that diethylcarbamazine has a direct effect on the nematode parasite and its effects are not 
exclusively mediated via the host as has been suggest by earlier experiments. It seems 
likely that the effects of diethylcarbamazine may involve effects on NO or arachidonic 
acid metabolites both in the host and in the parasite. Although the mechanism of action of 
diethylcarbamazine remains to be further defined, the synergistic effect of emodepside 
and diethylcarbamazine suggests that the combination of the two drugs could be 
considered for therapeutic use for the treatment of filarial nematode infections. 
 
A5.0 Tribendimidine 
Tribendimidine, Fig. 6, is a symmetrical diamidine derivative of amidantel which 




anthelmintic effective against soil-transmitted helminthiasis including hookworm, 
pinworms, roundworms, Strongyloides and flatworms of humans (Xiao et al., 2005 and 
Xu et al., 2014). Molecular studies (Hu et al., 2009) on C. elegans using null-mutants of 
the levamisole receptor subunits strongly suggested that tribendimidine is a cholinergic 
agonist that is selective for the same nematode muscle nAChR as levamisole. When we 
looked at these studies we found that there are no direct electrophysiological observations 
in nematode parasites that had been made to test this hypothesis and we were aware that 
sometimes observations on the model Clade V nematode were not always the same in 
parasitic nematodes, particularly for the parasites from a different Clade. We were also 
interested in trying to explain why tribendimidine is effective against some nematode 
parasites when levamisole is not. 
We tested the effects of tribendimidine on the electrophysiology, Fig. 6, and 
contraction of A. suum muscle (Robertson et al., 2015) and found that tribendimidine 
produces a dose-dependent depolarization associated with an increase in the conductance 
of the muscle membrane as the nicotinic receptors (nAChRs) open. We found that 
tribendimidine was more potent than acetylcholine and had an EC50 of 0.8 μM. We also 
tested the effects of the nicotinic antagonist mecamylamine, a potent antagonist of muscle 
nAChRs of parasitic nematodes and found that 3 μM was potent against tribendimidine; 
the antagonist effects of mecamylamine confirmed the cholinergic action of 
tribendimidine on the nAChRs of the parasite A. suum. 
We characterized the pharmacological profile of tribendimidine using our Ascaris 
muscle contraction assay systems (Qian et al., 2006 and Robertson et al., 2002) with 





Fig. 6. A: Chemical structure of tribendimidine. B: Diagram of the two-micropipette 
current-clamp technique used to record the membrane potential (v) and to inject 40 nA 
hyperpolarizing 500 ms current pulses (i) at 0.3 Hz. p is the microperfusion pipette used 
to apply and wash off the drugs. C: Application of 3 μM acetylcholine and then 0.1, 1 and 
10 μM tribendimidine to the same preparation. 1 μM tribendimidine produces a bigger 
depolarization response (upward movement) and conductance increase (reduction in the 
voltage responses to current injection, producing a narrowing of the width of the trace) 
than 3 μM acetylcholine (Robertson et al., 2015). 
 
antagonists to calculate the potency, pA2, of the antagonists and the subtype of the 
selectivity of tribendimidine. We found that tribendimidine was more selective for the B- 
subytpe (bephenium preferring) nAChRs than the L-subtype (levamisole preferring) or 
the N-subtype (nicotine preferring). These observations showed the selectivity for the 
different groups of nAChRs present on the Ascaris muscle was not the same as 
levamisole and it was possible that levamisole-resistant parasites would remain sensitive 
to tribendimidine. To test this we used, Oesophagostomum dentatum L3 larval migration 
inhibition assays with levamisole sensitive isolates and levamisole-resistant isolates and 
tested the effects of tribendimidine on motility. Levamisole was less effective (p < 0.001, 
F-test) in inhibiting migration of levamisole-resistant larvae than the migration of 





Fig. 7. Tribendimidine as an agonist of Ode-(29-8-38-63) and Ode-(29-63-38) receptors 
expressed in oocytes, currents recorded under voltage-clamp at −60 mV (Buxton et al., 
2014b) A: Tribendimidine and pyrantel at 100 μM is more potent than levamisole on the 
Ode-(29-38-63) receptor. B: Levamisole at 100 μM is more potent than acetylcholine 
tribendimidine, pyrantel and nicotine on the expressed Ode-(29-8-38-63) receptor. Note 
that derquantel produces competitive antagonism of the effects of levamisole but a non-
competitive antagonism of pyrantel, suggesting that the mode of action of levamisole and 
pyrantel are not identical. 
 
solubility, ∼30 μM, and found that tribendimidine was actually more potent on the 
levamisole-resistant isolate than on the levamisole-sensitive isolates (p < 0.001, F-test). 
The larger effect of tribendimidine on the levamisole-resistant, than the levamisole- 
sensitive isolates at lower tribendimidine concentrations, supports the view that 
levamisole and tribendimidine do not activate identical nAChR receptor subtypes. The 
higher efficacy of tribendimidine on the levamisole resistant O. dentatum isolate might 
indicate a case of negative cross resistance (Miltsch et al., 2013). 
We have been able to express, in Xenopus oocytes a range of different nAChR 
receptor subtypes derived from anthelmintic sensitive Oesophagostomum dentatum 
clones of their nAChR receptor subunits (Buxton et al., 2014b). Fig. 7 shows a diagram 
of the subunit composition of two nAChR subtypes expressed in oocytes, one composed 
of Ode-UNC-29:Ode-UNC-63:Ode-UNC-38, the other composed of Ode-UNC-29:Ode-




UNC-38 receptor was more sensitive to tribendimidine and pyrantel but not to levamisole 
or nicotine. We can see that the receptor subunit arrangements affect their pharmacology 
and that not all cholinergic anthelmintics have the same selectivity. 
Our understanding to date is that there are a range of pharmacologically different 
nAChR subtypes present in parasitic nematodes and the pharmacology of the receptor 
subtypes vary with the subunit composition of the receptor which varies with the tissue 
and species of the nematode parasite. There will therefore be cholinergic anthelmintics 
that act on different nAChR subtypes and it is therefore possible that there will not 
always be cross resistance between the cholinergic anthelmintics. 
 
A6.0 Discussion 
Diethylcarbamazine is used mostly for treatment of filariasis in humans but has effects 
against hookworm and ascariasis, intestinal nematode parasites (Meyrowitsch and 
Simonsen, 2001). In addition to the treatment of filariasis, diethylcarbamazine, as a single 
dose treatment, has modest effects on intestinal nematode parasite infections including 
ascariasis and trichuriasis but is more effective when combined with ivermectin or 
albendazole (Belizario et al., 2003). We have seen in our experiments that emodepside 
increases a Slo-1 K+ current in the parasite and that diethylcarbamazine can potentiate the 
effect of emodepside. Both of these compounds have been used separately as single 
anthelmintics but we do not have data on their therapeutic effect when used in 
combination. This information is desirable to obtain and if therapeutic combination of 




isolation, such synergism could slow the development of resistance and extend the 
spectrum of action of the therapy. 
Levamisole and tribendimidine have different selectivities for nAChR subtypes. 
In Ascaris tribendimidine is more selective for the B-subtype rather than the L-subtype of 
nAChR. Tribendimidine is more potent on expressed O. dentatum receptor subtypes 
composed of Ode-UNC-29:Ode-UNC-63:Ode-UNC-38 subunits, than on subtypes 
composed of Ode-UNC-29:Ode-UNC-63:Ode-UNC-38:Ode-ACR-8 subunits (Buxton et 
al., 2014b). The difference in selectivity suggests that tribendimidine has the potential to 
be effective against nematode parasites that are not sensitive to levamisole, including 
those parasites that have developed resistance. A careful combination of different 
cholinergic anthelmintics has the potential to extend the spectrum of action of the drug 
treatment. Tribendimidine has an interesting and promising pharmacology and has the 
potential for single-dose MDA with its broad-spectrum of action. Although 
tribendimidine appears safe and has broad-spectrum activity, a large-scale clinical study 
is advocated to further verify human safety. 
 
A7.0 Conclusion 
We have been excited by our discovery of further details of the modes of action of the 
different anthelmintics that we work on and believe that the information will be useful for 
defining mechanisms of resistance to the anthelmintic drugs that we have studied. We 
also think that the improved understanding of their mechanisms of action will lead to 
better use of these compounds and logical design of synergistic combinations. We do not 
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